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Abstract 
 
 
While the B cell antigen receptor (BCR) membrane IgM (mIgM) transmits signals via 
Igα/β, the cytoplasmic tail of mIgG is able to transmit signals directly. We have 
generated mice where the IgG1 cytoplasmic signalling tail was added to the C-
terminus of IgM (IgMg1 mouse). During B cell development, IgMg1 B cells 
experience stronger negative selection resulting in tonic BCR signal transduction 
being repressed and reduced mIgM expression. BCR stimulation of immature and 
mature IgMg1 B cells results in reduced signalling. This shows that IgMg1 B cells 
leave the bone marrow as anergic cells. 
 
IgMg1 B cells respond less efficiently to thymus-independent antigens. They do, 
however, respond well to the thymus-dependent antigen. The anergic pattern of 
IgMg1 B cells is maintained throughout the GC response and even after they become 
IgG switched memory B cells (MBCs). These effects may contribute to a delay in the 
shift of antigen-specificity of GC B cells. 
 
These results are in line with recent studies showing that anergic B cells are licensed 
to participate in Germinal Centre (GC) reactions, where they can undergo clonal 
redemption. We conclude that IgMg1 mice are a new model to study anergy in B cells 
with a complete repertoire of BCR-specificities. 
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Chapter 1 . Introduction 
	
	
1.1 General introduction of B cells 
	
Adaptive immunity is a highly evolved system which can specifically distinguish tiny 
differences between different “foreign invaders”, and also differences between 
“foreign” and “self”. This ability is driven by T and B lymphocytes in the immune 
system. During B cell development, gene segments encoding for B-cell receptor 
(BCR) variable region undergo a process called random re-arrangement. This random 
arrangement not only brings uniqueness of BCR expressed on each B cell, but also 
allows for the generation of a highly diverse BCR repertoire, which potentially 
enables our immune system to respond specifically to any foreign antigen.  
 
Antibody secretion is the most well-known and widely studied function of B cells. An 
antibody is the secreted form of a BCR, comprised of two regions; the variable 
antigen recognition and constant structural regions. After recognition and binding to 
foreign antigen, antibodies can inhibit virus infection through a process called 
neutralization, which then follows with agglutination. Also, they can help to destroy 
bacteria with the help of phagocytic cells through a process called opsonisation. 
Opsonisation is not working on its own, by activating the complement system through 
coating pathogens, antibodies can promote the lysis and ingestion of these pathogens. 
Recent studies have shown that antibody could regulate BCR signalling by ligating 
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with Fc receptors and thus affecting B cell development and differentiation (Nguyen, 
Klasener et al. 2017).  
 
Besides antibody secretion, B cells, especially plasma cells, have also been reported 
to have immune regulatory roles (Mauri and Bosma 2012, Fillatreau 2015, Kranich 
and Krautler 2016) and the role of B cells as antigen-presenting cells (APCs) has long 
been overlooked (Lassila, Vainio et al. 1988). However, a recent study has shown that 
B cells are as capable as dendritic cells to present certain viral antigens (Hong, Zhang 
et al. 2018). By presenting auto-peptides and activating T cells, this ability makes B 
cells capable of breaking immune tolerance and inducing auto-immune responses 
(Chan and Shlomchik 1998, Giles, Kashgarian et al. 2015). Memory B cells are 
antigen-experienced activated B cells which have long-term life span, and are able to 
reactivate an immune response immediately at the second time of exposure to a 
related antigen (Moran, Nguyen et al. 2018). (Decision events in the Germinal Centre: 
the role of ACKR4, LAURA GARCIA-IBANEZ, published thesis, 2016) 
 
One important transitional microstructure during T-cell dependent (T-D) immune 
response is the germinal centre (GC), where somatic hypermutation (SHMs) takes 
place. BCR on GC B cells are selected and modified, so that they respond with higher 
affinity to foreign antigen. GC B cells can further differentiate into plasma cells or 
memory B cells. 
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The characteristics discussed above are mainly based on observations on conventional 
B cells, termed B2 cells, such as follicular B cells and marginal zone B cells. 
However, there is another B cell population called B1 cells. B1 cells are CD21low/-
CD23low/- innate-like cells, with a relatively limited BCR repertoire. They are mainly 
generated in the fetal developmental stage and can self-renew once development has 
progressed past this stage. They are the producers of natural IgM, without the need for 
co-stimulatory help from T helper cells (Baumgarth 2016).  
 
Despite having advanced knowledge of B cell biology, we are yet to truly understand 
the diversity of the mature B cell pool in healthy individuals, and the regulations that 
these B cells experience during development and after activation.  
 
1.2 Structure of secondary lymphoid organs 
	
The secondary lymphoid organs consist of spleen, lymph nodes, Peyer’s patches and 
some other isolated lymphoid follicle structures. This study mainly focuses on spleen 
and lymph nodes. Each has distinct structure and function in the immune system. 
 
1.2.1 Lymph node 
	
Lymph nodes (LNs) are distributed all around the body along lymphatic vessels. Their 
locations are aimed at rapidly mounting immune response towards captured foreign 
antigens. On the midsagittal section of a lymph node, along the direction of lymphatic 
fluid, the afferent lymphatic vessel is on the top and connected with the capsule of 
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lymph node. The entire internal structure of the lymph node is enclosed within the 
capsule. Below the capsule, there is a lymphoid fluid filled sinus, called the sub-
capsular sinus. Beyond the sub-capsular sinus, B cell follicles sit side by side, with 
interfollicular cortex filling the space between them. T cells are also sitting in the 
interfollicular areas and localised below B cell follicles, forming a relatively large T 
zone. At the bottom of lymphoid lobule is the medullary area, comprised of medullary 
cords separated by medullary sinuses. The whole structure ends with efferent 
lymphatic vessels (Fig. 1.1) (Willard-Mack 2006).  
 
Antigens can travel to LNs via lymph vessels. It has been reported that antigen entry 
from lymph vessels is very rapid and can only take a few minutes (Gerner, Casey et al. 
2017). B cells and LN resident DCs efficiently capture those antigens and mount an 
immune response (Mempel, Henrickson et al. 2004, Batista and Harwood 2009). 
Antigen-bearing B cells are activated and migrate to T-B border, where they are in 
close contact with activated T cells to receive co-stimulation signalling (Reif, Ekland 
et al. 2002). After fate decision at this stage, a small fraction of antigen-specific 
activated B cells differentiate into germinal centre (GC) precursor B cells. These cells 
then migrate back to the B cell follicle and go through clonal divisions to form a 
distinct micro-anatomical structure called the germinal centre (MacLennan 1994).  
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Figure 1.1: The structure of lymph node.  
The whole structure is enclosed in the capsule, and is connected to the lymph system 
by the afferent and efferent lymphatic vessels (top and bottom, respectively). Similar 
to the structure of white pulp in the spleen, the lymphoid lobule contains an extended 
T-zone and several B cell follicles. The artery and vein spread out to form a network 
proximal to the T-zone, which is called medullary area. Within this area, there are 
medullary sinuses and cords. Cited and modified from Willard-Mack (Willard-Mack 
2006)  
6	
	
1.2.2 Spleen 
	
The spleen is a unique secondary lymphoid organ, distinct from lymph nodes which 
mainly function to mount immune responses toward foreign antigens. The spleen also 
functions to host the peripheral maturation of B cells. Structurally, the spleen spreads 
along the tree of afferent splenic artery. At the end of small arterial branches, there are 
well-organised lymphoid regions, which are called the white pulp of the spleen. The 
white pulp is further divided into the T-cell zone, also known as the periarteriolar 
lymphoid sheath (PALS), and B cell follicles. The structure of white pulp resembles 
the structure of lymph nodes, where one or more B cell follicles sit among T cells (Fig. 
1.2). B cell follicles contain recirculating follicular B cells and host transitional B 
cells to complete their maturation (Loder, Mutschler et al. 1999). Different from 
lymph nodes, in each island of lymphoid region within the spleen, there is a central 
arteriole in the middle of each T zone. The central arteriole is also connected to the 
marginal sinus, another unique structure within the white pulp of the spleen (Steiniger, 
Ruttinger et al. 2003). The marginal sinus is a transit area, where cells and foreign 
antigens exiting the central arteriole first come to this area before further migration to 
B cell follicles (Cyster and Goodnow 1995). The marginal zone contains a large 
amount of resident B cells, called marginal zone B cells (MZ B cells), which are the 
front-line defenders against blood-borne pathogens (Zandvoort and Timens 2002). 
MZ B cells have been reported to shuffle between B cell follicles and the marginal 
zone area to transport captured antigens (Cinamon, Matloubian et al. 2004, Arnon, 
Horton et al. 2013). 
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Figure 1.2: The structure of white pulp in mouse. 
T cells form the periarteriolar lymphoid sheath (PALS) around the central arteriole. B 
cell follicles are localised at the border of T-zone. The marginal zone area forms the 
border of white pulp, and it is directly connected with central arteriole. Cited and 
modified from Mebius et al. (Mebius and Kraal 2005).  
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Surrounding the white pulp, the collecting veins and the venous system form the red 
pulp of the spleen (Fig. 1.3) (Mebius and Kraal 2005). When arterial branches end in 
the cords of red pulp, the blood contains a large fraction of old erythrocytes, which 
not only gives the red pulp the “red” colour, but highlights the spleen’s function to 
filter blood and recycle iron (MacDonald, Ragan et al. 1987, Knutson and Wessling-
Resnick 2003, Mebius and Kraal 2005).  
 
  
 
 
 
Figure 1.3: The schematic structure of spleen in mouse.  
 
The white pulp is formed at the end of afferent splenic arterioles branches. This 
structure consists of T-zone (also known as PALS, green), B cell follicles (white) and 
marginal zone around T zone and B cell follicles (purple). Surrounding the white pulp 
is the red pulp, this structure spreads along the collecting vein and is comprised of the 
venous sinus and sinus cords, lined by discontinuous epithelial cells. Cited and 
modified from Mebius et al. (Mebius and Kraal 2005). 
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The highly organised structure of white pulp is dynamically regulated by chemokine 
receptors and chemokines. Follicular stromal cells, such as follicular dendritic cells 
(FDCs) and marginal zone reticular cells, both highly express CXCL13 (Forster, 
Mattis et al. 1996, Cyster, Ansel et al. 2000, Katakai, Suto et al. 2008). The high 
concentration of CXCL13 in B cell follicles attracts CXCR5 expressing B cells by 
chemotaxis into follicles. While stromal cells within the T zone highly express 
CCL19 and CCL21, which forms a chemokine gradient from the T zone to outer 
regions. T cells and DCs, with higher CCR7 expression on their surface are sensitive 
to this gradient and chemotaxis to locate in T zone (Forster, Schubel et al. 1999, 
Okada and Cyster 2007, Forster, Schubel et al. 2016).  CCR7 is also expressed on 
naïve mature B cells, although normally at lower level compared to T cells. After 
cognate antigen recognition and activation, B cells up-regulate CCR7 expression and 
chemotaxis through the CCL19/CCL21 gradient (Okada, Ngo et al. 2002, Phujomjai, 
Somdee et al. 2016). Newly generated plasmablasts or plasma cells migrate to the 
border of white/red pulp through chemotaxis, forming plasma clusters in the red pulp 
(MacLennan, Toellner et al. 2003). This delicate location ensures antigen-specific 
antibodies produced by these plasma cells rapidly enter into the blood stream for 
effective function. 
 
 
1.3 Two types of immune responses 
	
According to the different nature of antigens, B cell responses have been generally 
divided into two different classes: T cell dependent immune responses (T-D response) 
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and T cell independent response (T-I response). These are classified not only 
according to the nature of antigens, but also the B cell populations recruited and the 
different processes undergone during the responses. 
 
1.3.1 T-I immune response  
	
T-I immune responses are induced by antigens which can directly activate B cells to 
function through Toll-like receptors (TLRs) or BCRs, without the requirement for T 
cell co-stimulation help. Depending on the nature of antigens and their different 
distinct cognate receptors, T-I immune responses have been further divided into type I 
and type II (Mosier, Mond et al. 1977, de Vinuesa, Cook et al. 2000).  
 
Type I antigens are mitogenic stimuli which activate poly-clonal B cells via TLRs 
regardless of the specificity of BCRs. Typical Type I antigens are lipopeptides, 
lipopolysaccharide (LPS), CpG, poly-IC, some viral-coating particles and pathogenic 
nucleic acids (Bekeredjian-Ding and Jego 2009). These antigens mainly induce the 
production of extra-follicular plasma cells (Martin, Oliver et al. 2001), without the 
need for co-stimulatory help from T cells. And this process usually occurs faster than 
T-D immune response.  
 
Type II antigens are polysaccharide antigens which are present in the capsules of 
pathogenic bacteria or viruses (Garcia de Vinuesa, O'Leary et al. 1999). These highly 
repetitive structures activate B cells through surface BCRs and are dependent on the 
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signal transmitted through Bruton’s tyrosine kinase (Btk) (Amsbaugh, Hansen et al. 
1972). Still, the main B cell product from a TI-2 immune response is extra-follicular 
plasma cells. These antigens are able to elicit strong and long-term primary antibody 
responses (Garcia de Vinuesa, O'Leary et al. 1999). Germinal centres have been 
reported to be rapidly induced and of short duration in TI-2 immune responses. 
Different from germinal centres in T-D immune responses, only very low levels of 
somatic mutations and class switching have been observed in TI GC B cells. T cells 
are thought to be dispensable for the activation of B cells and initiation of TI GC 
responses (Lentz and Manser 2001). Besides plasma cells and GC B cells, studies 
have shown that TI-2 antigens can induce the generation of memory B cells and elicit 
antigen-specific recall response (Obukhanych and Nussenzweig 2006). 
 
Labour is divided between different B cell populations for different immune 
responses. Along with B1 cells, MZ B cells have been reported to be the dominant B 
cell population in the early T-I immune response (Martin, Oliver et al. 2001). MZ B 
cells respond through the generation of plasma cells and produce large amounts of 
IgM as the first wave of defence. 
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1.3.2 T-D immune response 
	
In T-D immune responses, the full activation of antigen-specific B cells for functional 
terminal differentiation requires the presence of co-stimulation signals from T cells 
(Feldmann and Easten 1971). Compared with T-I antigens, T-D antigens are normally 
proteins which have relatively complicated structures (Stein 1992). The recognition of 
these antigens through BCRs is strictly in compliance with BCR specificity. Antigens 
are captured and processed by APCs, such as DCs and B cells. The processed 
antigens need to be presented by Major Histocompatibility Class II (MHCII) 
molecules on the surface of APCs to initiate the activation of T cells (MacLennan, 
Gulbranson-Judge et al. 1997). In T-D immune responses, only after having received 
the initial activation signal from the BCR and followed by the co-stimulation 
signalling from T cells, can B cells be fully activated (Van den Eertwegh, Noelle et al. 
1993). The close contact of T and B cells happens at the T-B border in secondary 
lymphoid organs (Garside, Ingulli et al. 1998). Guided by surface chemokine 
receptors, activated B cells move from B cell follicle to the T-B border, where 
activated T cells also move towards. During this close T-B interaction, T cell 
receptors (TCRs) on the T cell surface recognize cognate MHCII-peptide complex 
presented by activated B cells. Then, activated T cells deliver co-stimulation signals 
such as CD40L or cytokines to fully activate B cells (Hollenbaugh, Grosmaire et al. 
1992, Lane, Brocker et al. 1993). Adhesion molecules such as LFA-1 and ICAM-1 
have also been reported to be involved in this process for the stable formation of T-B 
contact (Noelle and Snow 1990, Armitage, Macduff et al. 1993).  
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The dominant B cell population responding to T-D antigens is follicular B cells (Fo B 
cells). One hallmark feature of the T-D immune response is the formation of germinal 
centres, where affinity maturation takes place (MacLennan 1994). The early products 
from T-D immune response are GC-independent plasma cells and memory B cells. 
After the maturation of GCs, plasma and memory B cells are the outputs of GCs, and 
these are normally class-switched and contain hyper-mutations on their BCRs 
(MacLennan 1994, Toellner, Gulbranson-Judge et al. 1996, Methot and Di Noia 
2017).  
 
1.3.3 Hapten: (4-hydroxy-3-nitrophenyl)acetyl 
	
C57BL/6 mice consistently produce anti-(4-hydroxy-3-nitrophenyl)acetyl (NP) 
antibodies (Imanishi and Makela 1974). VDJ sequences encoding for this in-frame 
IgH gene rearrangement were cloned and BCR knockin mouse models were 
constructed (Reth, Hammerling et al. 1978, Bartlett, Kohan et al. 1979, Cascalho, Ma 
et al. 1996, Sonoda, Pewzner-Jung et al. 1997). These mouse models are widely used 
to help us reveal fundamental knowledge of B cell biology. NP-specific cells can be 
followed by flow cytometry and histology to study both T-I and T-D immune 
responses. Antibody maturation toward NP can be followed by ELISA. Key 
mutations on canonical VDJ regions during affinity maturation toward NP are 
identified. These together make NP the most widely used hapten in B cell research 
field. After conjugated with Ficoll, the synthetic polymer sucrose with high molecular 
weight, the product – NP-Ficoll can serve as a T-independent type II antigen (Inman 
1975). When NP conjugated with chicken gamma globulin (CGG), the product – NP-
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CGG can recruit B cells into T-D immune responses (Azuma, Sakato et al. 1987). In 
this study, we mainly used these hapten-conjugates to study T-I and T-D immune 
responses.  
 
1.4 B cell fate decisions after activation 
	
The first step to activate B cells is their engagement with antigens. This engagement 
is normally BCR dependent, like TI-2 and T-D immune responses, or in vivo TI-1 
immune response (Garcia De Vinuesa, Gulbranson-Judge et al. 1999). Follicular B 
cells have no direct access to blood-borne antigens. Opsonized antigens are 
transported by marginal zone B cells from marginal zone to follicles (Arnon, Horton 
et al. 2013). As the major population of re-circulating B cells, Fo B cells circulate 
between secondary lymphoid organs through blood and lymph (Nieuwenhuis and 
Ford 1976), where they can directly contact antigens and then selectively migrate to 
the spleen (Liu, Zhang et al. 1991, Toellner, Gulbranson-Judge et al. 1996). Unlike Fo 
B cells, MZ B cells do not recirculate. Located close to the marginal sinus, they are 
well-positioned within secondary lymphoid tissue to directly contact blood-borne 
antigens. In addition, they can also retrieve intact bacterial antigen from blood-borne 
immature DCs (Balazs, Martin et al. 2002). 
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1.4.1 The generation of plasma cells 
 
One major source of plasma cells generated is the extra-follicular response. In the 
spleen, after activation by T-I antigens, both B1 and MZ B cells are directly activated 
and differentiate into plasmablasts or plasma cells in the extra-follicular foci of spleen 
(Martin, Oliver et al. 2001). During T-D immune response, after stable contact with 
primed-T cells, activated B cells develop into GC precursor B cells, MBCs or 
plasmablasts. These plasmablasts reside in the extra-follicular foci of spleen or 
medullary cords of LN to generate PCs (MacLennan, Toellner et al. 2003).  
 
An alternative pathway for plasma cell generation is the germinal centre response (see 
chapter 1.4.2). Germinal centres are sites where antigen-specific activated B cells 
undergo affinity maturation (Klein and Dalla-Favera 2008, Zhang, Garcia-Ibanez et al. 
2016). As a transient B cell population, GC B cells ultimately differentiate into PCs or 
MBCs and output from GCs to exert immune functions. Unlike PCs generated during 
the extra-follicular response, GC-dependent PCs are normally class switched and have 
relatively high affinity toward the specific antigens (Shlomchik and Weisel 2012). 
 
1.4.2 Germinal centres and GC B cells 
	
As transient micro-anatomical structures, GCs are normally observed during T-D 
immune responses within secondary lymphoid organs, such as the spleen and LNs 
(Klein and Dalla-Favera 2008, Gabriel and Michel 2012, De Silva and Klein 2015).  
GCs start with a small number of antigen-activated B cells that become destined to 
differentiate into GC B cells at the T-B border. GC founder B cells migrate back into 
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B cell follicles to seed the GC response (MacLennan, Liu et al. 1990, De Silva and 
Klein 2015). They undergo clonal expansion to form the initial GCs. The timing of	
the presence of GCs varies, depending on different antigens and routes of 
immunisation, from several days to weeks (Jacob, Kassir et al. 1991, MacLennan 
1994). When visualized in conventional histology, a well-formed GC can be divided 
into two compartments: Dark Zone (DZ) and Light Zone (LZ) (Fig. 1.4). The DZ is 
close to the T-zone, consists almost exclusively of highly proliferative GC B cells, 
which give them a “dark” appearance in conventional histology. While the LZ is 
proximal to the sub-capsular sinus in LNs, contains spreading FDCs networks, CD4+ 
follicular T help (Tfh) cells and B cells interspersed among them (Victora and 
Nussenzweig 2012, Zhang, Garcia-Ibanez et al. 2016).  
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Different cell distributions in LZ and DZ endow different functions to these two 
compartments. DZ is the place where clonal expansion and somatic hyper-mutation 
occur (Kepler and Perelson 1993, Oprea and Perelson 1997). Both AID and error-
prone DNA polymerase η are highly expressed in DZ GC B cells (Victora and 
Nussenzweig 2012, McHeyzer-Williams, Milpied et al. 2015). During this stage, 
immunoglobulin genes in GC B cells have been subject to a high rate of mutation. 
 
 
Figure 1.4: Schematic structure of a germinal centre. 
This structure has been divided into two parts: light zone (LZ) and dark zone (DZ). 
The LZ is composed of B cells, T cells and DCs, while DZ mainly consists of B 
cells. GC B cells are selected and triggered to proliferate in LZ and the majority of 
them migrate to DZ to complete their cell cycle and go through SHM. Cite and 
modified from De Silva et al (De Silva and Klein 2015). 
18	
	
Original BCRs are replaced with newly mutated ones before B cells re-enter into LZ 
for further selection. B cells bearing damaging mutated BCRs are induced into rapid 
death (Stewart, Radtke et al. 2018). DZ is the place for B cell clonal proliferation, 
with the majority of mitotic GC B cells concentrate in this area (Victora, Schwickert 
et al. 2010). LZ has been generally accepted as the place for GC B cell selections. It is 
less compact and contains diverse cell populations, such as FDCs, Tfh and B cells 
(Mesin, Ersching et al. 2016). FDCs in LZ mainly display antigens on their surface 
and provide a platform for BCR dependent antigen-driven selection (Zhang, Meyer-
Hermann et al. 2013).  Besides BCR affinity, limited help signalling from Tfh cells 
has been reported to be another LZ selection point in GC response (Meyer-Hermann, 
Maini et al. 2006, Gitlin, Shulman et al. 2014, Gitlin, Mayer et al. 2015).  
 
LZ and DZ GC B cells are less different than previously expect, they can hardly be 
distinguished by size and morphology (Allen, Okada et al. 2007, Hauser, Junt et al. 
2007, Schwickert, Lindquist et al. 2007). Both of them are larger than unstimulated 
Fo B cells (Victora, Schwickert et al. 2010). Currently markers to distinguish these 
two populations by flow cytometry are identified. CXCL12 expression is enriched in 
DZ micro-environment (Bannard, Horton et al. 2013). Before re-entry into DZ, LZ 
GC B cells up-regulate CXCR4 expression to enable chemotaxis to DZ area (Allen, 
Ansel et al. 2004, Victora, Schwickert et al. 2010). Thus, surface markers CXCR4 and 
CD86 (or CD83) have been suggested to be used for identifying these two sub-
populations, with CXCR4  highly expressed on DZ GC B cells, while CD86 (CD83) 
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expressed at higher level on LZ GC B cells (Allen, Okada et al. 2007, Schwickert, 
Lindquist et al. 2007, Victora, Schwickert et al. 2010). 
 
GC B cells fate decisions happen during GC response. LZ GC B cells can either re-
enter the DZ, or generate output as GC-derived plasma cells and GC-derived MBCs. 
Plasma cells have been observed to leave GC through GC-T zone interface (Zhang, 
Tech et al. 2018), while MBCs leave the GC by migration  towards the sub-capsular 
sinus (Moran, Nguyen et al. 2018). (Decision events in the Germinal Centre: the role 
of ACKR4, LAURA GARCIA-IBANEZ, published thesis, 2016) 
 
1.4.3 The generation of memory B cells 
	
Over the years, MBCs have been defined as antigen specific, Ig class switched, non-
plasma and non-GC B cells. Despite the fact that the existence of non-switched IgM+ 
MBCs and non-mutated MBCs has long been known (Takahashi, Ohta et al. 2001, 
Dogan, Bertocci et al. 2009). Recently, several subpopulations of MBCs have been 
defined, which has led to a broadening of the definition of MBCs to be the population 
of cells which are resting, antigen-experienced and long-lived derived from the initial 
stimulus (Shlomchik and Weisel 2012). The maintenance of their long-term survival 
is antigen and T cell independent (Yefenof, Sanders et al. 1986, Maruyama, Lam et al. 
2000, Gagro, Toellner et al. 2003, Good, Avery et al. 2009), but, require B-
lymphocyte stimulator (BLyS/BAFF/TNFSF13B) (Scholz, Crowley et al. 2008). 
When re-challenged with the same antigen, MBCs can be activated more easily and 
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rapidly by either differentiating into plasma cells or re-entry into GCs (Kurosaki, 
Kometani et al. 2015, Moran, Nguyen et al. 2018).  
 
The fate decisions of memory B cells also occur at two stages. During early T-B 
interactions at the T-B border, a proportion of antigen-activated B cells would commit 
to the MBC fate. These MBCs are called GC independent memory B cells, and they 
can be isotype switched, but typically harbour very few mutations on their BCRs 
(Kurosaki, Kometani et al. 2015). The mechanism of fate decision at this stage 
remains unclear. Studies have shown that B cells with higher affinity are more prone 
to differentiate into plasma cells on T-B border (Paus, Phan et al. 2006), indicating B 
cells with lower affinity BCRs possibly would differentiate into MBCs. The second 
MBC generation pathway is GC dependent, supported by isotype switching and 
immunoglobulin hyper mutation observed in part of MBCs (McHeyzer-Williams and 
McHeyzer-Williams 2005). MBC fate decision in GCs is not fully understood either. 
According to a recent study, GC B cells with lower BCR affinity have higher 
expression of Bach2, which leads to the commitment of MBC fate (Shinnakasu, Inoue 
et al. 2016).  
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1.5 B cell development 
	
	
1.5.1 B cell development pathway 
 
In the fetus, B cells are primarily generated in the liver. However, in proceeding 
developmental stages, especially in adult, B cells are mostly produced in the bone 
marrow (BM) and mature in the spleen (Fig. 1.5). B cells are derived from 
multipotent hematopoietic stem cells (HSCs). The first descendants of HSCs are 
multipotent progenitor cells (MPPs). This cell population has the potentiality to give 
rise to all lymphocyte lineages. Signalling from FLT3, a receptor on MMP surface, 
drives the differentiation of MMPs into common lymphoid precursor cells (CLPs) 
(Adolfsson, Borge et al. 2001). CLPs are the direct precursor cells of B lymphocytes 
linage, as well as T lymphocytes and innate lymphoid cells (ILCs). The expression of 
B-lineage-specific transcription factor E2A, combined with induction of early B-cell 
factor (EBF) together promote ILCs to differentiate into pro-B cells (Lin, 
Jhunjhunwala et al. 2010). Pro-B cells are the first cell population to express B cell 
linage surface marker B220 (CD45). Sufficient expression of transcription factor Pax5 
is necessary for pro-B cells to further mature into pre-B cells and to immature B cell 
stage (Nutt, Heavey et al. 1999).  
 
Germline heavy chain V-D-J segments begin random re-arrangement during pro-B 
cell stage. The re-arranged μ chain, together with two surrogate light chains can be 
transiently expressed on the surface of pre-B cells (Karasuyama, Rolink et al. 1996). 
Light chain encoding segments start to re-arrange at the late stage of pre-B cells and 
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complete at immature B cell stage. This allows for the expression of mature IgM 
BCRs on the membrane of immature B cells.  
 
Around a quarter of immature B cells mature in BM from T2 cells directly into Fo B 
cells (Cariappa, Chase et al. 2007, Lindsley, Thomas et al. 2007). The majority of 
immature B cells emigrate from the BM to the periphery for further maturation. 
Shortly after emerging from BM, immature B cells become transitional 1 (T1) B cells 
and migrate to B cell follicles in secondary lymphoid organs to complete final 
maturation (Pillai and Cariappa 2009). T1 B cells mature into T2 B cells. Depending 
on their tonic BCR signalling strength, T2 B cells then differentiate into MZ B cells 
and Fo B cells (Pillai, Cariappa et al. 2005). However, recently it was shown that MZ 
B cells can directly differentiate from T1 B cells (Hammad, Vanderkerken et al. 2017). 
The existence of a third transitional B cells (T3 B cells) is described, they are 
AA4.1+CD23+IgMlow (Allman, Lindsley et al. 2001), an immature B cell population 
with typical follicular B cells surface markers. T3 B cells have been suggested to be 
the reservoir of physiological anergic B cells (Merrell, Benschop et al. 2006). 
 
MZ B cells and Fo B cells are named after their locations. MZ B cells are located at 
the marginal zone area around the B cell follicle, characterised by a low level of IgD 
and high level of CD21 expression on their cell surface membrane (Stein, Bonk et al. 
1980). Fo B cells are seated at the follicular region adjacent to T zone and is the 
dominate B cell population in the periphery, expressing high levels of IgM, IgD and 
CD23.  
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Figure 1.5: B cell and B cell receptor development. 
B cell development is accomplished in a two-stage process. The differentiation of 
hematopoietic stem cells (HSCs) to immature B cells takes place in bone marrow. 
Immature B cells then migrate from bone marrow to periphery, mainly in spleen, to 
complete B cell maturation. B cell receptors develop along with B cells, during bone 
marrow stage, and only IgM is expressed on the cell surface of B cells. The expression 
of IgD begins from transitional B cell stage in the spleen and on all mature B cells 
surface. Cited and modified from Janeway’s Immunobiology 9th Edition (Murphy and 
Weaver 2017). 
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1.5.2 B cell receptor development 
 
The B cell receptor simultaneously matures and plays decisive roles during B cell 
development (Fig. 1.5). BCRs are membrane-bound immunoglobulins, with two 
identical heavy chains and two identical light chains. They also contain trans-
membrane and cytoplasmic regions to help them anchor to B cell surface membrane. 
Both heavy and light chains can be further divided into two parts; the variable region 
and the constant region. The variable region is the product of random re-arrangement 
of V-D-J segments of the Ig heavy chain encoding region, or V-J segments in the light 
chain encoding region. This re-arrangement brings diversity to BCRs. Further P 
nucleotide insertions (palindromic) by recombination activation genes (Rags) and 
non-templated nucleotides (N regions) insertions by terminal deoxynucleotidyl 
transferase (TdT) add to this diversity (Sobacchi, Marrella et al. 2006). The wide 
spectrum of BCR repertoire enables B cells to specifically recognise any potential 
foreign antigens. After re-arrangement, the gene combination encoding for the 
variable region and the unique footprint of the V-D-J junction area in CDR3 is a 
unique sequence identity in each B cell and can be used to identify B cell clones. 
 
The re-arrangement of heavy chain D-J genes starts firstly in the CLPs, and normally 
finishes at early pro-B cells. Next is V-DJ rearrangement, which also takes place in 
the pro-B cell stage. After VDJ re-arrangement, the first heavy chain – μ chain, 
combined with surrogate light chain can be assembled to express pre-BCRs 
transiently expressed on the surface of pre-B cells (Karasuyama, Rolink et al. 1996). 
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The signalling capability of the pre-BCR complex is tested during this stage, and only 
the pre-BCRs which can transduce effective down-stream signalling would be 
selected to survive for further differentiation (Karasuyama, Rolink et al. 1994). This is 
the positive selection during B cell development. Positively selected pre-B cells go 
through light chain V-J re-arrangement, and generate the first mature IgM BCR and 
display this on the cell-surface membrane of immature B cells. Auto-reactivity of 
BCRs will be checked during immature B cell stage. Only B cells with no or weak 
self-binding are allowed for further peripheral maturation (Meffre and Wardemann 
2008, Pelanda and Torres 2012). Once entered into the periphery, immature B cells 
develop into transitional B cells and their BCRs are tested further for auto-reactivity 
during T1 stage (Meffre and Wardemann 2008). Cells permitted for further 
maturation become mature B cells and express IgD on their cell surface membrane as 
well. IgM and IgD co-expressed on the same B cell share the same antigen specificity, 
as they are generated by alternative mRNA splicing using the same variable region 
genes for both (Enders, Short et al. 2014).  
 
According to the different structures of their heavy chains, BCRs have been divided 
into five classes or isotypes; IgM, IgD, IgG, IgE and IgA (Bengten, Wilson et al. 
2000). Each class of BCRs can be further divided into subclasses, according to the 
subtle difference of their heavy chains as well, such as IgG1, IgG2a under IgG. Naïve 
B cells only express IgM and IgD, with marginal zone B cells expressing much lower 
levels of IgD than follicular B cells. Activated B cells can go through a process called 
class switch recombination, after which they start to express the other isotypes 
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(Chaudhuri and Alt 2004). This thesis will mainly focus on IgM and IgG1 and their 
downstream signalling. Downstream signalling events will be further reviewed in 
Chapter 3.  
 
 
1.5.3 Negative selection during B cell development 
 
The diversity of BCR repertoire comes from random re-arrangement, but, so does 
auto-reactivity. Thus, our immune system employs negative selection during B cell 
development to detect these self-reactive cells, and either eliminate or modify them to 
avoid potential risks. This elimination or inactivation of self-reactive immature B 
cells in BM is called central tolerance. The mature IgM BCR is expressed on the outer 
cell membrane of B cells at immature B cell stage. Unlike pre-BCR, the mature BCR 
has fully re-arranged light and heavy chains, providing each BCR with unique antigen 
specificity. The first negative selection happened during the stage during BM 
development (Pelanda and Torres 2012). According to recent studies, immature B 
cells are tested by self-antigens displayed in the micro-environment of BM. If surface 
BCRs strongly bind to self-antigen, the corresponding B cell is induced to enter 
apoptosis (Brink and Phan 2018). Alternatively, their Ig light chain genes can go 
through several rounds of re-arrangement which may reduce self-reactivity of the 
newly formed BCRs and rescue these cells, a process called light chain editing (Prak, 
Trounstine et al. 1994, Prak and Weigert 1995). BCRs with medium to weak self-
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binding can survive through this primary negative selection, however, they will be 
induced into a non- or low-responsive state of anergy (Brink and Phan 2018).  
 
B cell central tolerance induction is not perfect. In some cases, self-reactive B cells 
can be permitted to enter into the periphery, such as self-reactive B cells which are 
specific for tissue limited antigens, which has been called clonal ignorance (Goodnow 
1992). Thus, to enable their further development in the periphery, B cells have to be 
selected again based on the strength of self-reactivity. Peripheral tolerance takes place 
in transitional 1 stage, immediately after immature B cells enter into periphery (Jacobi 
and Diamond 2005). B cells strongly reacting with self-antigens displayed at this 
stage are eliminated immediately. If this binding is medium to weak, B cells can be 
induced to become anergic B cells. 
 
Self-reactive B cells that survive both central and peripheral negative selection enter 
the mature B cell pool as anergic B cells. 
 
 
1.6 B cell anergy 
 
1.6.1 General introduction of anergic B cells 
 
The functional silence of self-antigen specific B cells in Hen Egg Lysozyme (HEL) 
specific B cell receptor (BCR) transgenic mouse model was first described by 
Goodnow et al (Goodnow, Crosbie et al. 1988). The general concept of B cell anergy 
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has been developed based on this and related mouse models (Glynne, Ghandour et al. 
2000, Burnett, Langley et al. 2018).  
 
B cell anergy is defined by the absent or reduced activated downstream signalling in 
B cells after activation through B cell receptors only (Goodnow, Crosbie et al. 1988). 
Contrary to what would be expected, 75% of the immature B cells to some degree 
display self-binding ability (Wardemann, Yurasov et al. 2003), and anergic B cells 
have been estimated to account for as much as 20-30% of peripheral mature B cells 
pool (Grandien, Fucs et al. 1994, Wardemann, Yurasov et al. 2003). Healthy 
individuals silence these auto-reactive B cells, which are probably involved in the 
sudden breakout of auto-immune disease in some individuals (Wardemann, Yurasov 
et al. 2003, Smith, Packard et al. 2015). In homo sapiens, the use of heavy chain VH4-
34 has been reported to lead to self-binding, and cannot be rescued by light chain 
editing (Pugh-Bernard, Silverman et al. 2001). Despite this, there are still 0.5% of 
total serum antibodies containing the VH4-34 heavy chain within normal healthy 
individuals (Stevenson, Smith et al. 1989). These observations inevitably lead to one 
question: why does our immune system not eliminate these potentially auto-reactive B 
cells in the first place? Currently clonal redemption is the most widely accepted 
explanation, and was well-supported by experiments from Goodnow’s Lab (Sabouri, 
Schofield et al. 2014, Burnett, Langley et al. 2018). According to this theory, anergy 
is there to prevent the generation of holes in the primary B cell repertoire, as many 
pathogens adopt molecular mimicry to mimic self-antigens to evade immune 
surveillance (Pinschewer, Perez et al. 2004, Scherer, Zwick et al. 2007, Gristick, von 
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Boehmer et al. 2016).  Despite being silenced through negative selections during 
tolerance induction, anergic B cells are allowed to be recruited into responses to self-
crossreactive pathogens by entering GCs. During GC reactions, these recruited 
anergic B cells would be redeemed through mutating away from self-reactivity and 
accumulating affinity to foreign antigens (Sabouri, Schofield et al. 2014, Burnett, 
Langley et al. 2018). More detailed information on this topic will be reviewed in 
chapter 4.  
 
1.6.2 Characteristics of anergic B cells 
 
The most recognised and the defining feature of anergic B cells is impaired or absent 
down-stream BCR signalling. BCR signalling is usually measured by calcium 
mobilisation and phosphorylation of SYK, Igα and Igß, after stimulation through 
BCRs. In most of the anergic mouse models, there are no or reduced calcium 
mobilisation and reduced phosphorylated SYK, Igα and Igß (Erikson, Radic et al. 
1991, Goodnow, Brink et al. 1991, Benschop, Aviszus et al. 2001). The maintenance 
of this non-responding or low-responding state after activation through BCRs requires 
constant self-antigen occupancy (Gauld, Benschop et al. 2005). The weak constant 
stimulation from self-antigen can result in higher intracellular calcium mobilization 
and higher tonic phosphorylation levels, as observed in some anergic models 
(Goodnow, Brink et al. 1991, Benschop, Aviszus et al. 2001, Culton, O'Conner et al. 
2006). This constant surface BCR and auto-antigen interaction are regarded to be the 
cause for down-regulation of surface IgM as well. Studies have shown that this down-
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regulation is due to post-translational modification rather than reduced mRNA 
expression levels (Glynne, Ghandour et al. 2000). The lower surface IgM expression 
on B cells has been observed in most of the anergic models and is used to define 
anergic B cells in humans (Erikson, Radic et al. 1991, Goodnow, Brink et al. 1991, 
Benschop, Aviszus et al. 2001, Borrero and Clarke 2002, Duty, Szodoray et al. 2009).   
 
Additional characteristics of anergic B cells can be observed in some but not all 
anergic models. Following adoptive transfer of HEL-specific anergic B cells into WT 
mice, Cyster et al. have found that these anergic B cells are excluded from entry into 
B cell follicles, but are instead unusually localised to the T-B border (Cyster, Hartley 
et al. 1994). These B cells express higher levels of CCR7 on their surfaces and are 
more sensitive to the CCL19/CCL21 chemokine gradient, indicating a hyper-activated 
basal state (Cyster, Hartley et al. 1994). This exclusion of follicle entry has been 
observed in some models (Mandik-Nayak, Bui et al. 1997, Noorchashm, Bui et al. 
1999), however, in other models, anergic B cells can localise to follicles normally 
(Noorchashm, Bui et al. 1999, Borrero and Clarke 2002). Besides altered localisation 
to unusual anatomical sites, anergic B cells can also experience developmental 
blockade. In some models, studies have shown a remarkably biased cell 
differentiation into T3 B cells in periphery (Goodnow, Crosbie et al. 1989, Merrell, 
Benschop et al. 2006). T3 cells have been regarded to be the pool of natural anergic B 
cells (Merrell, Benschop et al. 2006). In addition to the transitional stage, the 
immature B cell stage is another critical auto-reactivity check point, and in some 
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models B cells have been shown to be blocked at the immature stage (Erikson, Radic 
et al. 1991, Nguyen, Mandik et al. 1997).  
 
It has been reported that anergic B cells normally have a shortened life span (Fulcher 
and Basten 1994, Mandik-Nayak, Seo et al. 2000). And this phenomenon has been 
observed in some of anergic mouse models, however, an almost equal number of 
mouse models also show that the life-span of anergic B cells is normal (Rojas, 
Hulbert et al. 2001, Cambier, Gauld et al. 2007). According to current studies, the 
decreased life-span of anergic B cells is not due to their intrinsic defect (Cyster, 
Hartley et al. 1994), but because they are less competitive to occupy the limited 
survival niche than non-anergic B cells (Cyster, Hartley et al. 1994, Cyster and 
Goodnow 1995, Mackay, Schneider et al. 2003). 
 
Overall, the phenotypes of anergic B cells vary among different anergic models. The 
diversity of these anergic phenotypes can be partly explained by BCR self-antigen 
recognition characteristics, such as affinity for that self-antigen and sites of 
encountering the antigen (Erikson, Radic et al. 1991, Santulli-Marotto, Retter et al. 
1998, Benschop, Aviszus et al. 2001, Rojas, Hulbert et al. 2001, Cambier, Gauld et al. 
2007).  It seems that BCR/ligand binding strength and subsequent BCR downstream 
signalling still play a decisive role on the phenotypic outcome of anergic B cells. 
 
These studies have shed light on B cell anergy and helped to reveal the break of 
tolerance of anergic B cells in auto-immune diseases. However, the questions of how 
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are these anergic B cells regulated in healthy individuals to avoid autoimmunity and 
why does our immune system preserve such a large proportion of these silenced auto-
reactive B cells in the periphery, still wait to be answered. 
 
1.7 B cell receptor signalling and B cell fate decision 
	
	
1.7.1 B cell receptor signalling 
	
B cell receptor signalling starts with the engagement of a BCR with cognate antigen. 
For years, observations on initiation of BCR signalling have been interpreted as the 
cross-linking of BCRs (Metzger 1992, Minguet, Dopfer et al. 2010). However, BCR 
segregation model promoted by Reth et al. have shown that BCRs are intrinsically 
prone to form oligomers on resting B cells, and the initiation of BCR signalling 
requires the segregation of these oligomers to form clustered monomers (Yang and 
Reth 2010).  
 
Possessing short cytoplasmic regions, mIgM and mIgD expressed on naïve B cell 
surface merely transduce a BCR-antigen binding event into signal that can be 
propagated. They achieve this by signalling through their non-covalently associated 
co-receptors: CD79a (Igα) and CD79b (Igß) (Campbell and Cambier 1990, Hombach, 
Tsubata et al. 1990). These two co-receptors have short extracellular regions, but have 
extended cytoplasmic tails containing immunoreceptor tyrosine-based activation 
motifs (ITAMs) (Yao, Flaswinkel et al. 1995). The ligation of the BCR with cognate 
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antigen leads to the phosphorylation of ITAMs in CD79a and CD79b (Gold, 
Matsuuchi et al. 1991). Following the phosphorylation of ITAMs, Src-family kinase 
(SFK), such as LYN in B cells, binds to this phosphorylation site through Src-
homology 2 (SH2) and upregulates its kinase activity to further phosphorylate ITAMs 
(Johnson, Pleiman et al. 1995). SYK then binds to dual phosphorylated ITAMs 
through its SH2 domain. This binding leads to SYK phosphorylation and activation 
(Kurosaki, Johnson et al. 1995, Rowley, Burkhardt et al. 1995). Activated SYK can 
then phosphorylate the adaptor protein B-cell linker (BLNK, SLP-65) (Kabak, Skaggs 
et al. 2002).  
 
Activated phospho-BLNK serves as a platform to recruit a group of proteins for the 
propagation of multiple down-stream pathways. Among them are: Bruton’s tyrosine 
kinase (Btk), Phospholipase C-gamma 2(PLCγ2) and Vav-1 (Fu, Turck et al. 1998). 
Btk phosphorylates its closely contacted PLCγ2, which then cleaves phosphoinositide 
PI(4,5)P2 to generate second messengers IP3 and DAG (Ransom, Harris et al. 1986). 
Additionally, activated LYN phosphorylates the cytoplasmic tail of CD19, creating a 
binding site for phosphoinositide-3-kinase (PI-3K). PI-3K phosphorylate PI(4,5)P2 to 
generate another critical second messenger Phosphatidylinositol 3,4,5-triphosphate 
(PI(3,4,5)P3). 
 
Through binding to IP3 receptor, IP3 leads to both release of intracellular Ca2+ and the 
influx of extracellular Ca2+ (Hogan, Lewis et al. 2010). Ca2+ is required for the 
activation and translocation of nuclear factors such as nuclear factor kappa B (NF-κB) 
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and nuclear factor of activation T cells (N-FAT) (Su, Guo et al. 2002). DAG signals 
through binding to Ras guanyl nucleotide-releasing protein (RasGRP) and the protein 
kinase C family, such as PKCβ in B cells, to regulate the mitogen-activated protein 
kinase (MAPK) family (Guo, Su et al. 2004, Roose, Mollenauer et al. 2007). The 
downstream branched distal signals together drive the biological events, including; 
cell activation, proliferation, differentiation and antigen-presentation.  
	
1.7.2 B cell receptor signalling and B cell development 
 
B cell receptor signalling has been generally divided into ligand-induced signalling 
and tonic signalling. Both pre-BCR and BCR tonic signalling, at least at minimally 
sufficient levels, are transduced by Igα and Igß, without the need for BCR co-
expression (Bannish, Fuentes-Panana et al. 2001, Fuentes-Panana, Bannish et al. 
2005). Studies have shown that BCR signalling and its strength play important roles 
and can affect B cell fate decisions during B cell maturation (Niiro and Clark 2002, 
Monroe 2006, Pillai and Cariappa 2009). At pre-B cell stage, only B cells with 
functional tonic signalling through pre-BCR can survive for further development. 
During immature B cell stage, the affinity of BCR toward self-antigens influences the 
fate of B cells. Immature B cells with strong self-binding are deleted or go through 
light-chain editing. The ones with intermediate to weak self-binding are induced into 
anergic state. A similar check point which still depends on the affinity of BCR toward 
self-antigen happens in transitional stage, inducing peripheral tolerance. 
 
35	
	
The fate decisions of peripheral MZ and Fo B cells depend in part on BCR signalling 
strength. During peripheral MZ B cell differentiation, BCR signalling has been 
reported to be critical for Taok3 activation and subsequent membrane expression of 
ADAM10. ADAM10 then cleaves Notch2 and CD23, which leads to the final 
commitment to MZ B cell fate (Gibb, El Shikh et al. 2010, Hammad, Vanderkerken et 
al. 2017). Genetically manipulated mice with altered BCR signalling have shown that 
lower BCR signalling favours MZ B cell fate, and transitional B cells with higher 
BCR signalling strength are prone to differentiate into Fo B cells (Cariappa, Tang et 
al. 2001, Samardzic, Marinkovic et al. 2002).  However, a recent study showed that 
lacking secreted IgM leads to increased BCR signalling and enhanced MZ B cell 
differentiation (Tsiantoulas, Kiss et al. 2017). Despite BCR signalling strength and its 
role in mature B cell fate commitment remaining open for debate, these studies 
suggest that mature B cell fate decisions are tightly connected with BCR signalling 
strength.  
 
Besides tonic BCR signalling, ligand-binding BCR signalling strength has also been 
suggested to be involved in MZ or Fo fate commitment decisions. Studies have shown 
that silenced or non-silenced self-reactive B cells are retained in the mature Fo B cell 
compartment (Wardemann, Yurasov et al. 2003, Zikherman, Parameswaran et al. 
2012), indicating that self-ligand binding BCR signalling possibly promotes Fo B cell 
fate.  
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Among these studies, one very useful transgenic reporter mouse is the Nur77-GFP 
reporter mouse. This is a BAC vector transgenic mouse in which the expression of 
GFP is under control of the regulatory region of the Nur77 coding gene Nr4a1 
(Zikherman, Parameswaran et al. 2012). Nur77 is an inducible orphan nuclear 
receptor. Its expression is rapidly up-regulated after receptor-antigen ligation in both 
T and B cells (Winoto and Littman 2002). In this transgenic or related mouse models, 
the expression of GFP is immediately induced after TCR or BCR activation, which 
enables us to visualise signalling strength and pattern in T and B cells (Zikherman, 
Parameswaran et al. 2012, Noviski, Mueller et al. 2018).  
 
 
1.7.3 B cell receptor signalling and B cell fate decision during GC response 
 
For years, we have known that the GC is where antigen-specific B cells achieve 
affinity maturation. This directed evolution towards higher affinity to a specific 
epitope is not a random process but is based on complicated selection within GCs. As 
mentioned earlier, immunoglobulin hyper-mutation occurs in the GC DZ, however, 
selection takes place in LZ. As the evolution of high affinity B cell clones requires the 
stepwise accumulation of many mutations, GC B cells need to cycle between the LZ 
and DZ. 
 
Currently there are two models to explain the selection mechanisms. The first is the 
“T cell centric” model. In this model, BCR affinity and signalling can be converted to 
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T-B interaction strength, and LZ GC B cells which receive stronger T cell co-
stimulation enter the DZ faster and undergo more cell cycles in DZ. This model has 
been conceived in different studies using different techniques (Batista and Neuberger 
2000, Allen, Okada et al. 2007, Schwickert, Victora et al. 2011, Gitlin, Mayer et al. 
2015). However, it has only helped us to understand regulation of GC B cells from LZ 
to DZ.  
 
Antibody-feedback is another model to explain LZ selection. According to this model, 
competition of GC B cells with different BCR affinities for the unlimited amounts of 
antigen displayed on FDC surfaces is achieved by a competition of B cells with 
antibody covering antigen epitopes on immune complexes presented by FDC (Zhang, 
Meyer-Hermann et al. 2013). Antigen – antibody binding kinetics would only allow 
higher affinity BCR variants to outcompete antibody covering the antigen and allow 
only higher affinity B cell variants to access, phagocytose, and present antigen to Tfh 
cells. This model can explain how an adequate continuously rising affinity selection 
threshold is achieved during the GC response, as antibody on immune complexes on 
FDC is continuously replaced by antibody variants produced by GC-derived plasma 
cells of ever increasing affinity. This generates adequate directional selection pressure 
leading to slow directional evolution towards rising affinity (Zhang, Garcia-Ibanez et 
al. 2016). 
 
A further hypothetical model is the BCR signalling based selection model. This model 
is not mutually exclusive with the T cell selection model. In fact, it laid the foundation 
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for T cell selection model. Studies have shown that B cells with higher affinity can 
better capture antigens and present increased p-MHCII complex to gain more T cell 
help (Gitlin, Shulman et al. 2014, Gitlin, Mayer et al. 2015), indicating an indirect 
effect of BCR affinity and signalling on GC B cell selection. 
 
BCR signalling has been reported to be repressed during the GC response (Khalil, 
Cambier et al. 2012) and GC B cells appear unresponsive after BCR stimulation by 
antigen in solution (Victora, Schwickert et al. 2010). However, a recent study has 
shown that BCR signalling in GC B cells can be effectively activated by antigens 
coated on immobilized plasma sheets (PMSs), suggesting the way of activating BCRs 
can be different in naïve and GC B cells (Nowosad, Spillane et al. 2016). Despite 
overall repressed BCR signalling in GC B cells, researchers have observed a small 
proportion of GC B cells which highly express GFP in Nur77-GFP reporter mice, 
with activated BCR signalling. These cells are mainly localised in the LZ of the GC, 
displaying a genetic pattern thought to be related with positive selection (Mueller, 
Matloubian et al. 2015). Recently, Luo et al. directly prove that BCR signalling is 
indispensable for retaining GC B cells in GC LZ (Luo, Weisel et al. 2018). Together, 
these observations indicate that BCR signalling can be directly involved in LZ 
selection during GC response.  
 
Except for the gain or loss function which BCR signalling plays during LZ selection, 
more insights come from fate decisions of different class-switched GC B cells. These 
B cells have different cytoplasmic regions and theoretically transduce varied down-
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stream signalling. IgE+ GC B cells, for example, are disfavoured during the GC 
response, and they mainly reside in the DZ and are likely to go through apoptosis 
(Yang, Sullivan et al. 2012, He, Meyer-Hermann et al. 2013). Although there is no 
direct evidence to show signalling differences in IgE+ and other isotype switched GC 
B cells, the only difference between them is the BCRs. 
 
Very recently, a study showed that GC B cells with damaging immunoglobulin 
mutations failed to enter into LZ, indicating BCR-dependent signalling is required for 
DZ GC B cells to re-enter LZ and complete the GC cycle (Stewart, Radtke et al. 
2018). 
 
Differences in BCR signalling and B cell activation in the GC can not only be derived 
from BCR/antigen binding affinity, but it can be intrinsically variable due to the 
activation state of B cells. While non-self-reactive normal naive B cells have been 
well studied, there is less information how changed signalling in anergic B cells 
affects their activation and selection during GC reactions. Chapter 4 in this study will 
focus on this topic. 
 
1.8 General aims of this thesis 
	
B cell receptor signalling strength plays a vital role in fate decisions during B cell 
development and B cell activation. Previous studies have shown that, compared to 
IgM, IgG1 or the addition of IgG1 cytoplasmic region to IgM is able to transduce 
hyper-activate BCR signalling. If there is a minimum BCR signalling threshold 
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needed to activate B cells, then, hypothetically, these hyper-activate B cells would get 
activated by lower-immunogenic antigens, unable to trigger activation in normal B 
cells. With this in mind, the IgMg1 mouse model was constructed. In this mouse, the 
IgG1 cytoplasmic region was inserted downstream of extracellular and 
transmembrane regions of IgM, preserving the complete germ-line VDJ repertoire. 
The general aim of this thesis is to characterise B cell development and differentiation 
in this newly constructed IgMg1 mouse model. 
 
Chapter 3 tests the hypothesis that hyperactive signalling of IgMg1 B cell receptors 
affects B cell development. B cell development and BCR signalling strength was 
followed in bone marrow and secondary lymphoid tissue in IgMg1 mice.  
Unexpectedly, chapter 3 shows that, rather than being hyper-activated, B cells 
produced in IgMg1 mice are anergic. Chapter 4 therefore tests how changed BCR 
signalling in anergic B cells affects the B cell response to T-I and T-D antigens, with 
a special focus on dynamic changes during the GC reaction.  
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Chapter 2 . Material and methods 
 
2.1 Mice 
 
Mice were bred and maintained under specific pathogen-free conditions at the 
Biomedical Services Unit, University of Birmingham, UK. All animal experiments 
were approved by the institutional ethics committee and the Home Office UK (Project 
license: PEAE5FA92). Mice were aged 6 - 10 weeks. For ageing experiment, mice 
were aged beyond 27 weeks. 
 
2.1.1 C57BL6 and C57BL/6-Ly5.1 (BoyJ) WT mice 
	
C57BL/6N WT mice were bred and maintained at the Biomedical Services Unit, 
University of Birmingham, UK. B cells in these mice express allotype marker CD45.2. 
C57BL/6-Ly5.1 (BoyJ) WT mice were purchased from Charles River and maintained 
at the Biomedical Services Unit, University of Birmingham, UK. B cells in these mice 
express allotype marker CD45.1. 
 
2.1.2 IgMg1 mice 
	
IgMg1 mice were generated by our collaborator MedImmune. A vector containing 
genome sequence encoding IgM heavy chain constant region M1 and M2 with 
cytoplasmic tail extension of IgG1 cDNA, as well as inverted terminal repeats (ITRs) 
flanked neomycin cDNA was microinjected into embryonic stem (ES) cells. The 75 
bp sequence coding for the 25 C-terminal amino acids of the IgG1 cytoplasmic region 
was inserted into the genome of C57BL6/N ES cells through homologous 
recombination. Positively recombined ES cells were selected by G418 (Geneticin) 
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and screened by PCR. PCR primers: Fwd: 5’- tgcaggtgaaatggatcttctcctc -3’; Rev: 5’ – 
aaccagagtgctatccattgg – 3’. The selection cassette containing an ITR flanked 
neomycin gene was deleted by PiggyBac transposase mediated excision. Positively 
selected ES cells were then injected into blastocysts to generate high percentage 
chimeras. Chimeric founder mice were bred to generate homozygous IgMg1 mice. 
 
2.1.3 IgMg1 Nur77 mice 
	
Nur77-GFPCre B6-820 mouse (MGI ID: 5007644) was a kind gift from Professor 
Graham Anderson (University of Birmingham). It was generated by embryo 
microinjection of a BAC vector containing Nr4a1 locus, 60 kb sequence flanking 
each side of Nr4a1 locus as well as an eGFP-Cre fusion protein cDNA sequence. The 
selected founder mice were then bred with C57BL/6NCr mice (Moran, Holzapfel et al. 
2011). Nur77-GFPCre B6-820 mice were backcrossed onto IgMg1 homozygous mice. 
Mice were genotyped to be homozygous for the IgMg1 insertion site and positive for 
GFP by real time PCR (Transnetyx).  
 
2.1.4 Ha/Hb heterozygous 
	
IgMg1 or C57BL/6N WT mice were crossed with BALB/c mice. F1 hybrid mice 
were used for experiments. As IgMg1 are C57BL/6N background and therefore 
express Ig heavy chain IgHb, whereas BALB/C mice allotype IgHa. Due to allelic 
exclusion B cells from F1 hybrid mice express either IgHa (IgMwt), or IgHb (IgMg1).  
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2.2 Construction of BM chimeras 
 
8 weeks old recipient C57BL/6 WT mice were purchased from Charles River. One 
week before irradiation, mice were treated with Baytril (Bayer) by adding this to 
drinking. Mice were irradiated with 5.5 Gy in the morning and 5.5 Gy in the 
afternoon.  
 
Immediately after the secondary irradiation, equal amounts of 2.5 x 106 BM cells 
from C57BL/6N CD45.2+ WT mice and C57BL/6-Ly5.1 CD45.1+ mice 
(IgMwt/IgMwt WT chimera controls) or from IgMg1 CD45.2+ mice and C57BL/6-
Ly5.1 CD45.1+ mice (IgMg1/IgMwt chimera experimental group) were transferred 
into irradiated recipients. Each mouse received 5 x 106 BM cells in total. Body 
weights of mice were recorded daily, before and after irradiation. Mice were culled if 
their body weight dropped 20% from their weight before irradiation.  
 
Recipient Mice were kept for hematopoietic reconstitution for 6-8 weeks, in the 
presence of Baytril for the first 2 weeks after cell transfer. After this, mice were 
immunised with NP-CGG in the foot as described in section 2.4.1. Popliteal LNs were 
collected to analyse the immune responses after 8 days of immunisation. BM and 
spleens were harvested to follow B cell development in BM chimeric mice.  
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2.3 Flow cytometry 
 
2.3.1 Staining for surface markers 
	
Spleens were harvested and cut into two parts. The larger parts of spleens were frozen 
immediately on dry ice for immunofluorescence histology. The smaller pieces were 
macerated in complete RPMI-1640 culture medium (Table I). Both the weight of 
complete spleens and weight of the smaller pieces were recorded for later cell 
counting. Lymph nodes were torn apart by needles firstly and then macerated in 
complete RPMI-1640 culture medium. Femur and tibia bones were the source of BM 
cells in our experiments. The two ends of the bones were cut off and then were 
flushed with complete RPMI-1640 culture medium. 
 
All cell suspensions were filtered through 70 um cell strainer (Thermo Fisher 
Scientific) to generate single cell suspensions. Samples were then spun down at 150 g, 
4 ˚C for 4 mins. After centrifugation, supernatants were discarded and cell pellets 
were re-suspended with complete RPMI-1640 culture medium again. Aliquots from 
each sample were added to V-shape 96-well microtitre plates (ThermoFisher) for 
staining.  
 
Before incubation with antibody cocktails, anti-CD16/32 antibody was added to block 
Fc gamma receptors (20 min, 4 ˚C). In standard surface staining, all antibodies were 
diluted in FACS buffer (Table II). After blocking, surface antibody cocktail (Table IV) 
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was added and incubated at 4 ˚C for 20 min. Then cells were washed twice at 150 g, 4 
˚C for 4 mins with FACS buffer before analysis. 
 
5 µl counting beads (Spherontech, Inc) were added to the samples, mixed thoroughly 
before loading the samples to a flow cytometer (BD LSRFortessa Analyzer, BD 
Biosciences, with BD FACSDiva). Results were exported and analysed by FlowJo v.9 
or 10 (FlowJo LLC, TreeStar). Percentages from threshold/rectangular gates and 
mean fluorescent intensity (MFI) of gated populations were analysed and exported for 
calculations. To calculate Nur77+ B cells, Overton % Positive was used (Overton 
1988). 
 
2.3.2 Staining for active Caspase3+ apoptotic cells 
	
Cell suspensions from different tissues were generated as described above. 
Intracellular active Caspase3 (aCaspase3) staining was carried out after surface 
staining.  
 
When surface staining was finished, cells were washed once and then fixed in 100 µl 
Fixation and Permeabilisation buffer (Foxp3 Transcription Factor Staining Buffer 
Kits, eBiosciences) at 4 ˚C for 30 min. Then, cells were spun down still in the 96-well 
plate at 150 g, 4 ˚C for 4 mins and re-suspended in 200 µl 1X Wash Buffer 
(eBiosciences) at 4 ˚C for 30 min. Cells were then washed with FACS buffer and 
stained with rabbit anti-mouse aCaspase3 antibody (BD biosciences). Secondary 
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antibody swine anti-rabbit biotin (DAKO) was added and followed by streptavidin 
PE-Cy7 (eBiosciences). 
 
2.3.3 EdU proliferation assay 
	
5-Ethynyl-2'-deoxyuridine (EdU), a thymidine analogue, was dissolved in PBS at the 
concentration of 2 mg/ml as stock and preserved at -20 ˚C. Mice were i.p. injected 
with 200 µg EdU in 200 µl PBS, 2 hours before dissection. EdU incorporation was 
detected using the Click-it EdU flow cytometry kit (Life Technologies).  
 
Nuclear EdU incorporation staining was carried out after surface staining (except 
antibodies with RPE, PE-tandem, or Qdot conjugates). After surface staining, cells 
were washed with PBS-1%BSA and fixed with click-it fixative buffer, 10 µl per 
sample (around 106 cells, 15min, R.T.). After fixation, cells were permeabilised with 
100 µl saponin-based permeabilisation and wash reagent from the kit. After these 
treatments, Click-it EdU reaction cocktail was added (60 µl per sample, Table III). 
Cells were incubated at R.T. for 30 min. After EdU staining, continued surface 
staining with antibodies with RPE, PE-tandem, or Qdot conjugates if needed.  
 
2.4 Calcium influx 
 
Single cell suspensions from spleens were spun down and supernatants were 
discarded. 2 ml ACK buffer (Sigma-Aldrich) was used to lyse red blood cells (RBCs). 
1 min after lysis, the same volume of complete culture medium was added to stop the 
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reaction and spun down again (repeated this step until RBCs have been lysed 
completely).  
 
In some experiments, harvested cells were “calmed” by culturing in complete culture 
medium at 37 ˚C, 5% CO2 for 1 h (Khalil, Cambier et al. 2012). After this, cells were 
spun down and re-suspended with HBSS buffer at the concentration of 2 x 106 cells / 
ml. DMSO dissolved Indo-1 (BD Biosciences, 1mM stock) or Fluo-4 (Thermo Fisher 
Scientific, 1mM stock) was added to the cell suspension to a final concentration of 1 
µM / ml. Cell suspensions were left in the dark at RT for 1 h to load Indo-1 or Fluo-4. 
The reaction was stopped by adding twice the volume of HBSS-10% FBS. Cell 
suspensions were spun down and re-suspended with 200 µl HBSS-10% FBS again to 
allow complete de-esterification of extra AM moieties, Indo-1or Fluo-4 (37 ˚C, 5% 
CO2 for 30 min). Cells were then labelled with anti-CD43 antibody as a dump marker 
in FACS buffer at 4 ˚C for 30 min, washed once, and processed by flow cytometry.  
 
Samples were analysed by BD LSRFortessa Analyzer (BD Biosciences) with BD 
FACSDiva. Laser line used was 405 (Violet), filters were set for BUV395 (379/28, 
calcium bound) and BUV496 (525/50, calcium free) for Indo-1. Raw data was 
exported and the ratio of bound to free was calculated in FlowJo (FlowJo, LLC) as a 
Derived Parameter. The signalling of Fluo-4 was detected by using laser 488 (Blue), 
filter (530/30) in the same machine. 
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2.5 Detection of protein phosphorylation 
 
BD PhosflowTM (BD Biosciences) was used to analyse intracellular phosphoproteins. 
Single cell suspensions from non-immunised mice were obtained as described in 2.3.1. 
Single cells were calmed in complete culture medium at 37 ˚C, 5% CO2 for 2 h after 
red blood cells lysis by ACK buffer (Khalil, Cambier et al. 2012). Anti-IgM F(ab)2 
antiserum (Jackson Lab) was added to cell suspensions (2 x 106 cells in 200 µl) at a 
final concentration of 10 µg/ml, incubated at RT for 5 min. After stimulation, the 
same amount of pre-warmed Fix Buffer I (BD Biosciences) was added immediately, 
mixed well and incubated at 37 ˚C for 10 min. Cells were spun down and resuspended 
in 400 µl pre-cold Perm Buffer III (BD Biosciences), incubated on ice for 30 min. 
Cells were then washed with 1 ml ddH2O once, and 1 ml PBS once. As a negative 
control, cells were treated with Lamda Protein Phosphatase (Lambda PP, New 
England BioLabs). 2.5 µl Lamda Protein Phosphatase was added to a final volume of 
100 µl, incubated at 30 ˚C for 30 min. After this, both negative control and 
experimental samples were incubated with antibody cocktails for surface and 
intracellular markers of interest at 4 ˚C for 30 min. Samples were ready to analyse by 
BD LSRFortessa Analyzer (BD Biosciences) with BD FACSDiva.  
 
2.6 Fluorescence-activated cell sorting (FACs) 
 
Single cell lymphocyte suspension was obtained and stained as described before. 
Cells were suspended and stained in RPMI1640 complete culture medium. Fc gamma 
receptors II and III on cell surface were blocked with anti-CD16/32 antibody at 4 ˚C 
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for 30 min in 200 µl. Cells then were stained with antibody cocktail at 4 ˚C for 30 min 
in 200 µl and washed twice at 150 g, 4 ˚C for 4 mins with FACS buffer before 
analysis. Dead cells were excluded by Hoechst 33342. Single cells were sorted in BD 
FACSAriaTM Fusion high-speed cell sorter (BD Biosciences) directly into 96-well flat 
bottomed microtitre cell culture plate (Falcon) for single cell culture. For bulk sorting, 
gated targeting cells were directly harvested in tubes for mRNA extraction. Samples 
for mRNA extraction were spun down immediately at 200 g, 4 ˚C for 5min after 
sorting. Supernatant was carefully discarded from each sample. Cell pellets were 
frozen in liquid nitrogen and stored at -80 ˚C for mRNA extraction. 
 
 
Table I: RPMI1640 complete culture medium 
Constituent Manufacturer Final concentration 
RPMI-1640 Medium (with 
phenored, L-Glutamine  and 2-
Mercaptoethanol) 
Sigma-Aldrich 89% (V/V) 
FBS (heat-inactivated) Thermo Fisher Scientific 10% (V/V) 
Penicillin. Streptomycin (10000 
units) 
Thermo Fishe Scientific 1% (V/V) 
 
 
 
Table II: FACS buffer 
Constituent Manufacturer Final concentration 
PBS (without Ca and Mg) Sigma-Aldrich 98% (V/V) 
FBS (heat-inactivated) Thermo Fisher Scientific 1% (V/V) 
EDTA 500 mM Sigma-Aldrich 2 mM  
Penicillin. Streptomycin (10000 
units) 
Thermo Fishe Scientific 1% (V/V) 
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Table III: Click-it EdU reaction cocktail (Life Technologies)  
Constituent Amount for 106 cells (1 sample, µl) 
PBS 43.8 
CuSO4 1 
Alexa Flour 647 azide 0.25 
1X Click-it EdU buffer 5 
Click-it Wash Buffer 10 
 
 
 
Table IV: Antibodies used in flow cytometry 
Target Clone Conjugation Dilution Manufacturer 
CD16/32 93 Purified 1:200 eBiosciences 
B220  RA3-6B2 FITC/BV510/BV4
21 
1:200 Biolegend 
B220 RA3-6B2 APC 1:1000 eBiosciences 
B220 RA3-6B2 PE 1:300 BD Biosciences 
CD45.1 A20 PerCP-Cy5.5 1:150 Biolegend 
CD45.1 A20 PE/FITC/PE-Cy7 1:100 eBiosciences 
CD45.2 104 PerCP-Cy5.5 1:150 Biolegend 
CD45.2 104 APC/FITC/PE 1:100 eBiosciences 
CD43 S7 Biotin 1:100 BD Biosciences 
IgD 11-26c.2a BV421/BV510 1:200 Biolegend 
IgM Poly-clonal FITC 1:300 Southern Biotech 
IgM 11/41 APC-AF780/PE-
Cy7 
1:300 eBiosciences 
IgMa DS-1 PE 1:300 BD Biosciences 
IgMa DS-1 FITC/BV421 1:300 BD Biosciences 
IgMb AF6-78 PE 1:300 BD Biosciences 
IgMb AF6-78 FITC 1:300 BD Biosciences 
IgG1 X56 APC 1:100 BD Biosciences 
Fas (CD95) Jo2 BV605 1:300 BD Biosciences 
CD38 90 FITC/PerCP-
Cy5.5/APC 
1:500 Biolegend 
CD138 281-2 BV711 1:300 Biolegend 
PD-1 J43 PE 1:200 Biolegend 
CD44 IM7 PerCP-Cy5.5 1:200 eBiosciences 
CD11c HL3 PE-Cy7 1:300 BD Biosciences 
CD4 RM4.5 eFlour450 1:200 eBiosciences 
CD4 GK1.5 BV510 1:200 Biolegend 
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CD3 145-2C11 PE 1:200 eBiosciences 
CD3 17A2 BV510/BV421 1:200 Biolegend 
CD62L MEL-14 BV510 1:200 Biolegend 
CXCR5 2G8 Purified 1:125 BD Biosciences 
Rat IgG Poly-clonal AF647 1:200 Jackson Lab 
CD5 53-7.3 Biotin 1:200 Biolegend 
CD5 53-7.3 PE-Cy5 1:200 BD Biosciences 
Streptavidin  FITC 1:300 BD Biosciences 
Streptavidin  PE-Cy7 1:400 eBiosciences 
Streptavidin  BV711/BV421 1:300 Biolegend 
NP  PE 1:500 In house 
Lambda JC5-1 PE 1:500 Southern Biotech 
Kappa H139-52.1 FITC 1:500 Southern Biotech 
CD19 eBio1D3 APC 1:100 eBiosciences 
CD19 6D5 AF700 1:100 Biolegend 
CD21 7G6 APC/FITC 1:400 BD Biosciences 
CD23 B3B4 FITC 1:300 BD Biosciences 
CD23 B3B4 PE-Cy7 1:500 eBiosciences 
CD11b M1/70 APC 1:500 eBiosciences 
Ly6c HK1.4 BV421 1:200 Biolegend 
Ter-119 TER-119 Pacific Blue 1:200 Biolegend 
AA4.1(CD93) AA4.1 PerCP-Cy5.5 1:100 Biolegend 
CD24 M1/69 BV510 1:200 Biolegend 
C-kit ACK2 BV605 1:200 Biolegend 
IL7Ra A7R34 PE-Cy 1:200 eBiosciences 
CD25 7D4 Biotin 1:400 BD Biosciences 
CD69 H1.2F3 APC 1:200 eBiosciences 
MHCII M5/114.15.2 PerCP-Cy5.5 1:200 Biolegend 
CD86 GL1 PE-Cy5 1:300 eBiosciences 
CD86 GL1 BV650 1:200 Biolegend 
Annexin V  APC 1:20 BD Biosciences 
7-AAD   1:20 eBiosciences 
aCaspase 3 C92-605 Purified 1:100 BD Biosciences 
Swine anti-
Rabbit  
Poly-clonal Biotin 1:200 DAKO 
Foxp3 FJK-16s eFluor450 1:100 ThermoFisher 
IgM F(ab’)2 Fragment Purified 1:100 Jackson Lab 
Syk (Y352) 17A/P-ZAP70 PE 1:50 BD Biosciences 
BLNK (pY84) J117-1278 AF647 1:50 BD Biosciences 
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2.7 Single cell culture 
 
To obtain plasma cell colony from single Fo B cell, NB-21.2D9 feeder cells (kind gift 
from Professor Garnett Kelsoe, Duke University) were employed in the single cell 
culture system. NB-21 feeder cells are retrovirally transfected to express mouse 
CD40L, BAFF and IL-21 in order to support and induce B cells to become plasma 
cells and support immunoglobulin production (Kuraoka, Schmidt et al. 2016).   
 
6 days before single cell sorting, NB-21.2D9 fibroblast cells were thawed. One frozen 
vial of cells was suspended with 15 ml pre-warmed feeder cell maintenance medium 
and seeded in a 10 cm petri dish. 4 days before single cell sorting, NB-21.2D9 cell 
cultures were divided into three dishes to produce a new generation. 0.05% Trypsin-
EDTA was used to dissociate and detach the cells from the culture dish. Once cells 
were tap-slided from the dish, 10 ml pre-warmed feeder cell culture medium was 
added to dilute Trypsin-EDTA. Cell suspension was spun down at 400 g for 5 min at 
4 °C, and cell were suspended in pre-warmed feeder cell maintenance medium and 
counted. NB-21.2D9 cells were seeded at the total number of 5 x 105 cells in 15 ml 
feeder cell culture medium per 10 cm dish. 1 day before single cell sorting, NB-
21.2D9 cells were harvested. After counting, cells were suspended in B cell complete 
culture medium, and were adjusted to the concentration of 1 x 104 cells/ml. 100 µl of 
the NB-21.2D9 cell suspension was added to each well in a 96-well cell culture plate. 
Feeder cells seeded 96-well plates were cultured at 37 °C, 5% CO2, overnight. 
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On the day of cell sorting, recombinant mouse IL-4 (Peprotech) was diluted with pre-
warmed B cell complete culture medium at the concentration of 4 ng/ml. 100 µl of  B 
cell complete culture medium with IL-4 was added to each well in the 96 well-plate to 
make a final IL-4 concentration of 2 ng/ml. Single Fo B cell was FACS sorted (as 
described in 2.6) directly into each well and incubated at 37 °C, 5% CO2 immediately 
after sorting to start single B cell culture. 
 
2 days after sorting, 100 µl culture supernatant was removed from each well. 200 µl 
pre-warmed B cell complete culture medium was gently added into each well. From 
day 3 to day 8, 200 µl of culture medium was replaced with 200 µl fresh pre-warmed 
B cell complete culture medium daily. Around 200 µl single cell culture supernatants 
were directly harvested 10 days after single cell culture, and 2.5 µl of 10% NaN3 was 
added into each supernatant. Supernatant from each well were aliquoted and stored at 
-20 °C for future use. 
 
Table V: Feeder cell maintenance medium 
Constituent Manufacturer Final concentration 
DMEM, [+] 4.5 g/L D-
glucose, [+] L-Glutamine 
Invitrogen 88% (V/V) 
Fetal Bovine Serum Thermo Fisher Scientific 10% (V/V) 
Penicillin. Streptomycin (10000 
units) 
Thermo Fishe Scientific 1% (V/V) 
MEM NEAA Invitrogen 1% (V/V) 
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Table VI: B cell complete culture medium 
Constituent Manufacturer Final concentration 
RPMI-1640, [+] L-Glutamine Invitrogen 86% (V/V) 
Fetal Bovine Serum (Hyclone) Thermo Fisher Scientific 10% (V/V) 
2-ME Invitrogen 55 uM 
Penicillin. Streptomycin (10000 
units) 
Thermo Fishe Scientific 1% (V/V) 
HEPES Invitrogen 10 mM 
Sodium Pyruvate Invitrogen 1 mM 
MEM NEAA Invitrogen 1% (V/V) 
 
 
 
2.8 Immunofluorescence 
 
2.8.1 Cryosection 
	
Spleens were frozen on dry ice in a pre-labelled aluminium foil paper and stored at -
80 ˚C. Lymph nodes were well-positioned in OCT tissue-freezing solution (Leica 
Microsystems), frozen on dry ice and stored in -80 ˚C. 6 µm sections from spleens 
and popliteal LNs were obtained by cryosection (Bright Instruments).  Sections were 
placed onto pre-labelled multi-spot slides (Hendley-Essex) and air dried at room 
temperature (R.T.) for at least 30 min. Slides were fixed in acetone (Fisher scientific) 
at 4 ˚C for 20 min and air dried for another 10 min. After fixation, slides were stored 
at -20 ˚C for later use. 
 
2.8.2 Immunofluorescence for tissue sections 
	
Slides were allowed to recover to RT before staining. After this, slides were 
rehydrated by putting them into a glass tank filled with PBS for 5 min. 80 µl of 10% 
normal horse serum (Sigma-Aldrich) in PBS-10%BSA (Sigma-Aldrich) was added as 
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blocking buffer and incubated at RT for 20 min. If intracellular or nuclear staining 
was needed, 0.2% Triton X-100 (Sigma-Aldrich) in PBS was added to each spot for 
permeabilization (10 min, RT). Slides were then incubated with primary antibody 
cocktails (Table V) for 1 hour in a dark humid chamber with gently shaking at RT. 
Secondary and tertiary antibodies (Table VI) were added to each spot and incubated at 
the same condition as primary antibodies. Between each step of incubation, slides 
were washed in PBS for 5 min. All the antibodies were diluted in PBS-10% BSA 
(Sigma-Aldrich). After final wash, slides were dried and mounted with mounting 
medium (ProLong Gold antifade reagent, Invitrogen). Mounting medium was cured 
overnight at RT in the dark. After this, mounted slides were used for wide field 
fluorescence microscopy or stored at -20 ˚C for later observation. 
 
2.8.3 Immunofluorescence for auto-immune slides 
	
Auto-immune slides were from the Rat Liver, Kidney, Stomach Kit (NOVA Lite). 
Sera from coagulated blood samples of young or aged mice were produced by clotting 
at 37 ˚C for 2 hours and then spun down at 10000 g, RT for 5 min. Supernatants (sera) 
were carefully harvested and put into pre-labelled autoclaved clean microtubes. 
 
Slides were allowed to warm to RT before staining. 50 µl net sera were added to spots. 
At least one positive and negative control was done on each slide. Positive controls of 
anti-mitochondrial antibodies, anti-nuclear antibodies and anti-smooth muscle 
antibodies were used from the kit. PBS and IFA system negative control from the kit 
were used as negative control. Loaded slides were incubated overnight at 4 ˚C. The 
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second day, slides were washed in PBS for 10 min and FITC conjugated rat anti-
mouse IgG1 (H+L) (Southern Biotech) antibody was added to spots required. Slides 
were incubated in a humid dark chamber for 1 hour at RT. 50 µl Hoechst 33342 was 
applied to each spot and incubated for 2 min. After this, slides were well washed and 
mounted with mounting medium from the kit. Slides were cured in the dark overnight. 
Slides were sealed with transparent nail polish. Slides observed in a widefield 
fluorescence microscopy (20 x) or stored in -20 ˚C for later observation. 
 
2.8.4 Microscopy 
	
Both tissue sections slides and auto-immune slides were tile scanned and observed 
under Zeiss AxioScan Z1 scanning fluorescence widefield microscope (Carl Zeiss). 
Beam Splitter for Alexa Fluor 647 was 660, for Alexa Fluor 488 was 498, for Alexa 
Flour 405 was 395, for Alexa Flour 555 was 568. Exported tile scanned images were 
off-line processed with software Zen, Blue edition (Carl Zeiss) and ImageJ-Fiji.  
 
Table VII: Primary antibodies used in immunofluorescence 
Target Isotype Clone Dilution Manufacturer 
B220 Rat anti-mouse RA3-6B2 1:100 BD Biosciences 
CD4     
IgM Goat anti-mouse Poly-clonal 1:200 Southern 
Biotech 
IgD Rat anti-mouse 11-26c.2a 1:200 Biolegend 
CD169 Rat anti-mouse 3D6.112 1:100 Biolegend 
CD1d Rat anti-mouse 1B1 1:100 Bioegend 
IRF4 Goat anti-mouse Poly-cloncal 1:50 SantaCruz 
NP Rabbit Ig 
conjugated 
 1:500 In house 
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Table VIII: Secondary antibodies used in immunofluorescence 
Target Conjugation Dilution Manufacturer 
Donkey anti-sheep 
(goat) 
AF488 1:200 Jackson ImmunoResearch 
Donkey anti-Rabbit Cy3 1:200 Jackson ImmunoResearch 
Streptavidin BV421 1:200 Biolegend 
 
 
 
2.9 Immunisation 
 
2.9.1 T-cell dependent antigen immunisation 
	
T cell dependent immune responses were triggered by subcutaneous immunisation 
with 20 µg alum-precipitated NP-CGG (4-hydroxy-3-nitrophenyl acetyl Chicken γ- 
globulin) on the plantar surface of rear feet and (or) intraperitoneal (i.p.) 
immunisation with 50 µg alum-precipitated NP-CGG. NP18-CGG was a gift from Ms 
Chandra Raykundalia.  
To prepare the antigen, 5 mg/ml of NP-CGG was mixed with equivalent volume of 
alum (9% AlK(SO4)2 in ddH2O) (Zhang, Garcia-Ibanez et al. 2017), 10 M NaOH was 
added to the mixture to adjust its pH value to 6.5~7. Then, the mixture was rotated in 
the dark for at least 45 min to allow for maximum precipitation. After spinning at 250 
g, R.T. for 5 mins, the pellet was washed in PBS twice. Then the pellet was suspended 
in PBS at 1 mg/ml for foot immunisation and 250 µg/ml for i.p. immunisation, 1x105 
chemically inactivated Bordetella pertussis (b.p.) bacteria (LEE laboratories, BC, 
USA) were added as an adjuvant in all primary immunisations. 
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For most experiments, popliteal LNs and spleens were harvested at 8 days after 
immunisation. In pilot experiments, LNs and spleens were harvested at days 4, 5, 6, 8 
and 14. 
 
2.9.2 T-independent antigen immunisation 
	
T cell independent immune response was induced by i.p. immunisation of 30 µg NP-
Ficoll (Biosearch Technologies) in 200 µl PBS. Spleens were harvested and the 
immune response was evaluated after 5 days of immunisation. 
 
2.9.3 T-dependent and T-independent mix immunisation 
	
Sheep red blood cells (SRBCs) can induce mixed activation of both T-D and T-I 
responses. SRBCs (TCS Biosciences) were washed in PBS for twice. Mice were then 
i.v. immunised with 2 x108 cells in 200 µl PBS. Normally, spleens were harvested 5 
days after immunisation. In pilot experiments, spleens were harvested at days 1, 2, 3, 
4, 5 and 8 after immunisation.  
 
2.10 Enzyme-linked immunosorbent assay (ELISA) 
 
2.10.1 ELISA for NP-specific antibody titre and affinity 
	
Samples used for ELISA were sera from coagulated blood samples of immunised or 
non-treated mice. Serum samples were collected and preserved as described in 2.8.3. 
Flat-bottom plates (Thermo Fisher Scientific) were coated with either NP15-BSA (in 
house) or NP2-BSA (in house) at 5 µg/ml in coating buffer (Table VIII), 4 ˚C, 
overnight. NP15-BSA was used to detect the titres of all NP-specific Ig class switched 
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antibodies (eg. IgG or IgG1). NP2-BSA was used to detect titres of the high affinity 
fraction of NP-specific Ig class switched antibodies (eg, IgG or IgG1) and the titres of 
all NP-specific IgM. The second day, plates were washed twice in wash buffer (Table 
VIII). 200 µl blocking buffer (PBS-1%BSA) was added and incubated at 37 ˚C for 
1~1.5 h. Serum samples were serially diluted in seven 3x dilutions, normally with a 
starting dilution of 1 : 30. Plates with loaded samples were incubated at 37 ˚C for 1 h. 
After incubation, plates were washed in wash buffer (PBS-0.05%Tween 20) and 
incubated with AP-conjugated secondary antibodies (eg. anti-IgM, anti-IgG, anti-
IgG1, anti-IgG3 et. al. Southern Biotech, Table VII), diluted in blocking buffer, at 37 
˚C for 45 min. Plates were well-washed before adding substrate buffer. 
 
The substrate of AP was p-nitrophenyl phosphate dissolved in Tris buffer 
(SIGMAFAST, Sigma-Aldrich). One tablet from each was dissolved in 20 ml ddH2O. 
After both tablets fully dissolved, 100 µl of this substrate buffer was added to develop 
the colour. The absorbance was read at 405 nm by using a Synergy HT Microplate 
Reader (BioTek). OD values were exported into Excel. OD values were plotted 
against dilution and smoothed lines were drawn through each dilution series. Relative 
antibody titres were read as maximal dilution where OD was above an arbitrary 
threshold. Antigen affinity was measured as the ratio of NP2 antibody titre to NP15 
antibody titre. To make OD values from different plates comparable, a standard 
sample was added into each plate and used to normalised OD values in different 
plates. 
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2.10.2 ELISA for Pigeon cytochrome C (PCC) specific antibody 
	
In order to measure PCC-specific antibody titres, plates were coated with PCC 
(Sigma-Aldrich). PCC detection plates were coated with PCC diluted in coating 
buffer at the concentration of 10 µg/ml. 
In both NP and PCC ELISA assays, negative controls and positive controls were 
included into each plate. 
2.10.3 ELISA for serum total IgM and IgG1 
	
Plates were coated with 2.5 µg/ml of anti-Kappa (Southern Biotech) and 2.5 µg/ml 
anti-Lambda (Southern Biotech) antibodies, to make a final total concentration of 5 
µg/ml total antibodies. 
 
Table IX: Antibodies used in ELISA 
Target Dilution Manufacturer 
Goat anti-mouse IgM-AP 1:2000 Southern Biotech 
Goat anti-mouse IgG3-AP 1:1000 Southern Biotech 
Goat anti-mouse IgG1-AP 1:1000 Southern Biotech 
Goat anti-mouse IgG-AP 1:1000 Southern Biotech 
 
 
Table X: Reagents used in ELISA 
Reagents Ingredients 
Coating buffer Na2CO3 1.95g, NaHCO3 2.93g in 1 L ddH2O, ph=9.6 
Blocking/Dilution buffer PBA-1%BSA (Sigma) 
Wash buffer PBS-0.05% Tween 20 (Sigma) 
Substrate 2 tablets in 20 ml ddH2O 
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2.11 Real-time (RT) PCR 
 
2.11.1 Extraction of total mRNA 
	
mRNA was extracted from spleen sections or sorted cells. Before extraction, all 
samples were stored and kept at -80 ˚C. RNeasy Mini kit or Micro kit (Qiagen) was 
used depending on the amount of cells. Spleen sections which contain more than 1 
million cells were treated with Mini Kit, smaller quantities were treated with the 
Micro kit. The procedures of mRNA extraction were strictly following manufacturer’s 
instructions. mRNA was eluted in 15 µl (Micro kit) or 30 µl (Mini Kit) of RNase free 
water.  
 
2.11.2 Reverse-transcription to generate cDNA 
	
3 µl of random oligo-dN6 primers (Promega Biosciences) was added to each 30 µl 
mRNA sample. Primer-template mixtures were denatured at 70 ˚C for 10 min, and 
placed immediately on ice for oligo-dT binding. The reverse-transcription reaction 
system (Table X) was set up by adding 27 µl reaction buffer to 33 µl of template-
primer mixture and left to incubate at 41 ˚C for 1 h, followed by 10 min inactivation 
at 90 ˚C. cDNA was stored at -20 ˚C for further use. 
 
2.11.3 Semi-quantitative RT-PCR 
	
RT-PCR was normally carried out in 384-well plates (Applied Biosystem). Taqman 
was performed in a reaction volume of 5.5 µl, including 0.5 µl cDNA template, varied 
optimalised amounts of primers and probes (Table IX), Taqman Universal PCR 
Master Mix (Applied Biosystem) and ddH2O. mIgh and mIgd relative expression 
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levels were detected using SYBR Green chemistry, using the reaction buffer 
SensiMix SYBR Hi-ROX (Bioline). PCR was performed in an ABI 7900 real-time 
PCR machine (Applied Biosystems). The PCR program was run by using the software 
SDS 2.2.2 (Applied Biosystems), 95 ˚C for 10 min for denaturation, then elongation 
at 95 ˚C for 15 s followed at 60 ˚C for 1 min for 40 cycles.  
 
Data were exported and analysed by using the software RQ Manager 1.2.1 (Applied 
Biosystems). mRNA relative expression level was calculated by using ΔCt value, 
which normalised to the housekeeping gene (β2-microglobulin). 
 
Table XI: Primers information 
Target Sequence information 
β2-micro  
globµlin  
Forward CTGCAGAGTTAAGCATGCCAGTAT  
Reverse ATCACATGTCTCGATCCCAGTAGA  
Probe CGAGCCCAAGACC  
mIghm Forward TGACCGAGAGGACCGTGGA 
Reverse CTTGAACAGGGTGACGGTGGT 
Probe  
mIghd Forward AACACCATCCAACACTCGTGTA 
Reverse CTTGATGAAGGTGACGAAGCCA 
Probe  
 
 
Table XII: Reverse-transcriptional system (per sample) 
Reagent Volumn (µl) 
5X first strand buffer (Invitrogen) 12  
0.1 M DTT (Promega) 6  
10 mM dNTPs (Invitrogen) 3  
M-MLV reverse transcriptase (Invitrogen) 3 
RNasin RNase inhibitor (Promega) 1.5 
RNase free water (Qiagen) 1.5 
Random primers (Promega) 3 
Total mRNA Templates 30 
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2.12 Western Blot 
 
2.12.1 Sample preparation 
	
Single splenocytes suspension was obtained as described (chapter 2.3.1). 1 x 107 
splenocytes were suspended in 90 µl MACS buffer (PBS (Thermo Fisher Scientific), 
0.5% BSA (Sigma-Aldrich), 2 mM EDTA (Sigma Aldrich). 10 µl of anti-CD43 
antibody labelled microbeads (Miltenyi Biotec) was added to each 1 x 107 of cells, 
mixed well and incubated at 4 ˚C for 15 min. After incubation, splenocytes were 
washed with MACS buffer 1-2 ml each 1 x 107, spun down and re-suspended each 1 x 
108 cells with 500 µl MACS buffer (if cell number was below 108, with 500 µl MACS 
buffer). Cell suspensions were then applied to a pre-washed LS column (Miltenyi 
Biotec) inside a magnetic field. The column was eluted with 9 ml MACS buffer inside 
a magnetic field. All pass-through fluid was collected, and re-suspended with 
complete RPMI1640 culture medium. Harvested cells were left to calm for 1 h in 
complete RPMI1640 culture medium at 37 ˚C (Khalil, Cambier et al. 2012).  
 
2 x 106 isolated B cells in 200 µl complete culture medium were stimulated with 10 
µg/ml Anti-IgM F(ab)2 (Jackson Lab) for 0 min, 5 min, 10 min, 30 min or 60 min. 
After stimulation, 1 ml 0.5% NaN3 was added immediately to stop the reaction. After 
spinning down, supernatants from samples were completely removed and discarded. 
200 µl RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific) with 1X Halt 
Protease & Phosphatase Single-Use Inhibitor Cocktail (Thermo Fisher Scientific) was 
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added, and incubated on ice for at least 30 min. Cell lysates were then stored at -20 ˚C 
for future use. 
 
2.12.2 Gel electrophoresis of Protein 
	
10 µl DNase (Qiagen) was added into aliquotes of cell lysates. The mixture was 
incubated at RT for 30 min to eliminate chromatin pellets. Then 5X Sample Buffer 
(10% SDS, 300mM Tris-HCL, 0.05% Bromophenol blue, 50% Glycerol, 10% 2-
mercaptoethanol), 100 mM DTT (Sigma-Aldrich) was added to each cell lysates, 
mixed well and heated to 95 ˚C for 10 min.  
 
After the incubation, 15 µl of each sample was loaded to NuPAGE 4-12% BT Gel 
(Thermo Fisher Scientific) with 5 µl Prime-Step Prestained Broad Range Protein 
Ladder (BioLegend). The gel was run at constant voltage at 10 V/cm for 2 h in an 
electrophoresis tank filled with 1X Running Buffer (Thermo Fisher Scientific).  
 
Before wet transfer, a polyvinylidene difluoride (PVDF) membrane (Immobilon) was 
activated by methanol (Fisher Scientific) for 10 min and washed with 1X transfer 
buffer (20X transfer buffer (Thermo Fisher Scientific), 20% methanol (Fisher 
Scientific)) to eliminate any residual methanol drops on the membrane. 2-Gel transfer 
system was set as (-) pre-wet pads, Blotting Filter Paper (Immobilon), gel, membrane, 
Filter Paper, pre-wet pads, Filter Paper, gel, membrane, filter paper, pre-wet pads (+), 
from (-) negative pole to (+) positive pole. The Electrophoresis system was filled with 
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transfer buffer, and the rest of tank was filled with ddH2O, intended to cool the whole 
system. The transfer was run at a constant voltage at 4 V/cm for 2 h. 
 
2.12.3 Immunoblot 
	
Protein loaded membrane was blocked in TBST-5% BSA (Sigma-Aldrich) for 30 min 
at RT with gentle shaking. The membrane was then blotted either with Tris-buffered 
saline with Tween 20 (TBST)-5% BSA diluted mouse anti-Phosphotyrosine antibody 
(Bio X Cell) or anti-Beta Actin Rabbit Polyclonal (Proteintech), incubated at 4 ˚C 
overnight. The second day, membranes was washed three time in TBST at RT for 5-
10 min under gentle shaking. The membrane was then blotted with TBST-5% BSA 
diluted secondary antibodies, anti-mouse or rabbit IgG HRP-linked antibody (Cell 
Signaling Technology) at RT for 1 h under gentle shaking. After the membrane was 
washed three times it was ready for imaging. Freshly prepared Clarity Western ECL 
Substrate (BIO-RAD) was spread on the membrane, incubated for 1 min and then 
discarded. The image was taken in a ChemiDocTM MP imaging system (BioRad) 
immediately afterwards. High resolution pictures were selected, analysed and 
exported by using software Image Lab 5.1 (BioRad).  
 
 
2.13 Data analysis 
 
GraphPad Prism 6 was used to perform statistical analysis and generate graphs.  
Comparison which involved two groups and only one variable parameter were tested 
for significance using unpaired two-tailed T test. Comparisons which involved two 
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groups, but two variable parameters were analysed using multiple t tests. P values 
were corrected for multiple comparisons using the Sidak-Bonferroni method.  
P values < 0.05 were considered significant (*). P values were indicated with stars in 
most figures: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
Comparisons in heterozygous mice which involved two groups and two variables 
were analysed using two-way ANOVA, corrected for multiple comparisons using 
Tukey’s multiple comparisons test to compute CIs and significance. Significance and 
confidence level: 0.05 (95% confidence interval). 
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Chapter 3 . Characterization of B cell development in mice 
with polyclonal chimeric IgMg1 B cell receptors 
	
	
	
3.1 Introduction 
	
3.1.1 B cell receptor signalling strength and B cell development 
	
B cells of mice and men can express five major classes of BCRs: IgM, IgD, IgG, IgE 
and IgA (Bengten, Wilson et al. 2000). Naïve follicular B cells express IgM and IgD 
simultaneously, while MZ B cells and B1 cells express high levels of IgM, with very 
little IgD expressed on their surface. After activation B cells start class switch 
recombination leading to the expression of downstream Ig classes (Chaudhuri and Alt 
2004). Different subclasses of BCRs not only have different extracellular domains, 
but also contain additional cytoplasmic signalling regions that can lead to different 
downstream signalling strength. IgG1 contains a small cytoplasmic region that has 
been shown to mount higher downstream signalling after BCR stimulation (Waisman, 
Kraus et al. 2007, Weston-Bell, Forconi et al. 2014).  
 
Previous studies have revealed that BCR signalling and its strength play important 
roles in B cell development and affect B cell fate decisions during B cell maturation 
(Niiro and Clark 2002, Monroe 2006, Pillai and Cariappa 2009). In bone marrow, B 
cells develop following the sequence from pre-pro B cells, pro-B cells, pre-B cells to 
immature B cells (Cambier, Gauld et al. 2007, Hobeika, Maity et al. 2016). Pre-BCRs 
with fully rearranged heavy chains and surrogate light chains are transiently expressed 
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on the surface of pre-B cells and tested for signalling capability as positive selections 
for pre-B cells (Saijo, Schmedt et al. 2003, Monroe 2006). During the immature B 
cell stage, B cells can be negatively selected if their BCR binds autoantigens, which is 
a first test for auto-reactivity. Here, B cells with strong self-binding strength are 
induced into apoptosis, B cells with weak to medium auto-reactivity are induced into 
an anergic state. Anergic B cells and non-self-binding B cells are allowed further 
maturation (Brink and Phan 2018). Light chain rearrangement during immature B cell 
stage can rescue some of the strong self-binding cells (Gay, Saunders et al. 1993, 
Tiegs, Russell et al. 1993). This mechanism is termed receptor editing and confers B 
cells a second chance for the production of a new BCR containing the same heavy 
chain with a new V-J combination light chain, which may generate a BCR that has no 
or only weak auto-reactivity.  
 
After exiting bone marrow, immature B cells differentiate into transitional B cells (T1 
B cells) that enter the periphery. T1 B cells are further selected and differentiate 
depending on their affinities toward self-antigens, particularly tissue-specific 
autoantigens (Russell, Dembic et al. 1991, Jacobi and Diamond 2005). During the 
final maturation of these surviving B cells, tonic BCR signalling strength can also 
affect B cell fate commitment (Cariappa, Tang et al. 2001, Cariappa, Takematsu et al. 
2009, Pillai and Cariappa 2009). B cells with higher BCR signalling prefer to 
differentiate into follicular B cells (Loder, Mutschler et al. 1999, Niiro and Clark 
2002), while lower BCR signalling may lead to MZ B cell differentiation (Cariappa, 
Tang et al. 2001, Pillai, Cariappa et al. 2005). Very recently, provoking work from the 
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Rajewsky group showed the instructive role of the BCR in driving mature B cell re-
differentiation from B2 to B1 cells (Graf R, Science 2019). 
 
3.1.2 B cell receptor signalling strength and B cell anergy 
	
There is a link between hyper-active BCR signalling and B cell auto-reactivity or B 
cell anergy. During B cell development, B cells with increased tonic BCR signalling 
due to expression of a weak to medium self-binding BCR can be induced into anergy. 
Studies in mutant mice, where BCR signalling has been artificially increased by 
mutating individual BCR signalling repressors, e.g. SHP-1, show that this can lead to 
spontaneous generation of polyclonal auto-reactive antibodies beyond a certain age 
(Hibbs, Tarlinton et al. 1995, Getahun, Beavers et al. 2016). Autoreactive B cells 
observed in these models always maintain hyperactive BCR signalling, while 
autoreactive anergic B cells generally have absent or reduced activated BCR 
signalling after BCR ligation (Goodnow, Crosbie et al. 1988, Glynne, Ghandour et al. 
2000). This is surprising, as BCR signalling by BCR self-antigen ligation as well as 
the mutation of repressors of the BCR signalling pathway should generate a similar 
effect -- generating B cells that display hyperactive BCR signalling. Why do B cells 
with mutant repressors fail to turn into an anergic state?  
 
During normal B cell development, repressors of BCR signalling, such as SHP-1, are 
used by the immune system to maintain the anergic state of B cells (O'Neill, Getahun 
et al. 2011, Getahun, Beavers et al. 2016). The mutations of them make the immune 
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system incapable to counter-regulate BCR signalling by inducing B cells into anergic 
state. On the other hand, the immune system always creates a wide spectrum of BCR 
specificities that may include autoreactive B cells. Therefore, B cell development is 
highly evolved to deal with diverse signalling strength from BCR/ligand binding 
during development (Melamed, Benschop et al. 1998, Loder, Mutschler et al. 1999). 
B cells emerging during B cell development with autoreactive BCR can be dealt with, 
as long as repressors are available to inhibit BCR signalling and differentiate these 
cells into anergic cells, whereas, mutations in BCR signalling repressor molecules 
will generate mice with overt autoimmunity. Therefore, it is possible to create mouse 
model with poly-clonal anergic B cells if the modification only affects signalling 
strength from BCR/ligand binding. 
 
Besides absent or reduced BCR signalling as the defining feature of anergy, there are 
some other recognized features shared by the majority of B cell anergy mouse models. 
Anergic B cells express lower levels of surface membrane IgM (Goodnow, Crosbie et 
al. 1988, Borrero and Clarke 2002, Merrell, Benschop et al. 2006). In some models, 
anergic B cells have shortened life spans, as they are less competitive to occupy 
survival niches (Cyster, Hartley et al. 1994, Cyster and Goodnow 1995, Mackay, 
Schneider et al. 2003). Furthermore, some studies report that anergic B cells are 
blocked at an immature or transitional stage and don’t proceed into further 
development. This is called developmental blockage (Goodnow, Crosbie et al. 1989, 
Merrell, Benschop et al. 2006). In other models, anergic B cells are unable to enter 
follicles in the presence of competition from non-self-reactive naïve B cells and 
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display altered location to the T-B border (Fulcher and Basten 1994, Cyster and 
Goodnow 1995, Cambier, Gauld et al. 2007). Surprisingly, anergic B cells have been 
estimated to account for as much as 20-30 % of peripheral mature B cells pool 
(Grandien, Fucs et al. 1994, Wardemann, Yurasov et al. 2003). Two recent studies 
confirmed that all healthy individuals have a major compartment of silenced anergic 
auto-reactive B cells (Wardemann, Yurasov et al. 2003, Smith, Packard et al. 2015).  
 
3.1.3 IgMg1 mouse model 
	
Two different mouse models have shown that naïve B cells expressing the IgG1 
cytoplasmic signalling chain show higher and longer-lasting calcium influx after 
stimulation. These are where B cells either express chimeric IgM with a IgG1 
cytoplasmic signalling chain (IgM-G1) with all B cells monospecific for HEL, or 
where B cells are polyspecific with a normal VDJ repertoire but express only surface 
IgG1  (Horikawa, Martin et al. 2007, Waisman, Kraus et al. 2007). In attempt to 
enhance BCR signalling in a polyclonal B cell repertoire where B cells express 
normal polyclonal extracellular IgM and IgD, our collaborator Mike Snaith 
(Medimmune) generated a IgMg1 mouse model by adding the gene sequence 
encoding for the IgG1 cytoplasmic region downstream of the germ-line IgM 
extracellular region, while keeping germ-line VDJ regions to allow for regular 
random re-arrangements (described in Chapter 3, Fig. 3.1). As mentioned above, the 
strength of tonic BCR signalling impacts B cell fate decisions during development 
and hyper-activated BCR can induce either anergy or auto-reactivity. Therefore, it 
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may be interesting to characterize B cell development and evaluate the state of mature 
B cells in this mouse model. 
 
3.1.4 Objective  
 
The work presented in this chapter is based on our new IgMg1 BCR knock-in mouse 
model. Compared to IgM and IgD that does not have a cytoplasmic signalling domain, 
the IgG1 cytoplasmic region is supposed to transduce additional down-stream 
signalling after BCR stimulation. The aim of this part of my thesis is to how a change 
in BCR signalling in the IgMg1 mouse model impacts on B cell development, how 
does this modification change BCR signalling, and to characterize the emergence of 
mature B cell populations. 
 
Aims are detailed as follows: 
 
1. What is the impact of IgMg1 BCR signalling on B cell development in IgMg1 mice? 
on 
A. B cell development in BM stage 
B. B cell development in periphery stage 
 
2.  How does BCR signalling change in IgMg1 developing and mature B cells: 
A. Tonic BCR signalling strength  
B. Activated BCR signalling 
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3.2 Results 
 
3.2.1 Expression of IgMg1 chimeric B cell receptor does not lead to major 
changes in bone marrow B cell development 
	
To construct IgMg1 mice, a gene segment encoding for the cytoplasmic region of 
IgG1 was inserted down-stream of the IgM transmembrane encoding region. A 
targeting vector containing: genome sequence encoding IgM heavy chain constant 
regions M1 and M2 immediately 5’ to cDNA encoding for the cytoplasmic tail 
extension of IgG1, and a neomycin selection cassette (inverted terminal repeats (ITRs) 
flanked neomycin cDNA), was microinjected into embryonic stem (ES) cells. The 75 
bp sequence coding for the 25 C-terminal amino acids of the IgG1 cytoplasmic region 
was specifically targeted into the genome of C57BL6/N ES cells through homologous 
recombination. Positively recombined ES cells were selected by G418 (Geneticin) 
and screened by PCR. The positive selection cassette containing an ITR flanked 
neomycin gene was deleted by PiggyBac transposase mediated excision. Selected ES 
cells were then injected into blastocysts to generate high percentage chimeras. 
Chimeric founder mice were bred to generate homozygous IgMg1 mice. The Germ-
line V-D-J regions remained intact in IgMg1 mice, which allows for random 
rearrangement during BCR development (Fig. 3.1A). Therefore, B cells in mice 
express IgMg1 chimeric B cell receptors: with IgM extracellular and transmembrane 
regions, but an IgG1 cytoplasmic tail (Fig. 3.1B). 
 
Previous studies show that tonic signalling strength transduced from membrane-
bound BCRs can affect B cell fate decisions during development (Niiro and Clark 
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2002, Monroe 2006, Pillai and Cariappa 2009). We reasoned that addition of the IgG1 
cytoplasmic signalling tail to IgM might alter BCR signalling strength and therefore 
affect B cell development. To explore this, B cell development in IgMg1 mice was 
compared to that in IgMwt mice. B cell development has been generally divided into 
two stages. Bone marrow is the location for the differentiation and maturation of 
common lymphoid progenitors (CLPs), pro-B cells, pre-B cells and immature B cells. 
and periphery (mainly spleen) hosts further B cell development from transitional B 
cells to mature B cells (Mebius and Kraal 2005). 
 
Bone marrow was collected from both IgMwt and IgMg1 mice. Percentages of 
developmental B subsets were assessed. Common lymphoid progenitor cells (CLPs) 
and pro-B cells (Fr.A) are gated from CD19-IgM-CD3-Ly6c-Ter119-CD93+CD24lowC-
kitintIL7-Ra+ precursors. Within this population, CLPs are the B220- subset, while pro-
B cells are the B220+ (Fig. 3.2A) (Kondo, Weissman et al. 1997). CLPs and pro-B 
cells do not yet express BCR heavy chain and, as expected, no difference was 
detected for CLPs and pro-B cell development in IgMg1 mice (Fig. 3.2B).  Pre-B 
cells are gated as B220+CD43-IgM-IgD- bone marrow lymphocytes, BM transitional B 
cells are B220+CD43-IgM+IgDlow, and immature B cells are B220+CD43-IgM+IgD- 
subset (Fig. 3.3A). In IgMg1 and IgMwt mice, percentages of pre-B, transitional and 
immature B cells were comparable (Fig. 3.3 B). However, consistently higher 
percentages of mature B cells were observed in IgMg1 mice (Fig. 3.3B right). Overall, 
these observations indicate that the expression of IgMg1 does not lead to major 
changes in B cell development during the bone marrow stage. 
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Figure 3.1: Schematic representation of Hc locus of both wild type and IgMg1 
mice. 
A. Detailed schematic process of IgM targeting. Genome sequence containing Hµ 
introns, two exons M1 and M2 (purple) with 75 bp cytoplasmic tail extension 
of IgG1 cDNA (red) was inserted into the genome of C57BL/6N ES cells 
through homologous recombination. Neomycin (Neo) was used for selection 
of the positively recombined clones. The selection cassette, inverted terminal 
repeats (ITR) flanked neomycin gene, was then deleted by Piggybac 
transposase-mediated deletion.  
B. Schematic representation of the structure of wildtype IgM, IgG1 and chimeric 
BCR IgMg1 
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Figure 3.2: Bone marrow precursor cells development is normal in IgMg1 mice. 
A. Gate settings for both CLPs and Fr.A cells in bone marrow. CLPs and Fr.A all 
derive from the precursor CD19-IgM-CD3-Ly6c-Ter119- (top left) 
CD93+CD24- (top right) C-kit+IL7-Ra+ (bottom right) population. CLPs are 
the B220-, while Fr.A are the B220+ cells (bottom left). 
B. The percentages of CLPs and pro-B cells within bone marrow lymphocytes 
and compared between IgMwt and IgMg1 mice. 
ns, not significant; unpaired Student’s t test. Bars indicate mean. Each symbol 
represent sample from one mouse. Data are from three independent experiments.  
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Figure 3.3: Pre-B and immature B cell development is normal in IgMg1 mice. 
A. Gates to identify pre-B cells, immature B cells, transitional B cells and mature 
B cells in bone marrow.  The four populations are all gated from CD43-B220+ 
cells (top), pre-B cells are IgM-IgD- cells, immature B cells are IgM+IgD- cells, 
transitional B cells are IgM+IgDlow and mature B cells are IgM+IgD+ cells 
(bottom). 
B. Percentages of pre-B, immature, transitional and mature B cells within bone 
marrow lymphocytes and compared between IgMwt and IgMg1 mice. 
**** p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each symbol represent 
sample from one mouse. Data are from three independent experiments. 
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3.2.2 Peripheral B cell development is severely affected in IgMg1 mice 
	
Immature B cells emigrate from the BM and become transitional B cells immediately 
when they enter the periphery. Transitional B cells mature in B cell follicles of the 
spleen to become MZ B cells or Fo B cells (Pillai, Cariappa et al. 2005, Pillai and 
Cariappa 2009). In order to test B cell development in peripheral lymphoid organs, B 
lymphocyte developmental stages were further assessed in the spleens of IgMg1 and 
IgMwt mice. 
 
The spleens of IgMg1 mice were bigger than those of IgMwt mice, containing more 
splenocytes (Fig. 3.4B). Within splenocytes, the overall percentage of B cells in 
IgMg1 mice were slightly increased, whilst the absolute numbers almost doubled (Fig. 
3.4C).  
 
Transitional and mature B cell populations were further gated and analysed. 
Transitional B cells were gated as CD19+B220+IgM+CD93+ cells (Fig 3.5A). Within 
this population, T1 cells were gated as the CD21-CD23- subset, and T2+T3 cells as 
CD21+CD23+ (Fig. 3.5A). Mature Fo and MZ B cells were gated from 
CD19+B220+IgM+CD93- mature B cells (Fig. 3.5A). Fo B cells were CD21intCD23int 
subset, while MZ B cells were CD21highCD23low/- subset (Fig. 3.6A). Despite having 
more B cells, the percentages of transitional B cells, particularly T1 B cells were 
significantly lower in IgMg1 mice (Fig. 3.5B). The absolute numbers of transitional B 
cell populations, however, were comparable with their IgMwt counterparts (Fig. 
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3.5C). The increase in total B cell numbers in IgMg1 mice was due to the increased 
numbers of Fo B cells (Fig. 3.6B), which is the dominant mature B cell population in 
the periphery. On the contrary, the percentages of MZ B cells were significantly 
reduced in IgMg1 mice, despite their absolute numbers remained similar to those in 
IgMwt mice (Fig. 3.6C). 
 
We further analysed B1 cell populations in both IgMwt and IgMg1splenocytes. B1 
cells have been defined as CD19+IgM+B220+CD93-CD21-CD23-IgDlowCD43+ (Fig. 
3.7A). There was no significant change in splenic B1 cell numbers (Fig. 3.7B).  
 
Overall, the expression of IgMg1 does not significantly affect B cell development in 
BM, however, it has a significant impact on peripheral B cell development with a 
strong increase in follicular B cell numbers, and reduced percentages, but no change 
in absolute numbers of transitional and other mature B cell populations. This 
phenomenon is possibly due to higher turn-over rate or longer life span of follicular B 
cells in IgMg1 mice. 
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Figure 3.4: IgMg1 mice have bigger spleens with higher number of splenocytes 
and B cells. 
A. Gate settings for CD19+B220+ B cells in IgMwt and IgMg1 spleens. 
B. Weights of spleens and absolute numbers of splenocytes. 
C. Percentages of B cells within spleen lymphocytes and their absolute numbers. 
* p < 0.05; ** p < 0.01 ; *** p < 0.001; unpaired Student’s t test. Bars indicate mean. 
Each symbol represent sample from one mouse. Data are from three independent 
experiments.  
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Figure 3.5: The percentages of transitional and T1 B cells are significantly 
reduced in IgMg1 mice. 
A. Gate settings for transitional, T1, T2+3 cells in spleen. Transitional B cells are 
gated as CD19+B220+CD93+ cells. T1 subset is CD21-CD23- within the 
transitional population, while T2+T3 are CD21+CD23+ ones. 
B. Percentages of transitional, T1 and T2+T3 B cells within spleen B cells. 
C. Absolute numbers of transitional, T1 and T2+T3 B cells compared between 
IgMwt and IgMg1 mice. 
* p < 0.05; **** p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each 
symbol represents sample from one mouse. Data are from three independent 
experiments.  
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Figure 3.6: Peripheral follicular B cells and MZ B cell development is affected in 
IgMg1 mice. 
A. Gate settings for Fo B cells and MZ B cells in spleen. These two populations 
are gated from CD19+IgM+B220+CD93- mature B cells. Fo B cells are gated 
as CD21intCD23int cells. MZ B cells are gated as CD21highCD23low/- cells. 
B. Percentages and absolute numbers of Fo B cells. 
C. Percentages and absolute numbers of MZ B cells. 
** p < 0.01; **** p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each 
symbol represents sample from one mouse. Data are from three independent 
experiments.  
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Figure 3.7: Spleen B1 cells are comparable between IgMwt and IgMg1 mice. 
A. Gate scheme for B1 cells in spleen. These cells are gated from mature spleen 
B cells and they are CD21-CD23-IgDlowCD43+ cells. 
B. Percentages of B1 cells within spleen B cells and compared between IgMwt 
and IgMg1 mice. 
ns, not significant; unpaired Student’s t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are from two independent experiments.  
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3.2.3 Slightly affected BM and significantly affected splenic B cell development in 
IgMg1 B cells 
 
To better understand the inconsistent results of percentages and absolute numbers of 
B cell populations observed in homozygous mice, IgMg1/IgMwt heterozygous mice 
were constructed. This would enable to directly compare the development of IgMwt 
expressing B cells and IgMg1 expressing B cells competing in the same physiological 
environment. IgMg1 or C57BL/6 WT mice, which are Ig heavy chain allotype b 
(IgHb), were crossed with BALB/c mice, which are Ig heavy chain allotype a (IgHa), 
to generate IgHa/IgHb F1 mice. These IgHa/IgHb F1 mice are heterozygous for IgH; 
one allele being IgHa and the other allele IgHb (Fig. 3.8). Due to allelic exclusion, B 
cells in these mice can express only one IgH allele. In the absence of selection 
pressure this should lead to 50% IgHa and 50% IgHb B cells. B cell development and 
competition between IgHa (IgMwt) and IgHb (IgMwt or IgMg1) expressing B cells 
was assessed by testing the percentages of each population in these F1 mice. The 
percentages of B cell precursor B cell subsets CLPs and pro-B cells were similar in 
both groups (Fig. 3.9 A and B). Overall percentages of immature B cells were the 
same in IgMwt/IgMwt and IgMwt/IgMg1 IgHa/IgHb heterozygous mice (Fig. 3.9 C). 
However, immature IgHb IgMg1 B cells developed at slightly smaller percentages 
than IgHa IgMwt B cells (Fig. 3.10A). This was due to the IgHa/b allotypic differences 
or the different VDJ repertoires, but not the expression of the IgMg1 cytoplasmic 
chain, as we observed the same trend in numbers of immature B cells in 
IgMawt/IgMbwt heterozygous mice (Fig. 3.10A). The number of IgHb IgMg1 
immature B cells in IgMg1/IgMwt heterozygous was slightly higher than IgHb IgMwt 
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immature B cells when related to IgHa IgMwt immature B cells (Fig. 3.10B). Overall 
mature B cell percentages were slightly increased in bone marrow of IgMawt/IgMbg1 
heterozygous mice (Fig. 3.9D). This may be explained by slight advantages of IgHb 
IgMg1 B cells compared to both IgHa and IgHb IgMwt B cells, although this was not 
significant (Fig. 3.10C and D).  
 
Taken together this confirms that IgMg1 does not endow B cells with a major 
advantage during B cell development in the bone marrow.  
 
Further B cell development in the spleen was assessed in IgHa IgMwt/IgHb IgMwt 
and IgHa IgMwt/IgHb IgMg1 heterozygous mice. The overall percentages of 
transitional and T1 B cells tended to be lower in IgHa IgMwt/IgHb IgMg1 
heterozygous mice (Fig. 3.11A and 3.11B left). IgHb IgMg1 B cells displayed a 
significant survival disadvantage compared to both IgHb and IgHa IgMwt B cells 
during T1 stage (Fig. 3.12B). On the contrary, there were higher ratios of T2+3 B 
cells derived from IgHb IgMg1 B cells (Fig. 3.12C). Overall percentages of mature Fo 
B cell were slightly higher while MZ B cells were slightly lower in IgHa IgMwt/IgHb 
IgMg1 heterozygous (Fig. 3.13A). Within those, IgHb IgMg1 B cells displayed a 
major advantage in differentiating into Fo B cells (Fig. 3.13B) and an impaired MZ B 
cell fate commitment (Fig. 3.13C). 
 
In summary this showed that IgHb IgMg1 B cells display a significant survival 
disadvantage when competing with IgMwt B cells during T1 stage. This is in line 
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with the significantly reduced percentages of T1 cells in homozygous IgMg1 mice 
(Fig. 3.5). The higher ratio of IgHb IgMg1 Fo B cells and lower ratio of IgHb IgMg1 
MZ B cells (Fig. 3.13B and C right) were also consistent with previous observations 
on their percentages in homozygous IgMg1 mice (Fig. 3.6). This suggests the 
percentages of B cell populations observed in homozygous IgMg1 mice reflect the 
impact of IgMg1 BCR signalling on peripheral B cell fate commitment rather than 
their absolute numbers. 
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Figure 3.8: The construction of Ha/Hb heterozygous 
Schematic representation of the generation of IgHa+ Balb/c and IgHb+ IgMg1 or 
IgMwt C57B/L6 heterozygous F1 mice. Due to allelic exclusion, B cells of F1 
heterozygous mice will express either allele, and B cells are either IgMa+ or IgMb+. 
This enables us to directly distinguish and compare two subsets of B cells developing 
alongside each other in F1 heterozygous mice. 
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Figure 3.9: The percentages of B cell subsets within BM are comparable between 
IgMwt and IgMg1 heterozygous. 
Gate setting of CLPs, Fr.A, immature B cells and mature B cells are the same as the 
ones displayed in Fig. 3.2 and Fig. 3.3 
A. Percentages of overall CLPs within bone marrow lymphocytes compared 
between IgMawt/IgMbwt and IgMawt/IgMbg1 heterozygous mice. 
B. Percentages of overall Fr.A (pro-B cells) within bone marrow lymphocytes  
C. Percentages of overall immature B cells within bone marrow lymphocytes. 
D. Percentages of overall mature B cells within bone marrow lymphocytes. 
ns, not significant; unpaired Student’s t test, Bars indicate mean. Each symbol 
represents sample from one mouse. Data is representative from two independent 
experiments.  
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Figure 3.10: Bone marrow IgMg1 B cell development is normal in the presence 
of competition. 
Gates for immature and mature B cells are the same as showed in Fig. 3.3. 
A. Percentages of Ha+ and Hb+ immature BM B cells. Lines connect percentages 
of IgHa+ and IgHb+ cells from within the same heterozygous mouse. 
B. Ratios of IgHa+ to IgHb+ immature B cell subsets within IgMawt/IgMbwt and 
IgMawt/IgMbg1 heterozygous mice. 
C. Percentages of Ha+ and Hb+ mature BM B cells. Lines connect percentages of 
IgHa+ and IgHb+ cells from within the same heterozygous mouse. 
D. Ratios of IgHa+ to IgHb+ mature B cell subsets within IgMawt/IgMbwt and 
IgMawt/IgMbg1 heterozygous mice. 
* p < 0.05; unpaired Student’s t test in B, D. 2-Way ANOVA in A, C. Bras indicate 
mean. Each symbol represents sample from one mouse. Data are representative from 
two independent experiments. 
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Figure 3.11: The percentages of transitional and T1 B cells are slightly reduced 
in IgMawt/IgMbg1 heterozygous mice. 
A. Gate settings for transitional, T1, T2+3 cells in spleen. Transitional B cells are 
gated as CD19+B220+CD93+ cells. T1 are CD21-CD23- subsets within the 
transitional population, while T2+3 are CD21+CD23+ ones. 
B. The percentages of overall transitional, T1 and T2+3 B cells within spleen B 
cells. 
ns, not significant; unpaired Student’s t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are representative from two independent 
experiments. 
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Figure 3.12: IgMg1 B cells are less efficient in generating T1 B cells. 
A. Gates for IgMb WT or IgMg1 B cells, and IgMa WT B cells within both T1 
and T2+3 B cells. 
B. Percentages of Ha+ and Hb+ T1 B cells. Lines connect percentages of IgHa+ and 
IgHb+ cells from the same heterozygous. Ratios of IgHa+ to IgHb+ T1 B cell 
subsets within each heterozygous. 
C. Percentages of Ha+ and Hb+ T2+3 B cells. Lines connect percentages of IgHa+ 
and IgHb+ cells from the same heterozygous. Ratios of IgHa+ to IgHb+ T2+3 B 
cell subsets within each heterozygous. 
* p < 0.05; ** p < 0.01; **** p < 0.0001; unpaired Student’s t test in B, C right; 2-
Way ANOVA in B, C left. Horizontal bars indicate mean. Each symbol represents 
sample from one mouse. Data are representative from two independent experiments. 
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Figure 3.13: IgMg1 B cells are more efficient than IgMwt B cells in generating 
Fo B cells, while less competitive in generating MZ B cells. 
Gates for Fo and MZ B cells are the same as in Fig. 3.6, sub-populations are the same 
as Fig.3.12 
A. The percentages of total Fo and MZ B cells within spleen B cells. 
B. Percentages of Ha+ and Hb+ Fo B cells. Lines connect percentages of IgHa+ and 
IgHb+ cells from the same heterozygous mouse. Ratios of IgHa+ to IgHb+ Fo B 
cell subsets within each heterozygous mouse. 
C. Percentages of Ha+ and Hb+ MZ B cells. Lines connect percentages of IgHa+ 
and IgHb+ cells from the same heterozygous mouse. Ratios of IgHa+ to IgHb+ 
MZ B cell subsets within each heterozygous mouse. 
* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; unpaired Student’s t test in A, 
B, C right; 2-Way ANOVA in B, C left. Horizontal bars indicate mean. Each symbol 
represents sample from one mouse. Data are representative from two independent 
experiments. 
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BM chimeras were also constructed and B cell development in these bone marrow 
chimeric mice was also assessed to detect CD45.2+ IgMg1 B cell development with 
the presence of CD45.1+ IgMwt counterparts. To construct BM chimeras, lethally 
irradiated C57BL/6 mice were reconstituted with equal numbers of CD45.2+ (IgMg1 
or C57BL/6 IgMwt) and CD45.1+ (C57BL/6-Ly5.1) bone marrow cells and were 
allowed to settle for 7-8 weeks (Fig. 3.14).  
 
This showed CD45.2 + BM cells had a developmental advantage over CD45.1+ BM 
cells after reconstitution. In BM mature B cells, CD45.2+ B cells accounted for 
around 75% of this population in IgMwt/IgMwt chimeras, with a ratio of CD45.2+ B 
cells to CD45.1+ B cells of around 3, while in IgMg1/IgMwt chimeras the ratio 
reached around 6 (Fig. 3.15B). This developmental advantage of CD45.2 BM cells 
was more obvious in early stages, such as in pre-B cells and immature B cells, where 
the ratios were larger than 10 in IgMwt/ IgMwt mice. However, CD45.2+ IgMg1 
precursor cells appear to be less competitive than IgMwt, as the ratio tended to be 
lower in IgMg1 chimeras (Fig. 3.15B). 
 
In spleens, the ratio of CD45.2+ to CD45.1+ total B cells in IgMg1 BM chimeras 
remained higher at around 5 than in IgMwt BM chimeric mice, which was around 3.5 
(Fig. 3.16A left). However, IgMg1 B cells do not show any advantage at T1 B cell 
stage, where the ratio of IgMg1 to IgMwt B cells tends to be lower than in WT 
chimeras (Fig. 3.16A middle), which is consistent with B cell blockage during T1 
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stage observed in homozygous IgMg1 mice (Fig. 3.8). The ratios of CD45.2+ B cells 
to CD45.1+ B cells reversed in T2+3 cells, to be as low as 0.3 in both WT and IgMg1 
chimeras (Fig. 3.16A right). The ratio increased to be even higher in IgMg1 Fo B 
cells, which was around 8 and almost double that of WT chimeras (Fig. 3.16C top 
left), confirming IgMg1 B cells prefer follicular B cell fate (Fig. 3.9). On the contrary, 
there were at least 4-fold fewer marginal zone B cells in IgMg1 mice compared with 
their wildtype counterparts (Fig. 3.16B and C).  
 
In summary, B cell development in bone marrow chimeras were quite consistent with 
the observations in homozygous mice (Fig. 3.7, 3.8 and 3.9) and IgHa/IgHb 
heterozygous mice. The ratio (CD45.2+ to CD45.1+) of peripheral mature B cells was 
around 5 in IgMg1 chimeras, and 3.5 in WT chimeras (Fig. 3.16A left). 
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Figure 3.14: The construction of bone marrow chimeras. 
Wildtype C57BL/6N of at least 20 g were fed on Baytril in water for one week before 
irradiation. Mice received 5.5 Gy irradiation in the morning and another 5.5 Gy 
irradiation in the afternoon. Right after the second irradiation, mice were adoptively 
transferred with a total amount of 5x106 bone marrow cells through i.v. injection. 
CD45.1+ C57BL/6-Ly5.1 (BoyJ) and CD45.2+ C57BL/6N (or IgMg1) were mixed at 
a ratio of 1:1. Mice were left to reconstitute for 7-8 weeks before immunisation. 
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Figure 3.15: Increased IgMg1 mature B cell populations during BM stage. 
The construction of bone marrow chimeras was described in Fig. 3.14. Gate settings 
for pre-B, immature and mature B cell populations in BM are the same in Fig. 3.3. 
A. Gate settings for CD45.1+ and CD45.2+ B cell subsets in BM pre-B cells, 
immature B cells and mature B cells from both IgMwt and IgMg1 mice. 
B. Ratios of CD45.2+/CD45.1+ are calculated and compared between groups. 
Ratios of CD45.2+/CD45.1+ is defined as percentages of CD45.2+ subsets 
divide the percentages of CD45.1+ subsets 
**** p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are representative from two independent 
experiments. 
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Figure 3.16: Increased differentiation of Fo B cells and decreased MZ B cells 
differentiation during peripheral development for IgMg1 B cells. 
The construction of bone marrow chimeras was described in Fig. 3.14. Gate settings 
for spleen B, T1, T2+3, Fo, MZ, and B1 cells are the same in Fig. 3.4-3.7. 
A. Ratios of CD45.2+/CD45.1+ are calculated and compared between groups. 
Spleen mature B cells and transitional B cell populations have been analysed 
and displayed. 
B. Gate settings for CD45.1+ and CD45.2+ B cell subsets in spleen follicular and 
MZ B cells from both IgMwt and IgMg1 mice. 
C. Ratios of CD45.2+/CD45.1+ are calculated and compared between groups. 
Ratio of CD45.2+/CD45.1+ is defined as percentages of CD45.2+ subsets 
divide the percentages of CD45.1+ subsets 
**p < 0.01; ****p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each 
symbol represents sample from one mouse. Data are representative from two 
independent experiments. 
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3.2.4 Increased Igl light chain usage during B cell development 
	
	
The significant reduction in the percentage of T1 B cells in spleens of IgMg1 mice 
(Fig. 3.5 and 3.11) suggests that IgMg1 B cells experienced enhanced negative 
selection during B cell development. Immature stage in bone marrow and T1 stage in 
spleen are the two major self-reactive selection checkpoints during B cell 
development (Pelanda and Torres 2012). Negative selection at the immature stage 
may induce B cell apoptosis, or alternatively, B cells can undergo secondary light-
chain rearrangements (Gay, Saunders et al. 1993, Tiegs, Russell et al. 1993, Prak and 
Weigert 1995). The first light chain rearrangement during B cell development 
happens in the Igk light chain locus. This, in mice, leads to preferential expression of 
Igk light chains, with 90% of mature B cells expressing Igk containing BCR. The Igl 
light chain locus is normally silenced and lambda light chain rearrangement is only 
activated if kappa light chain rearrangement completely fails (Prak, Trounstine et al. 
1994, Prak and Weigert 1995). Thus, expression of Igl light chain can serve as an 
indicator of negative selection B cells experienced during immature stage. We 
therefore measured the frequency and ratio of Igl to Igk light chain expressing B 
cells in BM immature, transitional B cells and all mature B cell populations. During 
immature stage the Igl/Igk ratio was varied between experiments (Fig. 3.17B left, 
solid and circle), however tended to be higher in the IgMg1 mice in each experiment 
(Fig. 3.17B left). This ratio increased to be significantly higher in IgMg1 BM 
transitional B cells (Fig. 3.17B right) and in all mature B cell populations of IgMg1 
mice (Fig. 3.17C). These results indicate that during immature stage of B cell 
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development the expression of IgMg1 makes B cells more prone to be negatively 
selected.  
 
The ratio of Igl to Igk was then assessed in BM chimeras, which was described in Fig. 
3.14. In IgMwt/IgMwt chimeras, both CD45.1+ and CD45.2+ B cells displayed similar 
lambda chain usage (Fig. 3.18C). In IgMwt/IgMg1 chimeras, however, there were 
significantly higher percentages of Igl+ B cells in CD45.2+ IgMg1 B cells and this 
started from immature stage (Fig. 3.18C). Consistent with the observation in 
homozygous IgMg1 mice, the ratios of Igl+ mature B cells in both BM and spleens in 
IgMg1 chimeric mice were significantly higher (Fig. 3.19B and D). This confirms 
enhanced l chain usage in IgMg1 B cells, indicating that IgMg1 B cells are regarded 
to be more auto-reactive during negative selection of B cell development.  
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Figure 3.17: Enhanced IgL Lambda chain usage in IgMg1 mice. 
Gates for BM immature and mature B cells are the same as the ones displayed in Fig. 
3.3. Spleen and LN B cells are gated as the one displayed in Fig. 3.7 
A. Gate settings for IgL Lambda+ and Kappa+ B cells in BM and spleen mature B 
cells. 
B. Ratio of percentage of IgL Lambda+ B cells to Kappa+ B cells in BM 
immature and transitional B cells. 
C. Ratio of percentage of Lambda+ B cells to Kappa+ B cells in BM mature B 
cells, spleen B cells and LN B cells. This ratio has been regarded as an 
indicator of lambda chain usage. 
***p < 0.001; ****p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each 
symbol represents sample from one mouse. Data are from two independent 
experiments.  
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Figure 3.18: Higher IgL Lambda chain usage in IgMg1 immature B cells in bone 
marrow chimeric mice. 
A. Gate settings of IgL Lambda+ B cells in CD45.1+ and CD45.2+ BM immature 
B cells. 
B. The percentages of total immature B cells within BM lymphocytes from both 
IgMwt and IgMg1 chimeras. 
C. Ratio of percentage of IgL Lambda+ B cells to IgL Kappa+ B cells in both 
CD45.1+ and CD45.2+ immature B cells from IgMwt and IgMg1 chimeras. 
This ratio has been regarded as an indicator of lambda chain usage. 
**p < 0.01; ****p < 0.0001; 2-way ANOVA. Each symbol represents sample from 
one mouse. Data are representative from two independent experiments.  
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Figure 3.19: Higher IgL Lambda chain usage in IgMg1 mature B cells. 
Gates for BM mature B cells and spleen B cells are the same as the ones displayed in 
Fig. 3.3 and Fig. 3.4. 
A. Percentages of total mature B cells within BM lymphocytes from both IgMwt 
and IgMg1 chimeras. 
B. Ratio of percentage of IgL Lambda+ B cells to IgL Kappa+ B cells in both 
CD45.1+ and CD45.2+ BM mature B cells from IgMwt and IgMg1 chimeras.  
C. Percentages of total spleen B cells within splenocytes from both IgMwt and 
IgMg1 chimeras. 
D. Ratio of percentage of IgL Lambda+ B cells to IgL Kappa+ B cells in both 
CD45.1+ and CD45.2+ spleen B cells from IgMwt and IgMg1 chimeras.  
*p < 0.05; ****p < 0.0001; 2-way ANOVA. Each symbol represents sample from one 
mouse. Data are representative from two independent experiments.  
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3.2.5 Reduced expression of surface IgM on IgMg1 B cells from the immature 
stage of development 
	
	
The significantly reduced numbers of T1 cells and enhanced lambda chain usage in 
IgMg1 mice indicate IgMg1 B cells are more prone to undergo negative selection 
similar to self-reactive B cells during development. Previous studies showed that the 
majority of B cells displaying auto-reactivity are either deleted or induced into 
anergic state during B cell development (Brink and Phan 2018). Down-regulation of 
surface IgM has been observed in anergic B cells in the majority of anergic mouse 
models (Erikson, Radic et al. 1991, Goodnow, Brink et al. 1991, Benschop, Aviszus 
et al. 2001, Borrero and Clarke 2002). Thus, surface IgM and IgD expressions in 
IgMg1 B cells were assessed. 
 
Flow cytometry showed that membrane IgM (mIgM) expression was reduced in all 
IgMg1 B cell subsets compared to IgMwt counterparts. mIgM expression level was 
reduced in IgMg1 mice since mIgM is initially expressed on immature B cells, and in 
IgMg1 mice mIgM expression level of immature B cells was 74% of IgMwt B cells 
(Fig. 3.20A and B). Lower expression of mIgM was also found in transitional and 
mature BM B cells, which were 65% and 53% of their WT counterparts, respectively 
(Fig. 3.20C and D left). In the spleen transitional B cell populations, mIgM expression 
in IgMg1 B cells were 49% in T1 B cells and 40% in T2+3 B cells of the expression 
levels on IgMwt B cells (Fig. 3.21A, B and C, D). While IgMwt B cells express 
mIgM at 2-fold higher levels when they differentiate into MZ B cells, mIgM levels 
remained low and were more than 3-fold lower in IgMg1 MZ B cells compared to 
106	
	
IgMwt MZ B cells (Fig. 3.22C and D). Fo B cells in IgMg1 mice express 2-fold lower 
surface IgM than their WT counterparts (Fig. 3.22B and D left). Different from this, 
initial expression of mIgD during T1 stage in the spleen was comparable between 
IgMg1 and IgMwt mice (Fig. 3.21B). However, mIgD expression levels were slightly 
decreased in BM mature B cells (Fig. 3.20D), T2+3 cells (Fig. 3.21D) and Fo B cells 
(Fig. 3.22D). MZ B cells in IgMg1 and IgMwt mice also displayed low but similar 
levels of mIgD expression (Fig. 3.22B). Overall, mIgM expression was significantly 
downregulated in all IgM expressing B cell populations, but the expression of mIgD 
was only slightly reduced mainly in re-circulating B cells, such as Fo B cells. The 
expression of mIgM and mIgD on B cells is dynamically regulated and is tightly 
connected with BCR signalling and the responsiveness of B cells (Goodnow, Crosbie 
et al. 1989, Zikherman, Parameswaran et al. 2012). The changes in mIgM and mIgD 
expression levels suggest BCR signalling or the state of B cell activation may be 
altered in IgMg1 mice. 
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Figure 3.20: Reduced surface IgM (mIgM) and IgD (mIgD) expression in 
immature and mature BM B cells. 
A. Representative 2-D plot displaying IgD and IgM expression in both immature 
and mature BM B cells. 
B. The MFI of mIgM in immature B cells from both IgMwt and IgMg1 mice. 
C. The MFI of mIgM in BM transitional B cells from both IgMwt and IgMg1 
mice 
D. The MFI of mIgM and mIgD in BM mature B cells from both IgMwt and 
IgMg1 mice 
**p < 0.01; ***p < 0.001; ****p < 0.0001; unpaired Student’s t test. Bars indicate 
mean. Each symbol represents sample from one mouse. Data are representative from 
four independent experiments.  
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Figure 3.21: Reduced surface IgM (mIgM) and IgD (mIgD) expression in 
transitional B cells. 
A. Representative 2-D plot displaying IgD and IgM expression in T1 B cells. 
B. The MFI of mIgM in T1 B cells from both IgMwt and IgMg1 mice. 
C. Representative 2-D plot displaying IgD and IgM expression in T2+3 B cells. 
D. The MFI of mIgM and mIgD in T2+3 B cells from both IgMwt and IgMg1 
mice 
***p < 0.001; ****p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each 
symbol represents sample from one mouse. Data are representative from four 
independent experiments.   
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Figure 3.22: Reduced surface IgM (mIgM) and IgD (mIgD) expression in spleen 
MZ and Fo B cells. 
A. Representative 2-D plot displaying IgD and IgM expression in MZ B cells. 
B. The MFI of mIgM in Fo B cells from both IgMwt and IgMg1 mice. 
C. Representative 2-D plot displaying IgD and IgM expression in Fo B cells. 
D. The MFI of mIgM and mIgD in MZ B cells from both IgMwt and IgMg1 mice 
***p < 0.001; ****p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each 
symbol represents sample from one mouse. Data are representative from four 
independent experiments.   
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To test whether the lower IgMg1 BCR expression was due to transcriptional 
regulation, primers were designed to specifically amplify mRNA encoding for 
membrane bound IgM or IgD (Fig. 3.23A). Surprisingly, there was no significant 
difference in relative mRNA levels encoding for mIgM between IgMwt and IgMg1 
mice (Fig. 3.23B), suggesting that the reduced mIgM expression was not due to 
transcriptional regulation.  
           
 
Figure 3.23: Ighm mRNA expression level is comparable between IgMwt and 
IgMg1 mice. 
A. Schematic mRNA sequences encoding for membrane-bound IgM (Ighm) and 
IgMg1 (Ighmg1), extracellular part (green), transmembrane (TM) part (red), 
cytoplasmic part (yellow). Forward and reverse primers are designed as 
indicated (arrow shows). 
B. Relative mRNA expression levels of Ighm and Ighd. Relative mRNA levels 
are normalised to house-keeping gene β-2 microglobulin, compared between 
IgMwt and IgMg1 mice. 
Bars indicate median. Each symbol represent sample from one mouse.  
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3.2.6 Evidence for hyper-active tonic signalling transducing from IgMg1 during 
B cell development 
	
As B cell fate is tightly regulated by their tonic BCR signalling strength	 (Niiro and 
Clark 2002, Monroe 2006, Pillai and Cariappa 2009), the effects on peripheral B cell 
development seen in IgMg1 mice suggested that tonic BCR signalling strength had 
changed in IgMg1 B cells. In order to directly measure tonic BCR signalling strength 
in all B cell subsets in IgMg1 and IgMwt mice, Nur77-GFP reporter mice were 
utilised	 (Moran, Holzapfel et al. 2011). Nur77 is an inducible orphan nuclear receptor, 
its expression is rapidly up-regulated after cognate receptor-antigen ligation in both T 
and B cells (Winoto and Littman 2002). As the expression of GFP is under the control 
of Nur77 regulatory region Nr4a1, the expression of GFP is immediately induced 
after TCR or BCR activation and the intensity of GFP can reflect TCR and BCR 
signalling strength (Zikherman, Parameswaran et al. 2012). 
 
During BM development, mIgM starts signalling after initial expression on immature 
B cells (Tze, Schram et al. 2005). During this stage, IgMg1 transduced stronger 
signalling than wildtype IgM (Fig. 3.24B and C left). At transitional stage IgMg1 B 
cells showed significantly stronger tonic signalling than their wildtype counterparts 
(Fig. 3.24B and C middle). Only 25% of IgMwt transitional B cells expressed 
stronger than background signalling, while around 60% of IgMg1 B cells expressed 
Nur77-GFP levels higher than background (Fig. 3.24D middle). The average Nur77-
GFP expression in transitional B cells was 1.7 times higher than background in 
IgMwt B cells, while transitional IgMg1 B cells expressed 3 times higher Nur77-GFP 
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than background (Fig. 3.24C middle). This hyper-active signalling in IgMg1 B cells 
disappeared once B cells had entered the mature BM B cell stage, with the average 
Nur77-GFP expression level not further increasing, and IgMwt B cells reaching 
slightly higher levels of Nur77-GFP expression than IgMg1 B cells (Fig. 3.24B and C 
right). This was also reflected in the frequency of Nur77+ B cells being slightly lower 
in mature IgMg1 B cells than in IgMwt B cells (3.24B and C right). 
 
In the periphery, both T1 and T2+3 IgMg1 B cells tended to have slightly lower 
Nur77-GFP expression than their WT counterparts, although none of this was 
significant (Fig. 3.25A and B). Relative Nur77-GFP expression levels in transitional 
B cells reached levels of around 4 to 6 times above background (Fig. 3.25B) and 
around 50% considered positive by Overton subtraction (Fig. 3.25C). The average 
Nur77-GFP expression level increased in MZ B cells compared to transitional B cells, 
being around 7 in IgMwt mice and around 9 in IgMg1 mice (Fig. 3.26A). Around 90% 
MZ B cells from IgMg1 mice expressed Nur77-GFP higher than background (Fig. 
3.26C left). Average Nur77-GFP expression levels in Fo B cells were similar to 
transitional B cells (Fig. 3.26B). Fo B cells in IgMg1 mice tended to show slightly 
lower expression levels but had a similar percentage of Nur77+ B cells of around 60% 
(Fig. 3.26B and C).  
 
In summary, IgMg1 was able to transduce stronger tonic BCR signalling at the stage 
when it was firstly expressed on immature B cells. This stronger signal became 
attenuated during BM development, indicating negative regulation of IgMg1 B cells 
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happening during BM B cell development. IgMg1 MZ B cells showed considerably 
stronger tonic BCR signalling, while the remaining peripheral IgMg1 B cell 
populations showed slightly repressed tonic BCR signalling. 
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Figure 3.24: Dynamic Nur77-GFP expression levels during B cell development in 
BM. 
A. Gate settings for the four different stages of BM B cell populations: pre-B 
cells, immature B cells, transitional B cells and mature B cells. 
B. Overlays of both Nur77 IgMwt (black) and Nur77 IgMg1 (red) B cells Nur77-
GFP expression levels in the above four B cell populations. Non-fluorescent 
counterpart of each cell population is gated as negative control (gray). 
C. Relative MFI (median FI) of Nur77-GFP expression level and compared 
between groups. Data merged from two independent experiments. Nur77-GFP 
expression level are normalised between independent experiments by defining 
the MFI (median FI) of the Nur77-GFP negative control (grey curve) as 1. 
D. Percentages of Nur77+ B cells and compared between groups. The percentages 
of Nur77+ B cells were calculated by Overton subtraction. 
**p < 0.01; ****p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each 
symbol represents sample from one mouse. Data are combined from two independent 
experiments.  
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Figure 3.25: Nur77-GFP expression level is comparable in IgMg1 transitional B 
cells. 
Gate settings for transitional B cells are the same as the ones displayed in Fig 3.5. 
A. Overlays of Nur77-GFP expressions in both T1 and T2+T3 B cells from 
Nur77 IgMwt (black) and Nur77 IgMg1 (red) mice. Non-fluorescent 
counterpart of each cell population is gated as negative control (gray). 
B. Normalised Nur77-GFP expression level in T1 and T2+T3 B cells. Nur77-
GFP expression level is normalised between independent experiments by 
defining the MFI of the Nur77-GFP negative control (grey curve) as 1. 
C. The percentages of Nur77+ B cells and compared between groups. The 
percentages of Nur77+ B cells were calculated by Overton subtraction.  
ns, not significant; unpaired Student’s t test. Bars indicate mean. Each symbol 
represent sample from one mouse. Data are combined from two independent 
experiments.  
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Figure 3.26: Nur77-GFP expression level is enhanced in MZ B cells. 
Gate settings for MZ and Fo B cells are the same as the ones displayed in Fig 3.6. 
A. Overlays of Nur77-GFP expressions in both MZ and Fo B cells from Nur77 
IgMwt (black) and Nur77 IgMg1 (red) mice. Non-fluorescent counterpart of 
each cell population is gated as negative control (gray). 
B. Nur77-GFP expression levels in MZ and Fo B cells and compared between 
groups.  
C. The percentages of Nur77+ B cells and compared between groups. The 
percentages of Nur77+ B cells were calculated by Overton subtraction. 
***p < 0.001; ****p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each 
symbol represent sample from one mouse. Data are combined from two independent 
experiments.  
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3.2.7 Dampened calcium influx and phosphorylation signalling after activating 
IgMg1 B cells through BCR 
	
The Nur77-GFP expression experiments demonstrated that tonic BCR signalling 
strength in IgMg1 mice were either higher, shown in MZ B cells, or were comparable 
to their wildtype counterparts, shown in mature follicular B cells. In order to test 
whether IgMg1 BCR leads to similar changes after BCR activation, the calcium influx 
of splenic B cells after activation with anti-IgM antibody was assessed. Splenic B 
cells were stained with Indo-1, and stimulated with anti-IgM to activate B cells 
directly through their BCRs. Basal soluble Ca2+ levels (R0) were comparable between 
IgMg1 and IgMwt B cells (Fig. 3.27B and C). After stimulating with anti-IgM, IgMwt 
B cells mounted an instant and strong calcium influx (Fig. 3.27A and B). IgMg1 B 
cells generated a slower and remarkably weaker calcium influx after activation (Fig. 
3.27B), reflected by weaker peak flux (Rp/R0) and longer time taken to reach peak 
levels after stimulation (Fig. 3.27B and C). 
 
The changes observed in signalling pattern of Ca2+ influx indicate that activated 
signalling transduced from IgMg1 BCR in mature B cells is lower than that of IgMwt 
BCR. 
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Figure 3.27: Lagging and weaker calcium influx of IgMg1 B cells after 
stimulation through IgM, after Indo-1 loading. 
A. Calcium influx in both IgMwt and IgMg1 B cells. Left: emission of Indo-1 
after binding to Ca2+; Right: emission of free Indo-1. RBC-depleted 
splenocytes are calmed at 5% CO2 at 37 ℃ for three hours. Then labeled with 
1 µM Indo-1 for 1 hour at RT. After labelling, cells are stained with anti-
CD43. The stained cells were first acquired for 1min to record the basal 
soluble calcium level, then stimulated with 10 µg/ml anti-IgM F(ab’)2 
antibody and acquired their calcium influx for 8min.  
B. Overlays of kinetic calcium influx from both IgMwt and IgMg1 splenic B 
cells. 
C. Strength and lasting time for calcium influx. The strength of calcium influx is 
calculated as the ratio between peak value (Rp) to basal value (R0). Time to 
peak is the duration of time used from start to reach the peak. 
*p < 0.05; **p < 0.01; unpaired Student’s t test. Bars indicate median. Each symbol 
represent sample from one mouse.  
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3.2.8 Weaker BCR-activation induced SYK and BLNK phosphorylation in 
IgMg1 B cells  
 
To further confirm these observations and test phosphorylation levels of specific 
signal transducing proteins downstream of the BCR, PhosFlow was utilized to detect 
tonic and BCR activation induced signalling in various B cell subsets. In bone 
marrow immature and mature B cells, tonic p-SYK and p-BLNK levels were quite 
comparable (Fig. 3.28A, B and C). While BCR activation with anti-IgM induced a 
clear increase in p-SYK and p-BLNK in IgMg1 B cells, these levels were consistently 
and dramatically lower than the ones induced in IgMwt B cells (Fig. 3.28B and C), 
indicating that downstream BCR activation induced signalling in IgMg1 B cells is 
repressed from immature B cell stage. 
 
In the spleen, tonic and activated p-SYK and p-BLNK levels were detected in the two 
major peripheral mature B cell populations – mature Fo B cells and MZ B cells. Of 
these, MZ B cells showed significantly increased tonic p-SYK signalling in IgMg1 B 
cells (Fig. 3.29A and B), consistent with the stronger Nur77-GFP reporter levels 
observed in these cells (Fig. 3.26A). However, tonic p-BLNK levels were similar in 
MZ B cells and Fo B cells (Fig. 3.29C). Within 5 minutes of BCR activation with 
anti-IgM, p-SYK was significantly elevated in IgMwt B cells, with the strongest 
increases happening in MZ B cells (Fig. 3.29B). This increase was less in all IgMg1 B 
cell populations. Again, this attenuation of signal was strongest in MZ B cells, while 
the attenuation of the weak signal seen in Fo B cells was not significant (Fig. 3.29A 
and B). BCR-stimulation induced BLNK phosphorylation in different splenic B cell 
122	
	
populations with a similar pattern to what was seen for p-SYK. In both populations of 
splenic IgMg1 B cells, BLNK phosphorylation was significantly attenuated compared 
to their WT counterparts (Fig. 3.29C).  
 
The reduced elevation levels of p-SYK and p-BLNK after BCR ligation in both 
immature and mature IgMg1 B cells were consistent with pervious observations of 
weaker calcium influx. Together, these results suggest that IgMg1 B cells represent 
anergic B cells. Despite immature B cells displaying slightly stronger tonic Nur77-
GFP expression level in IgMg1 mice (Fig. 3.24), the tonic p-SYK and p-BLNK levels 
were quite comparable to WT counterparts. Furthermore, BCR ligation induced BCR 
signalling was significantly reduced in immature B cells from IgMg1 mice, indicating 
IgMg1 B cells are induced into anergy during this stage. 
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Figure 3.28: Comparable tonic signalling, but constant lower activated 
phosphorylation levels of SYK and BLNK in immature and mature B cells in 
BM. 
Gates for BM immature and mature B cells are the same as displayed in Fig. 3.3. 
A. Overlays of phosphorylated SYK and BLNK from both IgMg1 (red line) and 
IgMwt (Black line) mice. BM lymphocytes are collected, for activated 
signalling, lymphocytes are stimulated with 10 µg/ml anti-IgM antibody for 
5min.Both non-treated (tonic) and treated (activated) cells are fixed and 
permeabilised. Anti-pSYK and anti-pBLNK are added along with other 
needed antibodies to stain the cells. Lambda-phosphatase treated counterparts 
are set as negative control (gray histogram). 
B. Tonic and activated relative p-SYK MFI levels. The MFI of tonic and 
activated p-SYK in immature and mature B cells of one representative 
experiment is shown (left). In order to merge data from two independent 
experiments (right), the relative MFI of p-SYK is calculated by taking the 
average MFI for tonic IgMwt in each population as 1.   
C. Tonic and activated relative p-BLNK MFI levels. The MFI of tonic and 
activated p-BLNK in immature and mature B cells of one representative 
experiment is shown (left). In order to merge data from two independent 
experiments (right), the relative MFI of p-BLNK is calculated by taking the 
average MFI for tonic IgMwt in each population as 1.   
***p < 0.001; ****p < 0.0001; 2-way ANOVA. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are representative from two independent 
experiments.  
 
  
125	
	
 
 
126	
	
Figure 3.29: Higher tonic signalling while reduced activated signalling in IgMg1 
MZ B cells. 
Gates for Fo and MZ B cells are the same as displayed in Fig. 3.6. 
A. Overlays of phosphorylated SYK and BLNK from both IgMg1 (red line) and 
IgMwt (Black line) mice. Lymphocytes are isolated from spleens, either non-
treated or treated as described before (Fig. 3.29). Lambda-phosphatase treated 
counterparts are set as negative control (gray histogram). 
B. Tonic and activated relative p-SYK MFI levels. The MFI of tonic and 
activated p-SYK in Fo and MZ B cells of one representative experiment is 
shown (left). In order to merge data from two independent experiments (right), 
the relative MFI of p-SYK is calculated by taking the average MFI for tonic 
IgMwt in each population as 1.  
C. Tonic and activated relative p-BLNK MFI levels. The MFI of tonic and 
activated p-BLNK in Fo and MZ B cells of one representative experiment is 
shown (left). In order to merge data from two independent experiments (right), 
the relative MFI of p-BLNK is calculated by taking the average MFI for tonic 
IgMwt in each population as 1.  
****p < 0.0001; 2-way ANOVA. Bars indicate mean. Each symbol represents sample 
from one mouse. Data are from two independent experiments.  
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3.2.9 Activation markers are not elevated but are slightly lower in IgMg1 B cells 
	
Nur77-GFP expression levels in peripheral Fo B cells were quite comparable between 
IgMwt and IgMg1 mice (Fig. 3.26B). In line with this, the basal intracellular Ca2+of 
splenic B cells in IgMg1 mice were also similar to their WT counterparts (Fig. 3.27B), 
as were the tonic p-SYK and p-BLNK levels in Fo B cells (Fig. 3.29B). Together, 
these results suggest that the dominant splenic B cell population, naïve Fo 
recirculating B cells, is not hyper-activated in IgMg1 mice. To further test this, the 
expression levels of activation markers CD25, CD69 and CD86 on IgMg1 B cells 
were compared to their WT counterparts. These markers are induced on the surface of 
all lymphocytes and are up-regulated after B cell activation (Dugas, Paul-Eugene et al. 
1991, Ziegler, Ramsdell et al. 1993, Nashar, Webb et al. 1996). They would be 
expected to be increased if B cells in IgMg1 mice received increased tonic BCR 
signalling. 
Flow cytometry showed that the expression of CD25 and CD86 was quite comparable 
between IgMg1 and IgMwt total splenic B cells, whereas background CD69 
expression was slightly but significantly lower in IgMg1 splenic B cells (Fig. 3.30A 
and B). IgMg1 B cells from total LNs showed similar expression level of both CD25 
and CD69 on their surface (Fig. 3.30C and D). Together these results confirm that at 
least the peripheral Fo B cell subset is not hyper-activated, whereas MZ B cells in 
IgMg1 mice displayed hyper-activated steady state reflected by higher tonic Nur77-
GFP, p-SYK and p-BLNK levels. Further detailed flow cytometric markers and 
gating strategies in splenic B cells are needed to separate this population and detect 
CD25 and CD69 expression levels on them. 
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Figure 3.30: Activation markers expression levels were either comparable or 
lower on IgMg1 B cells. 
Gates for B cells were the same as showed in Fig. 3.4 
A. Overlays of surface CD25, CD69 and CD86 expression levels on total splenic 
B cells from IgMwt (black) and IgMg1 (red).   
B. Surface CD25, CD69 and CD86 expression levels on total spleen B cells from 
IgMwt (black) and IgMg1 (red).   
C. Overlays of surface CD25 and CD69 expression levels on total LN B cells 
from IgMwt (black) and IgMg1 (red).   
D. Surface CD25 and CD69 expression levels on total LN B cells from IgMwt 
(black) and IgMg1 (red).   
*p < 0.05; unpaired Student’s t test. Bars indicate mean.  
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3.2.10 Down-regulation of IgM expression and altered MZ B cell localisation in 
IgMg1 mice 
 
Anergic B cells are not just characterised by their reduced BCR signalling after 
activation, other features include: the down-regulation of surface IgM, altered 
localisation to unusual anatomical sites, and blockade of B cell development 
(Cambier, Gauld et al. 2007). Results shown above show that IgMg1 B cells display 
reduced activated signalling and down-regulate mIgM. Although there were no 
obvious signs that B cell development was blocked, IgMg1 B cells experienced 
increased negative selection during immature and transitional stages, as evidenced by 
the increased IgL λ/κ ratio. It was therefore interesting to test if there was any change 
in micro-anatomical location of mature IgMg1 B cells. 
 
To explore this, the anatomical structures of spleen white pulp were detected by 
fluorescence immunohistology, looking for the presence and location of Fo and MZ B 
cells. Spleens from both non-immunised IgMg1 and IgMwt mice were cryo-sectioned. 
Fluorophore-labelled anti-IgM and anti-IgD antisera and CD4 and CD169 antibodies 
were used to mark different micro-anatomical regions of the splenic white pulp (Fig. 
3.31). Using this marker combination, the B cell follicles are IgDhiIgMmedCD4-
CD169-, the MZ region is IgDloIgMhi CD4-CD169-, and the T zone is IgD-IgM-
CD4+CD169-. CD169-specific staining of macrophages was used to identify the 
marginal sinus macrophages, separating follicles from MZ (Fig. 3.31A). IgM was 
expressed at much lower levels in the B cell follicles of IgMg1 mice than in IgMwt 
mice, confirming the lower expression of surface and also intracellular IgM on B cells 
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of IgMg1 mice (Fig. 3.21 and 3.22). There was no obvious difference in the location 
of follicular B cells or of B cell follicle size (Fig. 3.31). However, the MZ seemed to 
have disappeared in IgMg1 spleens, shown by a loss of IgMhighIgDlow MZ cells 
around the IgDhigh follicular areas (Fig. 3.31B). This difference in MZ compartment 
was more pronounced seen in flow cytometry, which showed a 65% reduction of the 
percentages of MZ B cells (Fig. 3.6C).  
 
As IgMg1 MZ B cells significantly down-regulate mIgM (Fig. 3.22), it is possible 
that the disappearance of MZ area in IgMg1 spleen was due to IgM levels being too 
low to be detected by immunofluorescence. CD1d is highly expressed on MZ B cells 
(Roark, Park et al. 1998, Makowska, Faizunnessa et al. 1999, Pillai, Cariappa et al. 
2005). To confirm MZ B cell absence, we stained spleen sections with B220 and 
CD1d (Fig. 3.32). This showed B220+CD1d+ MZ B cells present in both marginal 
zone area and follicular region of spleen from IgMwt mice (Fig. 3.32A right). There 
were still some MZ B cells in IgMg1 mice, but all of them were relocated to the 
follicular areas (Fig. 3.32B). The normal micro-anatomincal location of follicular B 
cells confirms that there is little change in the activation state of these cells. The small 
number of MZ B cells in IgMg1 mice however do show signs of increased tonic 
activation, which is reflected by their increased appearance in follicular areas and the 
T-B borders, indicating that these cells may be in an increased state of shuttling 
between follicles and the MZ (Arnon, Horton et al. 2013) (Figure. 3.32B). 
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Figure 3.31: Immunofluorescence images of spleen sections from both IgMwt 
and IgMg1 non-immunised mice. 
A. Immunofluorescent staining of spleen cryosection from IgMwt non-
immunised mice. Sections are stained for anti-IgM (green), anti-IgD (red), 
anti-CD4 (blue) and anti-CD169 (gray). MZ B cells are IgMhighIgDlowCD4- 
(green); Fo B cells are IgMmediumIgDhighCD4- (yellow); T cell were are IgM-
IgD-CD4+ (blue). 
B. Immunofluorescent staining of spleen cryosection from IgMg1 non-
immunised mice. Sections are stained for anti-IgM (green), anti-IgD (red), 
anti-CD4 (blue) and anti-CD169 (gray). MZ B cells are IgMhighIgDlowCD4- 
(green); Fo B cells are IgMmediumIgDhighCD4- (yellow); T cell are IgM-IgD-
CD4+ (blue). 
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Figure 3.32: Impaired MZ B cell differentiation and the dislocation of them to 
follicular region. 
A. Immunofluorescent staining of spleen cryosection from IgMwt non-
immunised mice. Sections are stained for anti-B220 (red), IgD(Blue or white) 
and anti-CD1d (green). MZ B cells are CD1d+B220+ (yellow); Fo B cells are 
CD1d-B220+ (red). Arrow indicates CD1d+B220+ MZ B cells. 
B. Immunofluorescent staining of spleen cryosection from IgMg1 non-
immunised mice. Sections are stained for anti-B220 (red), IgD(Blue or white) 
and anti-CD1d (green). MZ B cells are CD1d+B220+ (yellow); Fo B cells are 
CD1d-B220+ (red). Arrow indicates CD1d+B220+ MZ B cells. 
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3.2.11 Changed surface chemokine receptor expression levels in IgMg1 MZ B 
cells 
 
Chemokine receptors are dynamically expressed on the surface of lymphocyte. These 
receptors have a role in locating cells to different micro-anatomical compartments, for 
example, guiding cells to local responding site after stimulation. Thus, altered 
localisation of IgMg1 MZ B cells should be reflected by changes on their surface 
chemokine receptor expression levels. CCR7 guides cellular migration towards the T 
zone, is highly expressed on T cells, and is up-regulated during initial B cell 
activation in order to attract B cells towards T-B border (Forster, Schubel et al. 1999, 
Okada and Cyster 2007, Forster, Schubel et al. 2016), reacting to chemotactic cues 
from CCL19 and CCL21 produced by T zone stroma. CCR7 has also been reported to 
play roles in locating MZ B cells to follicles (Muppidi, Arnon et al. 2011), indicating 
its potential role in MZ B cell shuttling (Arnon, Horton et al. 2013). Another 
important chemokine receptor is CXCR5, which is highly expressed on B cells. Its 
ligand CXCL13 is enriched in B cell follicles and forms a gradient from follicle to 
outer regions. CXCL13 and CXCR5 paired to help B cells localise to B cell follicles. 
In order to follow these processes, the expression levels of CCR7 and CXCR5 on 
IgMg1 and IgMwt B cells were detected by flow cytometry.  
 
Follicular and MZ B cells subpopulations were gated as described before (Fig.3.6). 
While there was no significant difference in CCR7 expression on follicular B cells, 
the expression of CCR7 on MZ B cells was slightly but significantly higher in IgMg1 
mice (Fig. 3.33A). CXCR5 expression was unchanged between IgMg1 and IgMwt 
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MZ B cells (Fig. 3.33B). Higher expression level of CCR7 suggests that IgMg1 MZ B 
cells are more sensitive to the CCL19/21 chemokine gradient produced by the T zone, 
and confirms that these cells are in a pre-activated stage with increased movement 
into the follicular areas. 
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Figure 3.33: Increased CCR7 expression but similar CXCR5 expression on MZ 
B cells in IgMg1 mice. 
Gates for MZ and Fo B cells are similar as showed before in Fig. 3.6. 
A. Overlays and summarizing statistics of surface CCR7 expression levels on 
follicular and MZ B cells from IgMwt (black) and IgMg1 (red).   
B. Overlays and summarizing statistics of surface CXCR5 expression levels on 
spleen B cells from IgMwt (black) and IgMg1 (red). Gray: CXCR5 expression 
level on T cells as a control. 
***p < 0.001; 2-way ANONA. Bars indicate mean. Data are representative from two 
independent experiments.  
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3.3 Discussion 
	
3.3.1 IgMg1 B cells have been induced into anergic state during B cell 
development 
	
Previous studies on BCR signalling have shown that mutations in repressors 
of BCR signalling result in hyper-activated B cells and auto-immune diseases (Hibbs, 
Tarlinton et al. 1995, O'Keefe, Williams et al. 1996, Getahun, Beavers et al. 2016). 
Mutation of CD22 for example, leads to enhanced calcium influx, higher expression 
levels of CD86 and increased proliferation after BCR ligation (O'Keefe, Williams et 
al. 1996). B cells of Lyn-/- mice show enhanced Jun N-terminal kinase (JNK) activity 
and increased calcium influx after activation through BCR (Chan, Lowell et al. 1998, 
Cornall, Cyster et al. 1998). Furthermore, loss of SHP-1 in anergic B cells leads to 
restoration of activated BCR signalling (O'Neill, Getahun et al. 2011, Getahun, 
Beavers et al. 2016). In this study, we were trying to enhance BCR signalling by 
adding the IgG1 cytoplasmic region to IgM. However, contradictory to what we 
expected, after BCR ligation by anti-IgM, immature B cells display reduced BCR 
signalling, shown by significantly lower elevation of p-SYK and p-BLNK, 
resembling anergy. This anergic-like signalling pattern was also observed in all 
mature B cell populations. Following stimulation via BCR ligation, recirculating 
IgMg1 Fo B cells generate lower signalling levels than IgMwt B cells, reflected by 
lower calcium influx and weaker elevation of protein phosphorylation. Additionally, 
BM immature B cells, another circulating naïve B cell population, also display 
significantly lower elevation of p-SYK and p-BLNK after BCR ligation. More 
significant inhibition of activated BCR signalling is observed in MZ B cells. The 
138	
	
defining feature of B cell anergy is the absence of or reduced signalling down-stream 
of the BCR (Goodnow, Crosbie et al. 1988, Shlomchik 2008), these results suggest 
that rather than being hyper-activated after BCR ligation, both immature and mature 
B cells in IgMg1 mice are in a state of anergy. 
 
Anergic B cells in the classical anergic HEL mouse model (MD4 × ML5) and lupus 
mouse models display a hyper-activated tonic state (Cambier, Gauld et al. 2007), 
which leads to the assumption that anergic B cells are hyper-activated cells at steady 
state. In this IgMg1 mouse model, BM immature B cells display slightly higher tonic 
Nur77-GFP levels compared to WT, but display comparable tonic p-SYK and p-
BLNK expression levels. The two recirculating naïve mature B cell subsets, spleen Fo 
B cells and BM mature B cells, show slightly lower or comparable tonic BCR 
signalling levels in IgMg1 mice compared to WT, reflected by: Nur77-GFP 
expression levels, basal soluble calcium level after in vitro rest and tonic p-SYK and 
p-BLNK levels (Fig. 3.26, 3.27, 3.29 and 3.30). However, MZ B cells in IgMg1 mice 
are hyper-activated at the steady state, showing significantly stronger tonic BCR 
signalling and up-regulated surface expression of CCR7. As recirculating B cells are 
the dominant mature B cell populations in IgMg1 mice, these results demonstrate that 
unlike anergic HEL-specific B cells, the majority of B cells in IgMg1 mice are not 
hyper-activated at the tonic state.  
 
Apart from reduced BCR signalling after IgM ligation, surface IgM expression on all 
B cell populations in IgMg1 mice is found to be ≤50% that of their WT counterparts. 
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The down-regulation of surface IgM is observed in the majority of anergic B cell 
mouse models (Cambier, Gauld et al. 2007), and has been used to define anergic B 
cell populations in humans (Duty, Szodoray et al. 2009). There is a trend of increased 
suppression of surface IgM expression from immature B cells to mature B cells in 
IgMg1 mice during B cell development. However, the enhanced suppression of IgM 
does not seem to link with a more stringent anergic state. With less than 30% 
reduction of surface IgM expression compared to IgMwt B cells, IgMg1 immature B 
cells show more significant repression of activated BCR signalling than IgMg1 Fo B 
cells, which show more than 50% reduction of surface IgM expression.  
 
In some models of B cell anergy, anergic B cells were reported present in ectopic 
locations, such as the T-B border (Mandik-Nayak, Bui et al. 1997, Noorchashm, Bui 
et al. 1999, Cambier, Gauld et al. 2007). In the IgMg1 model, MZ B cells are 
ectopically present in the follicular region, which can be interpreted as a movement 
towards the T zone.  
 
In the IgMg1 model, significantly reduced BCR signalling following BCR ligation, 
combined with the reduced surface IgM expression in all B cell populations again 
strongly suggests that B cells in IgMg1 mice have entered an anergic state, and this 
phenotype begins to show at the immature B cell stage. 
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3.3.2 Extra signalling from the cytoplasmic region of IgG1 leads to anergy 
induction during immature B cell stage of B cell development 
 
B cell anergy is induced by extra signalling from BCR ligation with self-antigen 
during negative check points of B cell development (Brink and Phan 2018). Results 
from Nur77-GFP reporter mice show that IgMg1, containing the IgG1 cytoplasmic 
region, is initially able to transduce stronger downstream signalling than IgM in 
immature and transitional B cells during BM stage. As IgMg1 is intrinsically able to 
transduce a stronger down-stream BCR signal, IgMg1 BCRs with low affinity toward 
self-antigen may transduce signalling that is relatively stronger than WT IgM BCR 
with the same specificity. This stronger signalling from IgMg1/self-ligand binding 
could be translated into increased negative selection during B cell development. 
 
There are two negative selection checkpoints against auto-reactivity during B cell 
development: (i) immature B cell stage and (ii) transitional T1 stage. During these 
two stages, self-antigens are displayed in the BM micro-environment or are expressed 
on peripheral tissues (Mandik-Nayak, Bui et al. 1997, Noorchashm, Bui et al. 1999, 
Cambier, Gauld et al. 2007) . Depending on their affinity toward self-antigen, B cells 
are either deleted, modified, induced into anergy, or allowed to further differentiate 
(Jacobi and Diamond 2005, Meffre and Wardemann 2008, Pelanda and Torres 2012). 
The Nur77-GFP expression level is attenuated during BM development in IgMg1 
mice, with significantly decreased Nur77-GFP expression in BM mature B cells 
compared to transitional B cells. There is no such attenuation of Nur77-GFP 
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expression during peripheral development of IgMg1 B cell subsets. Furthermore, 
IgMg1 immature B cells have already acquired the features of anergic B cells. Thus 
the key process of anergy induction should happen no later than immature B cell stage. 
This is consistent with a previous observation showing that the main strategy of 
negative regulation at the immature B cell and T1 stages are different. Immature B 
cells are more resistant to apoptosis induction, while 70-80% of T1 cells are deleted 
(Carsetti, Kohler et al. 1995). Thus, anergy induction or light chain editing could be 
the main strategies adopted at the immature B cell stage to deal with auto-reactive B 
cells (Gay, Saunders et al. 1993, Tiegs, Russell et al. 1993, Prak and Weigert 1995). 
However, auto-reactive B cells are mainly deleted at the T1 stage (Russell, Dembic et 
al. 1991, Jacobi and Diamond 2005) . In line with this, results in this study show 
either percentages or absolute numbers of IgMg1 T1 B cells are significantly reduced 
in IgMg1homozygous mice or in IgMwt/IgMg1 heterozygous.  
 
Previous studies show that the maintenance of unresponsiveness of anergic B cells 
requires continuous presence of inhibitory signalling by both SHP-1 and SHIP-1 
(O'Neill, Getahun et al. 2011, Getahun, Beavers et al. 2016). These pathways could be 
involved in the maintenance of a low-responsive state of IgMg1 B cells as well. After 
BCR stimulation, the elevation of p-SYK in IgMg1 Fo B cells is quite similar to 
IgMwt Fo B cells. However, there is a significantly reduced elevation of p-BLNK in 
IgMg1 Fo B cells, suggesting that the signalling transduction from p-SYK to p-BLNK 
is impaired in IgMg1 Fo B cells. SHP-1 is known to down-regulate p-SYK activity 
(Maeda, Scharenberg et al. 1999, Rolli, Gallwitz et al. 2002) and is reported to repress 
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phosphorylation of BLNK by p-SYK in B cells (Mizuno, Tagawa et al. 2000). Thus 
SHP-1 could inhibit signalling transduction from p-SYK to BLNK and maintain the 
low-responsive state of IgMg1 B cells. The impaired phosphorylation of BLNK might 
lead to weaker calcium influx and decreased elevation of total phosphotyrosines 
observed in IgMg1 splenic B cells. The function of SHP-1 and the mechanism behind 
the maintenance of the low-responsive state of IgMg1 B cells could be further studied. 
 
3.3.3 The expression of IgMg1 chimeric BCR affected B cell development  
 
In both IgMg1 homozygous and heterozygous mice, no major effect on IgMg1 B cell 
development during BM stage is detected, despite significantly higher numbers of 
mature IgMg1 B cells in BM. The majority of BM mature B cells come from 
recirculation of peripheral mature Fo B cells, but 15% derive from direct maturation 
in BM (Cariappa, Chase et al. 2007, Lindsley, Thomas et al. 2007). The increased 
number of mature IgMg1 B cells could either come from enhanced circulation from 
the periphery, or from increased direct maturation of IgMg1 Fo B cells in BM.  
 
During peripheral stage, the percentages of T1 B cells are significantly reduced in 
IgMg1 homozygous mice. Consistent with this trend, Hb IgMg1 B cells are less 
competitive at differentiating into T1 B cells compared to Ha IgMwt B cells. However, 
IgMg1 B cells show a survival advantage when they differentiate into T2+3 cells, 
which leads to only a slightly reduced percentage of T2+3 B cells in homozygous 
IgMg1 mice and a higher percentage of T2+3 B cells in IgMwt/IgMg1 heterozygous 
mice. These results suggest that IgMg1 T1 B cells can possibly proliferate faster to 
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generate more daughter T2+3 B cells. T2 B cells are the direct precursors of MZ and 
Fo B cells (Pillai, Cariappa et al. 2005). Previous studies have shown that fate 
decisions of MZ and Fo B cells are highly sensitive to BCR signalling strength 
(Cariappa, Tang et al. 2001, Samardzic, Marinkovic et al. 2002). Results of peripheral 
B cell development demonstrate that the changed signalling from the IgMg1 BCR 
seem to preferentially promote Fo B cell generation. The larger Fo B cell populations 
in IgMg1 mice could be explained by three different situations. Firstly, altered 
signalling in IgMg1 T2 B cells could favour Fo B cell differentiation. Secondly, the 
proportion of T2 cells committing to Fo B cell fate could be the same in IgMg1 and 
IgMwt mice, but T2 IgMg1 B cells could proliferate faster to produce higher numbers 
of Fo B cells. Thirdly, the percentages of precursor cells and proliferation rate both be 
unchanged in T2 IgMg1 B cells, but newly generated Fo B cells in IgMg1 mice could 
have a longer life span. Additional experiments are needed to verify these possibilities 
and reveal the mechanisms of the impact of IgMg1 BCR signalling on peripheral B 
cell fate decisions. 
 
Studies have shown that silenced or non-silenced self-reactive B cells are retained in 
the mature Fo B cell compartment (Wardemann, Yurasov et al. 2003, Zikherman, 
Parameswaran et al. 2012). This can be evolutionarily advantageous. MZ B cells have 
higher levels of tonic BCR signalling (Fig. 3.26 and 3.29) and CD21 (Oliver, Martin 
et al. 1999, Cariappa, Tang et al. 2001), can be immediately activated and can mount 
an immune response when they encounter cognate antigen, without the need for T cell 
help (Oliver, Martin et al. 1997, Oliver, Martin et al. 1999). On the contrary, Fo B 
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cells have relatively fine-tuned tonic BCR signalling (Noviski, Mueller et al. 2018)), 
which is lower than MZ B cells (Fig. 3.26 and 3.29). They localise in B cell follicles 
and are less likely to encounter antigen directly from blood. Fo B cells are normally 
involved in the T-D immune response and require co-stimulation signals from T cells 
for complete activation. Thus, Fo B cells can be better controlled and are more easily 
supervised during their activation. From this point of view, with the extra signalling 
from the IgG1 tail, IgMg1 B cells are treated as auto-reactive B cells and are more 
likely to be induced into Fo B cell fate. 
 
3.3.4 Outlook on the next chapter 
	
The results of the current studies on IgMg1 B cells suggest that these cells have been 
induced into an anergic state during B cell development. By preserving germ-line 
VDJ regions and allowing for random rearrangements, mature B cells in IgMg1 mice 
should be poly-clonal anergic B cells. This enables us to further study the behaviours 
of poly-clonal anergic B cells during immune responses, with a focus on the 
regulation of anergic B cells during GC reactions. 
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Chapter 4 . Antigen-induced differentiation of anergic B 
cells in the IgMg1 mouse model 
 
 
4.1 Introduction 
 
4.1.1 Animal models of B cell anergy and their limitations 
 
The functional silence of self-antigen-specific B cells was first described by Goodnow 
et.al using hen egg lysozyme (HEL)-specific B cell receptor (BCR) transgene mouse 
model which also has general endogenous expression of HEL (Goodnow, Crosbie et 
al. 1988). The general knowledge of B cell anergy has developed based on this model 
(Glynne, Ghandour et al. 2000, Burnett, Langley et al. 2018).  However, the 
application of this HEL mouse model to study breakage of immune tolerance in 
autoimmune diseases such as lupus failed. The limitation of BCR specificities, being 
only HEL-specific, contributed to the failure of these experiments (Shlomchik 2008). 
More recently generated animal models of B cell anergy which are specific for natural 
endogenous auto-antigens, such as chromatin and insulin to study lupus or diabetes, 
are also limited by the fact that specificity only toward one or limited number of auto-
antigens can be investigated. The endogenous wild type VDJ repertoire for the BCR 
is lost in all of these BCR transgene anergic models and B cells are not able to 
respond to other self-antigens. Further, the anergic patterns in these animal models 
varied (Erikson, Radic et al. 1991, Santulli-Marotto, Retter et al. 1998, Benschop, 
Aviszus et al. 2001, Rojas, Hulbert et al. 2001). The diversity of these anergic 
phenotypes can be partly explained by their distinct BCRs binding to different self-
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antigens in different ways, such as different affinities for self-antigens, different sites 
of encountering the antigen (Cambier, Gauld et al. 2007). As anergic B cells have 
been estimated to account for almost a quarter of peripheral mature B cells and have a 
wide spectrum of both BCR specificities and affinities (Grandien, Fucs et al. 1994, 
Cambier, Gauld et al. 2007), a mouse model with poly-clonal anergic B cells would 
be useful to study this diverse population. 
 
Until recently, the main interest of anergic B cell studies remained to be the 
relationship between anergic B cells and auto-immune diseases. Less attention has 
been paid to why our immune system would risk to preserve such a big quantity of 
these potentially auto-reactive B cells. 
 
It has been shown that anergic B cells can be involved in immune responses by 
recruiting them into germinal centres (GCs) (Cappione, Anolik et al. 2005, Sabouri, 
Schofield et al. 2014, Williams, Bonami et al. 2015). Very recently, the activation and 
salvage of HEL-specific anergic B cells through recruitment into the GC response and 
hypermutation away from self-specificity has been described by Burnett et al. 
(Burnett, Langley et al. 2018). This process has been labelled “clonal redemption”. 
By generating BM chimeras, HEL-specific BCR transgenic B cells were exposed in a 
HEL expressing (self-antigen) environment, which induced an anergic state. These 
mice were then immunised with duck egg lysozyme (DEL) as a model for a non-self 
(foreign) antigen. DEL is highly crossreactive with HEL and has only 4 amino acid 
residues difference to HEL. It was observed that these HEL-specific anergic B cells 
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were recruited well into the GC response. During the GC reaction, HEL-specific B 
cells were allowed to evolve away from self-reactivity through mutations to remove 
self-binding. This was followed by an accumulation of higher affinity B cells specific 
for DEL (Schofield et al. 2014, Burnett, Langley et al. 2018). Molecular mimicry is 
adopted by many pathogens in order to mimic self-antigen and to escape immune 
surveillance (Pinschewer, Perez et al. 2004, Scherer, Zwick et al. 2007, Gristick, von 
Boehmer et al. 2016). Thus, keeping self-antigen cross-reactive B cells in the 
repertoire, but silencing them by inducing anergy, from which they can escape by 
clonal redemption, is a potential benefit in the defence against invasion of pathogens 
using molecular mimicry. This way these silenced self-reactive B cells can stay in the 
repertoire at low risk of causing auto-immune diseases. 
 
The studies mentioned have shed light on the physiological function of anergic B cells, 
however, inevitably brought another question: how are anergic B cells regulated to 
accomplish clonal redemption during GC reactions?   
 
4.1.2 B cell receptor signalling and B cell fate decisions during the GC response 
 
The GC is the place where antigen-specific B cells undergo affinity maturation. This 
evolution towards higher affinity for specific epitope is not a random process but is 
based on complex selection within GCs. Currently, the favoured model is the “T cell 
centric” model (Mesin, Ersching et al. 2016), where B cells take a passive role and B 
cell fate decisions are directed by Tfh cells (Batista and Neuberger 2000, Allen, 
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Okada et al. 2007, Schwickert, Victora et al. 2011, Gitlin, Mayer et al. 2015). Another 
well-known model is antibody feedback, where B cells with higher BCR affinity 
could get greater access to antigens and thus present more antigen through p-MHCII 
in order to receive T cell help for selection (Meyer-Hermann, Mohr et al. 2012, Zhang, 
Meyer-Hermann et al. 2013). This suggests BCR affinity and signalling strength 
could be additional factors which drive the selection. In this model, stronger BCR 
signalling would cause B cells with higher affinity to become more competitive by 
presenting higher amounts of antigen as p-MHCII or forming stronger T - B cell 
interactions. The duration and strength of this T-B interaction will affect GC B cell 
fate decisions. 
 
Potential differences in BCR signalling strength not only derives from the affinity of 
the BCR - antigen interaction, but can also come from intrinsic changes in the 
activation state of B cells. Compared to normal non-self-reactive naïve B cells, 
anergic B cells present a unique gene expression pattern and reduced BCR signalling 
after activation (Goodnow, Crosbie et al. 1988, Glynne, Ghandour et al. 2000). Being 
a large population within peripheral mature B cells (Grandien, Fucs et al. 1994, 
Wardemann, Yurasov et al. 2003), it is hard to ignore anergic B cells and their 
involvement into GC reactions. Clonal redemption has been proposed as a model 
where anergic B cells evolve away from auto-reactivity and towards specificity to 
cross-reactive foreign antigens in the GC (Sabouri, Schofield et al. 2014, Reed, 
Jackson et al. 2016, Burnett, Langley et al. 2018). However, the selection mechanisms 
behind clonal redemption are not clear. The study from Chan et al suggests that the 
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selection against auto-reactivity in GCs depends on the concentrations and locations 
of auto-antigens (Chan, Wood et al. 2012). Thus, the selection and modification of 
GC B cells generated from activated anergic B cells should also depend on the 
presence of self-antigen. It remains elusive how the positive selection signalling from 
foreign antigen and negative selection signalling from self-antigen work together to 
modify these B cells during GC reactions. Besides these hypothetical positive and 
negative signals, active BCR signalling in anergic B cells is intrinsically different 
from naïve non-self-reactive B cells, as shown by observations of in vitro stimulated 
anergic and normal mature B cells through their BCRs (Erikson, Radic et al. 1991, 
Goodnow, Brink et al. 1991, Benschop, Aviszus et al. 2001).  It is not known how 
long this rewired BCR signalling in anergic B cells remains after they are activated 
and become GC B cells, and how far this rewired BCR signalling would affect BCR 
selection during the GC response.  
 
Another potential effect which might affect BCR signalling in GC B cells are the 
isotypes of surface BCRs. During or preceding the GC response, the majority of GC 
B cells lose surface IgM expression and go through class-switch to express IgG1 or 
other isotypes (Toellner, Gulbranson-Judge et al. 1996, Toellner, Luther et al. 1998, 
Marshall, Zhang et al. 2011). Different BCR isotypes have different length 
cytoplasmic regions that can transduce different strength down-stream BCR signalling. 
Among these, the best understood is IgG1, which can signal independently of Igα/β 
and can transduce stronger downstream BCR signals (Waisman, Kraus et al. 2007, 
Engels, Konig et al. 2009, Weston-Bell, Forconi et al. 2014). IgE+ GC B cells are 
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known to be disfavoured during GC selection. Despite having the same specificity, 
once GC B cells have switched to express IgE+ on the surface, they are more prone to 
be induced into apoptosis (Yang, Sullivan et al. 2012, He, Meyer-Hermann et al. 
2013). However, the mechanisms of the influence of different signalling patterns from 
different isotypes of BCRs on GC B cell selections remains to be revealed. In our 
IgMg1 mouse model, altered BCR signalling through IgMg1 would disappear after 
they cease IgM expression and switch to express other isotypes, such as IgG1.  
 
4.1.3 Objective  
 
The work presented in this chapter is based on the hypothesis that changed BCR 
signalling, in the poly-clonal IgMg1 knock-in mouse model described in Chapter 3, 
generated a mouse model with poly-clonal anergic B cells. In vivo responses of 
anergic B cells to TI-II antigens are not well studied. However, when stimulated in 
vitro with anti-IgM antibody to activate anergic B cells through BCR, anergic B cells 
are not able to respond or only mount reduced activated BCR signalling. In this 
chapter, the immune responses of these anergic IgMg1 B cells toward TI-II were 
analysed in order to test the capability of these cells to undergo plasma cell responses 
after activation through surface BCRs without T cell help. The ability of anergic B 
cells to join GC responses through clonal redemption is reported, however, factors 
involved into this directed selection within GC response are poorly understood. In this 
chapter, the immune response of these anergic IgMg1 B cells toward TD antigens and 
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the detailed process of GC reactions were investigated by immunisation and the study 
of antigen-induced B cell differentiation in time course experiments.  
 
Aims are detailed as follows: 
1.  How do anergic IgMg1 B cells respond to TI-II and T-D antigens? Are they 
behaving differently to IgMwt non-self-reactive B cells?  
A. B cell differentiation in the TI-II immune response  
B. B cell differentiation in the T-D immune response  
 
2. The dynamic process of GC reactions in IgMwt and IgMg1 mice. 
A. The emergence B cell populations generated during GC response 
B. Proliferation and apoptotic rates during the GC response 
C. Class switch of GC B cells  
D. BCR signalling strength during the GC response 
 
3. Are IgMg1 B cells influencing Tfh differentiation 
A. Test the generation of Tfh cells during GC responses 
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4.2 Results 
	
	
In Chapter 3 we have characterised the newly generated IgMg1 mouse, and noticed 
that IgMg1 B cells are displaying an anergic pattern, with clearly suppressed BCR 
signalling after activation. In this chapter we utilise this poly-clonal anergic B cell 
mouse model to study the impact of the changed signalling in anergic B cells on their 
in vivo activation and fate decisions.  
 
4.2.1 Impaired TI-II immune response in IgMg1 mice 
 
Previous studies aimed at revealing the role of anergic B cells in auto-immune 
diseases were limited by single or limited specificity of transgenic BCR(s) present in 
the B cell repertoire of anergic mouse models used in these studies. The in vivo 
response of anergic B cells toward TI-II antigens is poorly studied. Despite this, it has 
been shown that in vitro stimulation of anergic B cells through IgM ligation leads to 
absent or severely reduced activation BCR signalling (Erikson, Radic et al. 1991, 
Goodnow, Brink et al. 1991, Benschop, Aviszus et al. 2001). This indicates that the 
ability of anergic B cells responding to TI-II antigens might be impaired. Therefore, 
we studied the responses of our poly-clonal anergic IgMg1 B cells to the TI-II antigen 
NP-Ficoll in vivo.  
  
In order to induce splenic TI-II B cell responses, both IgMg1 and IgMwt control mice 
were immunised with i.p. NP-Ficoll. Development of splenic plasma cells and NP-
responding B cells was followed at the peak of the extrafollicular plasmablast 
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response (Garcia de Vinuesa, O'Leary et al. 1999). Fig. 4.1B shows percentages of 
plasma cells and antigen-specific plasma cells and B cells 5 days after NP-Ficoll 
immunisation. A summary of all experiments, normalized to remove variation 
between different immunisation experiments is shown in Fig. 4.1C. Flow cytometric 
analysis showed that significantly fewer NP-specific B cells were generated in IgMg1 
mice at day 5 after immunisation with NP-Ficoll, with antigen-specific CD138- B 
blasts accounting for 0.7% of lymphocytes in IgMwt and 0.2% of B220+ cells in 
IgMg1 mice (Fig. 4.1A, B and C left). Plasma cells are the main responding B cell 
population generated in TI-II immunisation (Garcia de Vinuesa, O'Leary et al. 1999). 
Both total plasma cells and NP-specific plasma cells were reduced by 50% in IgMg1 
mice (Fig. 4.1B and C middle, right).  
 
As NP-PE may bind B cells non-specifically, unimmunised control mice were used to 
identify non-specific background staining of B cells (Fig 4.2A). While five days after 
immunisation there was a clear increase of NP-specific CD138- B blasts in IgMwt 
mice, the percentages of NP-binding B cells in IgMg1 mice remained low and did not 
rise above the high background levels observed by flow cytometry (Fig. 4.2A and B). 
Staining of NP-specific plasma cells, however, was specific and no antigen-specific 
PCs were detected in unimmunised mice (Fig. 4.2 C). In summary, Fig. 4.1 and Fig 
4.2 indicate that IgMg1 B cells can form plasma cells in response to NP-Ficoll, but at 
significantly lower efficiency than IgMwt B cells, while B blast numbers at day 5 post 
immunisation are severely reduced and not detectable using this method. 
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To confirm this observation, spleen sections from immunised IgMwt and IgMg1 mice 
were stained, to assess plasma cell clusters in situ. Transcription factor IRF4 is 
required for the generation of plasma cells, is strongly expressed by plasma cells 
(Klein, Casola et al. 2006) and therefore was selected as a marker for plasma cells. 
Anti-IgD, staining naïve B cells, was used to identify follicular areas. NP conjugated 
to sheep Ig was used to check the antigen-specificity of these plasma cells, CD4 was 
used to outline T-zone (Fig. 4.3A). Images confirmed that IRF4+NP+IgD-CD4- plasma 
cell clusters (white arrow heads) accumulating in the splenic bridging channels in 
IgMg1 spleens were significantly smaller than their IgMwt counterparts (Fig. 4.3A, B 
and C). This further confirmed smaller numbers of antigen-specific B blasts (green 
arrow heads) formed in IgMg1 mice. There was no obvious difference in the 
migration of these cells, as they had similar locations in both IgMg1 and IgMwt mice 
in the outer T zone and bridging channels (Garcia de Vinuesa, O'Leary et al. 
1999)( Fig, 4.3A).  
 
Furthermore, NP-specific serum antibodies in IgMg1 mice were analysed. This 
showed that the median titres of antigen-specific IgM and IgG3 were also reduced by 
30% and 32% respectively in IgMg1 mice, although these differences were not 
significant (Fig. 4.4). Surprisingly, although class switch recombination leads to a loss 
of expressed IgMg1 BCR, meaning IgG3 switched B blasts from IgMwt and IgMg1 
mice should be genetically identical, IgM and IgG3 antibody titres in IgMg1 mice 
show a similar slight reduction. 
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Together, the results from both flow cytometry and immunofluorescence suggest 
IgMg1 B cells have a reduced ability to respond to TI-II antigens by forming lower 
numbers of B blasts and plasma cells. This is consistent with the in vitro BCR 
stimulation experiments described in chapter 3 (Fig. 3.27-3.30), which showed that 
anti-IgM stimulation induced BCR signalling of IgMg1 B cells results in a lower 
induction of protein phosphorylation and lagging calcium influx. This observation is 
consistent with IgMg1 B cells representing an anergic state that is not licensed to 
effectively differentiate into plasma cells without first undergoing GC differentiation 
(Burnett, Langley et al. 2018).  
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Figure 4.1: Impaired NP-Ficoll induced B cell response and plasma cell 
differentiation in IgMg1 mice. 
Both IgMg1 and IgMwt mice are immunised i.p. with 30 µg NP-Ficoll. Spleens are 
collected 5 days after immunisation. 
A. Gate settings of T-I immune response after NP-Ficoll immunisation. Gates for 
plasma cells (PCs), NP-specific B cells and NP-specific PCs are displayed. 
B. The percentages of NP-specific B cells, total plasma cells and NP-specific 
plasma cells. Representative data from three independent experiments. 
C. Normalized data merged from all three independent experiments. Data are 
normalized to the arithmetic average of the wild type data of each experiment, 
taking this as 1. 
* p < 0.05; ** p < 0.01; **** p < 0.0001; unpaired Student’s t test. Bars indicate 
mean. Each symbol represents sample from one mouse. Data are from three 
independent experiments. 
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Figure 4.2: IgMg1 mice respond to NP-Ficoll less efficiently than IgMwt mice. 
Both IgMg1 and IgMwt mice are immunised i.p. with 30 µg NP-Ficoll. Spleens are 
collected 5 days after immunisation. Spleens from unimmunised IgMwt and IgMg1 
mice as control. 
A. Gate settings of T-I immune response after NP-Ficoll immunisation. Gate 
settings for plasma cells (PCs), NP-specific B cells and NP-specific PCs are 
displayed. 
B. The percentages of NP-specific B cells are calculated and compared with 
unimmunised mice. 
C. The percentages of NP-specific plasma cells are calculated and compared with 
unimmunised mice. 
ns, non-significant; * p < 0.05; **** p < 0.0001; unpaired Student’s t test. Bars 
indicate mean. Each symbol represent sample from one mouse. 
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Figure 4.3: Smaller plasma cell clusters in IgMg1 spleen sections. 
Spleen sections are from IgMg1 and IgMwt mice at day 5 after i.p. immunised with 
30 µg NP-Ficoll. 
A. Representative immunofluorescence images of spleen sections from both 
IgMwt and IgMg1 mice. Sections are stained with NP (green), IRF4 (red), IgD 
(blue) and CD4 (gray). Plasma cluster is indicated with white arrows. NP-
specific B blasts are indicated with green arrows.  
B. Area of NP-specific plasma clusters in IgMg1 and IgMwt mice. Each symbol 
represents one PC cluster, data are combined from 4 mice in one 
representative experiment. 
C. Relative sizes of NP-specific plasma cell clusters are merged from two 
independent experiments. Data are normalized to the arithmetic average of the 
wild type data of each experiment, taking this as 1. Data analysis done by Dr. 
Juan Carlos Yam-Puc. 
** p < 0.01; unpaired Student’s t test. Bars indicate mean. Each symbol represents 
sample from one mouse. Data are from three independent experiments. 
159	
	
 
 
Figure 4.4: IgM and IgG3 tend to be slightly lower in IgMg1 mice. 
Both IgMg1 and WT mice are immunised i.p. with 30 µg NP-Ficoll. Serum samples 
are collected 5 days after immunisation. 
A. NP specific IgM antibody titers. NP2-BSA is used to coat plate and used to 
detect anti-NP IgM titers in both IgMg1 and WT serum samples. 
B. NP specific IgG3 antibody titers. NP14-BSA is used to coat plate and used to 
detect anti-NP IgG3 titers in both IgMg1 and WT serum samples. 
ns, not significant; unpaired Student’s t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are from three independent experiments. 
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4.2.2 Consistently larger NP-specific GC B cell compartment in IgMg1 mice 8 
days after immunisation with T-D antigen  
 
It was then of interest to know how anergic IgMg1 B cells would behave in a T-
dependent antibody response. Mice were immunised in the foot with alum-
precipitated NP-CGG with heat-inactivated Bordetella pertussis (BP) as an adjuvant. 
Eight days later, responding B cell populations in the popliteal LNs were analysed. 
Gate settings for different responding B cell populations are shown in Fig. 4.5. 
Plasma cells (PCs) were gated as CD138+B220low/- cells. The NP-specific B cell 
response was analysed by gating on NP-PE binding B cells. Within this population, 
NP+ GC B cells (CD138-B220+NP+CD38low/-Fas+) and NP+ memory B cells (CD138-
B220+NP+CD38+Faslow/-; MBCs) (Conter, Song et al. 2014) were gated (Fig. 4.5).  
 
Fig. 4.6 shows representative percentages of all populations analysed from a 
representative experiment, while Fig. 4.7 shows a summary of all four experiments. 
Eight days post immunisation there were no significant changes in overall B cell (Fig. 
4.6A, 4.7A) or plasma cell numbers (4.7B), however TD antigen led to an increase in 
the GC response (Fig. 4.7C). Memory B cell numbers did not significantly change 
(Fig 4.6D, 4.7D). Analysis of NP-specific B cells showed a more pronounced increase 
in overall NP-specific B cells (Fig. 4.6E, 4.7E) and NP-specific GC B cells in IgMg1 
mice (Fig. 4.6 F, 4.7F). This indicates that IgMg1 B cells, in response to T-D antigens, 
differentiate more efficiently into GC B cells than IgMwt B cells. The larger 
population of NP+ GC B cells (Fig. 4.6F, 4.7F) could either be due to a larger 
population of NP+ precursor B cells in IgMg1 mice (Fig. 4.6E, 4.7E), or to a 
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preferential differentiation of activated NP-specific IgMg1 B cells into GC B cells. To 
test this, GC B cell percentages within the NP-specific B cells were calculated. While 
it is impossible to make firm conclusions about fate decisions at the time when GCs 
are formed, which is 3-5 d before the tissues were analysed (Toellner, Luther et al. 
1998), this suggested that a significantly higher percentage of NP-specific B cells had 
committed to GC B cell fate in IgMg1 mice (Fig. 4.6G, 4.7G).  
 
The analysis of the T-D B cell response 8 d after immunisation indicates that, in the 
presence of T cell help, IgMg1 B cells are prone to produce good GC response 
reflected by slightly more total GC B cells and significantly more NP+ GC B cells. 
However, the size of both the plasma cell and memory B cell populations, which at 
this stage of the T-D immune response contains a mix of GC-derived and non-GC-
derived cells, are the same (Sze, Toellner et al. 2000, Zhang, Tech et al. 2018), 
(Kurosaki, Kometani et al. 2015). This would support the idea that anergic B cells are 
licensed to form GC responses (Sabouri, Schofield et al. 2014, Reed, Jackson et al. 
2016, Burnett, Langley et al. 2018), however, non-GC dependent differentiation and 
GC outputs of plasma cells and memory B cells is not increased, and might even be 
impaired.  
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Figure 4.5: Gate settings to analyse T-D immune response in both IgMg1 and 
WT mice. 
Both IgMg1 and WT mice are immunised with 20 µg alum precipitated NP-CGG and 
heat-inactivated Bordetella pertussis (BP) as adjuvant on each plantar surface of foot. 
Popliteal LNs are collected 8 days after immunisation. Gates for plasma cells (PCs), 
NP-specific B cells, NP-specific GC B cells and NP-specific memory B cells (MBCs) 
are displayed. 
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Figure 4.6: Increased GC response after T-D immunisation of IgMg1 mice. 
Representative experiment of WT and IgMg1 mice are immunised with 20 µg alum 
precipitated NP-CGG and heat-inactivated Bordetella pertussis (BP) as adjuvant on 
the plantar surface of the hind feet. Popliteal LNs are collected 8 days after 
immunisation. 
A. Percentages of B cells within lymphocytes.  
B. Percentages of plasma cells within lymphocytes.  
C. Percentages of total GC B within B cells. 
D. Percentages of memory B cells within B cells. 
E. Percentages of NP-specific B cells within B cells. 
F. Percentages of NP-specific GC B cells within B cells. 
G. Percentages of NP-specific GC B cells within NP+ B cells. 
* p < 0.05; *** p < 0.001; unpaired Student’s t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data were one representative experiment from 
four independent experiments. 
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Figure 4.7: Increased GC response after T-D immunisation of IgMg1 mice. 
Merged and normalised data of all four independent experiments. WT and IgMg1 
mice are immunised with 20 µg alum precipitated NP-CGG and heat-inactivated 
Bordetella pertussis (BP) as adjuvant on plantar surface of foot. Popliteal LNs are 
collected 8 days after immunisation. 
A. Relative percentages of B cells merged from four independent experiments. 
Data are normalized to the arithmetic average of the wild type data of each 
experiment, taking this as 1.  
B. Relative percentages of plasma cells. 
C. Relative percentages of total GC B cells. 
D. Relative percentages of total memory B cells. 
E. Relative percentages of NP-specific B cells. 
F. Relative percentages of NP-specific GC B cells. 
G. Relative percentages of NP-specific GC B cells within NP+ B cells. 
* p < 0.05; ** p < 0.01; *** p < 0.001; unpaired Student’s t test. Bars indicate mean. 
Each symbol represents sample from one mouse. Data were merged from four 
independent experiments.  
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4.2.3 Delayed early B cell response after immunisation with SRBC in IgMg1 
mice  
	
The observations described above were based on results obtained at the peak time of 
either TI-II or T-D immune responses to the hapten NP. To better understand the early 
stages of the B cell response, time courses after i.v. immunisation with sheep red 
blood cells (SRBCs) were performed. SRBC immunisation induces polyclonal B cell 
activation. They represent complex and large antigens with repetitive carbohydrate 
epitopes that can induce fast primary responses in the spleen. Unlike hapten-carrier 
conjugates, such as NP-CGG, SRBCs can induce a relatively strong poly-clonal T-D 
immune response in the absence of adjuvants (McAllister, Apgar et al. 2017). IgMwt 
and IgMg1 mice were immunised with SRBC i.v. and numbers of plasma cells 
(CD138+B220-) and GC B cells (CD138-B220+CD38low/-Fas+) were followed over the 
first 8 days. 
 
Immunisation with SRBCs leads to a significant increase in plasma cell and GC B cell 
differentiation from day 4 (Fig. 4.8B and C). Interestingly, while 3 days after 
immunisation there was no increase in plasma cells or GC B cells yet, there was a 
reproducible reduction of plasma cells and GC B cells in IgMg1 compared to IgMwt 
mice (two experiments with 4+4 and 4+3 animals; plasma cell reduction: p=0.0006 
and p=0.001, GC B cell reduction: p=0.001 and p=0.06). Immunisation leads to a loss 
of GC B cells not specific for the immunogen in the first few days of the response 
(Szakal, Taylor et al. 1990). Therefore, it can be speculated that the smaller numbers 
of plasma and GC B cells 3 days after immunisation in IgMg1 may represent a 
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smaller population of newly emerging immunisation induced cells. A similar trend 
was seen on day 4 (Fig. 4.8). Five days after immunisation is the peak of the extra-
follicular plasma cell response, and at the same time plasma cell output from GCs 
starts to be generated (Sze, Toellner et al. 2000, Zhang, Tech et al. 2018). From day 5 
there is no longer a significant difference in plasma cell population between IgMg1 
and IgMwt mice (Fig. 4.8A right and B), which could indicate a saturation of 
extrafollicular niches for plasma cells or the impact of increasing plasma cell output 
from the GC. GC B cells in IgMg1 mice appear in larger numbers from day 5, which 
may indicate that an equilibrium of proliferation and survival of GC B cells 
developing by day 5, which makes the effects of the slower onset of GC B cell 
differentiation and/or GC B cell recruitment disappear (Fig. 4.8A left and C).  
 
The small changes in quantity of GC B cells are due to the combined effects of 
immigration, proliferation, emigration, and apoptosis. In order to test whether the 
changes in GC B cell numbers in IgMg1 mice were due to cell proliferation, in vivo 
EdU incorporation was measured. 
 
To measure B cell proliferation rates, EdU was injected i.p. two hours before spleens 
were being taken. While there was no statistical difference in EdU uptake between 
IgMg1 and IgMwt mice, EdU incorporation into GC B cells tended to be slightly less 
on day 3 after immunisation in IgMg1 mice (Fig. 4.9A top and B). One day later, the 
proliferation rate of GC B cells increased to become slightly higher in IgMg1 mice 
(Fig. 4.9 A bottom and B). This is in line with changes in accumulation of GC B cells 
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3 and 4 d after immunisation (Fig. 4.8C). EdU incorporation into plasmablasts was 
the same on day 3, which would be in line with the hypothesis that the lower number 
of plasma cells was due to lower recruitment on day 3 (Fig. 4.10A and B). Four days 
post immunisation there was significantly less EdU incorporation into IgMg1 
plasmablasts (Fig.4.10B), indicating that the lower percentages of plasma cells in 
IgMg1 mice on day 4 can be explained by changes in recruitment and proliferation. 
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Figure 4.8: Early-delayed response of IgMg1 B cells towards SRBCs 
immunisation. 
IgMwt and IgMg1 mice are i.v. immunised with 2 x108 SRBCs. Spleens are collected 
at each indicated time point from day 0 to day 8 after immunisation. 
A. Gate settings for plasma cells (PCs) and GC B cells 3 days after immunisation. 
B. Percentages of IgMg1 (red) and IgMwt (black) GC B cells over time after 
immunisation.  
C. Percentages of IgMg1 (red) and IgMwt (black) plasma cells over time after 
immunisation. 
Multiple t test. Bars and whiskers indicate mean ± SD. Data are combined from two 
independent experiments, with a total number of 6 to 8 mice per time point. 
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Figure 4.9: Similar EdU incorporation rate in GC B cells from both IgMwt and 
IgMg1 mice. 
IgMwt and IgMg1 mice are i.v. immunised with 2 x108 SRBCs, spleens are collected 
at each indicated time point from day 1 to day 8 after immunisation. 
A. Representative histograms and thresholds for EdU+ GC B cells 3 and 4 days 
after immunisation. 
B. EdU incorporation rate within CD38-Fas+ GC B cells over time, showing 
IgMg1 (red) and IgMwt (black).  
Multiple t test. Bars indicate mean ± SD. Data are combined from two independent 
experiments, with a total number of 6 to 8 mice per time point. 
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Figure 4.10: Slightly different EdU incorporation rate in plasma cells from 
IgMg1 mice. 
IgMwt and IgMg1 mice are i.v. immunised with 2 x108 SRBCs, spleens are collected 
at each indicated time point from day 1 to day 8 after immunisation. 
A. Representative histograms and thresholds for EdU+ GC B cells 3 and 4 days 
after immunisation. 
B. EdU incorporation rate within CD38-Fas+ GC B cells over time, showing 
IgMg1 (red) and IgMwt (black). 
Multiple t test. Bars indicate mean ± SD. Data are combined from two independent 
experiments, with a total number of 6 to 8 mice per time point. 
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4.2.4 Increased early apoptosis rate and higher proliferation rate during the TD 
antibody response to NP-CGG in IgMg1 mice 
 
The kinetics of the GC response after SRBCs immunisation suggested a higher 
proliferation rate of GC B cells resulting in slightly larger GC in IgMg1 mice on day 
5 after immunisation (Fig. 4.8-4.11). As there were also slightly larger GCs in IgMg1 
mice 8 days after NP-CGG immunisation (Fig. 4.6 and 4.7), we next explored if this 
is also due to higher early rates of proliferation. We conducted time-course 
experiments in response to NP-CGG to assess GC B cell proliferation and apoptosis. 
Mice were immunised by plantar surface of foot injections with alum-precipitated 
NP-CGG with heat-inactivated Bordetella pertussis (b.p.), and responding B cell 
populations were analysed in popliteal LNs on days 4, 5, 6, 8 and14 after 
immunisation. EdU was i.p injected 2 hours before pLNs being taken. EdU 
incorporation rate was used to indicate cell proliferation rate. Intracellular staining of 
activated Caspase3 (aCaspase 3) was used to label apoptotic cells. 
 
While there was no obvious difference in the total size of GCs (Fig. 4.11), IgMg1 
mice showed a slightly higher frequency of proliferating GC B cells at day 8 after NP-
CGG immunisation (Fig. 4.12A and B). Interestingly, this was preceded by a phase of 
increased apoptosis in IgMg1 GC B cells 6 days after immunisation (Fig. 4.12A and 
C).  
 
This confirms observations from the SRBC time course experiments, showing an 
improved expansion of GC B cells in IgMg1 mice towards the peak of the response 
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despite increased apoptosis earlier on. This equilibrium of proliferation and apoptosis 
may lead to comparable percentages of total GC B cells in both IgMg1 and IgMwt 
mice 8 days after immunisation (Fig. 4.11B). Despite there being no obvious 
differences in the total number of GC B cells, there were subtle effects on the 
numbers of NP-responding GC B cells (Fig. 4.13). Reproducing the result of the 
single time point experiment described earlier (Fig. 4.7B), IgMg1 mice contained 
significantly higher numbers of NP-specific GC B cells 8 days after immunisation. 
This was also the case for the percentage of NP-specific GC B cells within B cells, 
which corresponds to the absolute numbers of hapten specific B cells generated 
(4.13B), as well as for the percentage of NP-specific GC B cells within the total GC B 
cell population (Fig. 4.13C). 
GCs formed in response to NP-CGG are initially preferentially colonized by NP-
binding cells (Toellner, Sze et al. 2018). At later stages these may be overtaken by 
GC B cells specific for the carrier-protein. This has been explained by the higher 
initial affinity of NP-specific B cells in the naïve repertoire, which may make it more 
difficult for B cells specific for more complex single copy epitopes on the carrier 
protein to be recruited and expand as GC B cells (Toellner, Sze et al. 2018). Fig. 
4.13C shows a similar decline in the percentage of NP-binding B cells within GCs in 
IgMwt and IgMg1 mice, however this decline is delayed in IgMg1 mice, which may 
reflect small differences in recruitment and survival of the initial wave of NP-specific 
B cells and later recruited carrier specific B cells.  
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Figure 4.11: Comparable numbers of GC B cells after NP-CGG immunisation of 
IgMg1 and IgMwt mice. 
Mice are immunised with 20 µg alum precipitated NP-CGG on plantar surface of foot, 
heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation, popliteal 
LNs are collected sequentially from day 4 to day 14.  
A. Representative dot plots with gates for total GC B cells in IgMwt and IgMg1 
mice 4 ad 14 days after immunisation. 
B. Percentages of GC B cells within B cells in WT and IgMg1 mice. 
ns, not significant; multiple t test. Bars indicate mean. Each symbol represents sample 
from one mouse. Data are combined from three independent experiments. 
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Figure 4.12: Increased apoptosis and proliferation of IgMg1 B cells in early stage 
GCs. 
Mice are immunised with 20 µg alum precipitated NP-CGG and heat-inactivated 
Bordetella pertussis (BP) as adjuvant on plantar surface of foot. After immunisation, 
popliteal LNs are collected sequentially from day 4 to day 14. 2 hours before 
dissection, 200 µg EdU is injected by i.p. Gates for total GC B cells were displayed in 
Fig. 4.13. 
A. Representative samples and gate settings used to analyse proliferation and 
apoptosis in GC B cells. Apoptosis was detected by anti-aCaspase3 antibody, 
while proliferation was assessed by EdU incorporation rate. 
B. The percentages of EdU+ GC B cells, and compared between WT and IgMg1 
mice.  
C. The percentages of aCaspase3+ GC B cells, and compared between WT and 
IgMg1 mice. 
Multiple t test. Bars indicate mean. Each symbol represent sample from one mouse. 
Data are combined from three independent experiments. 
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Figure 4.13: Delayed specificity shift within total GC response in IgMg1 mice. 
Mice are immunised with 20 µg alum precipitated NP-CGG on plantar surface of foot, 
heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation, popliteal 
LNs are collected sequentially from day 4 to day 14.  
A. Gate settings for NP-specific GC B cells in IgMwt and IgMg1 mice after 
immunisation from day 4 to day 14. 
B. The percentages of NP-specific GC B cells within B cells from IgMwt and 
IgMg1 mice. 
C. Dynamic ratio changes of NP-specific GC B cells to total GC B cells. The 
ratio of NP-specific GC B cells to total GC B cells is calculated by using the 
percentages of NP-specific GC B cells divide the percentages of total GC B 
cells. 
Multiple t test. Bars indicate mean. Each symbol represents sample from one mouse. 
Data are combined from three independent experiments. 
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In order to test whether there is a difference in B cell activation in the IgMg1 mouse, 
we tested expression levels of two early B cell activation markers (CD25 and CD69) 
on B cells responding to NP-CGG (Fig. 4.14A and B). This showed that the 
expression of CD25 and CD69 was similar between IgMwt and IgMg1 mice (Fig. 
4.14B and D), suggesting a similar activation status of IgMg1 B cells in the presence 
of T cell help, at least as indicated by these two activation markers. This, of course, 
does not exclude that there are other changes in signals downstream of BCR 
signalling in early activated IgMg1 B cells. 
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Figure 4.14: Similar expression levels of CD25 and CD69 in NP-specific B cells of 
IgMg1 and IgMwt mice. 
Mice are immunised with 20 µg alum precipitated NP-CGG and heat-inactivated 
Bordetella pertussis (BP) as adjuvant on plantar surface of foot. After immunisation, 
popliteal LNs are collected day 4, 6 after immunisation. 
A. Overlays of CD25 expression levels on NP-specific B cells (activated) and 
NP- B cells (non-activated) from day 4 after immunisation. Gates from NP-
specific B cells was the same as Fig. 4.5. Red: IgMg1 NP-specific B cell; 
Black: IgMwt NP-specific B cells. 
B. MFI of CD25 expression levels. 
C. Overlays of CD69 expression levels on NP-specific B cells (activated) and 
NP- B cells (non-activated), from day 4 after immunisation. Gates from NP-
specific B cells was the same as Fig. 4.5. Red: IgMg1 NP-specific B cell; 
Black: IgMwt NP-specific B cells. 
D. MFI of CD69 expression levels. 
Bars indicate mean. Each symbol represents sample from one mouse.  
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4.2.5 IgMg1 B cells have equal potential to become activated and populate GCs 
 
IgMg1 B cells were shown to have reduced ability to respond to TI-II antigen (Fig. 
4.1). The observation on NP-CGG induced immune responses described above (Fig. 
4.7F, 4.13) showed there was a larger hapten-specific GC B cell population generated 
at the peak of the response in IgMg1 mice. Further, activated IgMg1 B cells were 
more prone to differentiate into GC B cells (Fig. 4.7G). These observations raise the 
possibility that IgMg1 B cells, being anergic B cells, are intrinsically programmed to 
preferentially differentiate into GC B cells. Gene expression patterns of anergic B 
cells are different from naïve B cells (Glynne, Ghandour et al. 2000), which can be 
the reason for the biased GC B cell fate decision. Negative selection happening in 
GCs may serve as a checkpoint for antigen-activated anergic B cells (Chan, Wood et 
al. 2012). In this environment, anergic B cells may undergo clonal redemption and, 
through hypermutation, turn into low-risk, useful cells that have lost self-reactivity 
and become highly specific for foreign antigens (Burnett, Langley et al. 2018). 
 
In order to better resolve subtle changes in IgMg1 B cell recruitment, expansion, and 
loss from the GC, bone marrow chimeric mice were created to produce a system 
where IgMg1 and IgMwt B cells could differentiate in direct competition (chapter 
3.14). Equal numbers of CD45.2 (IgMg1 or C57BL/6 IgMwt) and CD45.1 (BoyJ 
IgMwt) bone marrow (BM) cells were transferred into irradiated C57BL/6 mice (Fig. 
3.14). Seven weeks later IgMwt/IgMwt chimeras were immunised with NP-CGG. 
Spleens in IgMwt/IgMwt chimeras contain on average 3.5 times higher numbers of 
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CD45.2 than CD45.1 mature B cells. This ratio is 5 times more CD45.2 than CD45.1 
in IgMg1/IgMwt chimeras (Fig 3.16). 
 
Eight days after NP-CGG immunisation, popliteal LNs were harvested from both 
IgMwt/IgMwt and IgMg1/IgMwt chimeras. Naïve and responding CD45.2+ (IgMwt 
or IgMg1) and CD45.1+ (IgMwt) B cell populations were analysed. The B220+ NP-
nonbinding CD138- population from the popliteal LN were gated as naïve control B 
cells (Fig. 4.15A and B). Similar to what is seen in the spleen (Fig. 3.19), non-
activated naïve B cells in LN consist of on average 2 times more CD45.2 than CD45.1 
B cells. In IgMg1/IgMwt chimeras this ratio becomes 4.5 times more CD45.2 than 
CD45.1 (Fig. 4.15C).  Analysing the total NP-responding cells, neither IgMwt/IgMwt 
nor IgMg1/IgMwt chimeras displayed a significant change in the ratio of 
CD45.2/CD45.1 B cells (Fig. 4.15B and C). Similarly, there was no change in the 
ratio of CD45.2/CD45.1 in the NP-specific GC B cell population. Surprisingly, this 
seems to indicate that when in direct competition, IgMg1 B cells are just as capable as 
IgMwt B cells to populate GCs 8 days after immunisation. 
 
As earlier experiments had indicated that NP-specific IgMg1 B cells have an 
increased capacity to populate GCs 8 days after immunisation (Fig. 4.6G, 4.7G, 
4.13B), the sizes of the NP-specific GC B cell populations in both types of chimeras 
were calculated as well. Surprisingly, this confirmed a consistent trend toward larger 
GCs if IgMg1 B cells were present, with larger relative and absolute GC B cell 
compartments (Fig. 4.16A and B), and highly significant increased percentage of GC 
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B cells within NP-specific B cells (Fig. 4.16C). An increase in the size of the GC 
compartment in IgMg1/IgMwt chimeras (Fig. 4.7G and 4.16C) in the absence of a 
change in the ratio of IgMg1 to IgMwt B cells (Fig. 4.15C) could indicate that the 
presence of IgMg1 B cells in GCs produces an environment that allows enhanced B 
cell expansion or survival, or enable reduced loss from the GC. This change of 
environment does not seem dependent on B cell intrinsic signalling changes induced 
by the type of BCRs (IgMg1 or IgMwt) on individual GC B cells, but a general 
change in environment that is induced by the presence of IgMg1 B cells. In order to 
better resolve this, similar experiments performed at earlier time points following 
immunisation would be necessary, which could not be done due to time constraints. 
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Figure 4.15: IgMg1 B cells compete equally well to be activated and commit to 
GC B cell fate. 
Mice are immunised with 20 µg alum precipitated NP-CGG on plantar surface of foot, 
heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation after 8 
days, popliteal LNs are collected. 
A. Gates for B cells, NP-specific B cells and NP-specific GC B cells. 
B. Gates for CD45.2+ and CD45.1+ B cell sub-populations within each subset. 
C. Ratio of CD45.2+/CD45.1+ have been calculated and compared between 
groups. Ratio of CD45.2+/CD45.1+ has been defined as percentages of 
CD45.2+ subsets divide the percentages of CD45.1+ subsets 
2-way ANOVA. Each symbol represents sample from one mouse. Data are combined 
from two independent experiments. 
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Figure 4.16: Overall more NP+ GC B cells in IgMg1 chimeras. 
IgMwt and IgMg1 bone marrow chimeras are immunised with 20 µg alum 
precipitated on plantar surface of foot, heat-inactivated Bordetella pertussis (BP) as 
adjuvant. Popliteal LNs are collected 8 days after immunisation. 
A. The percentages of NP+ GC B cell within total B cells, and compared between 
IgMwt/IgMwt and IgMwt/IgMg1 mice.  
B. The absolute numbers of GC B cells, and compared between IgMwt/IgMwt 
and IgMwt/IgMg1 mice.  
C. The percentages of GC B cells within NP-specific B cells, and compared 
between IgMwt/IgMwt and IgMwt/IgMg1 mice. 
****p < 0.0001; unpaired Student’s t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are combined from two independent 
experiments. 
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4.2.6 Changes in IgM and IgG1 usage in GC B cells of IgMg1 mice 
 
GCs are known to be the place where Ig gene hypermutation happens and are 
populated by Ig class-switched B cells. IgMg1 BCR signalling changes may affect the 
efficiency of Ig class switching. While Ig class switched IgMg1 B cells become 
genetically identical to IgMwt Ig class switched B cells, it is still possible that 
rewiring of BCR signalling in IgMg1 B cells or epigenetic differences can lead to 
continued decreased signalling, leading to changes in the expansion and survival of Ig 
class switched B cells.  
 
In order to test for Ig class usage, IgMwt and IgMg1 mice were immunised in the foot 
with NP-CGG in alum and B.p. adjuvant, and numbers of NP-specific IgM and IgG1 
positive GC B cells followed on days 6, 8, and 14 after immunisation. GC B cells 
were gated as described before as CD138-B220+CD38low/-Fas+ cells, and the changes 
of GC B cells followed over time after immunisation (Fig. 4.17A). Similar to what 
has been shown previously (Fig. 4.13C), this confirmed that while the size of the total 
GC response increased until 14 days post immunisation (Fig. 4.17A and B), the 
percentage of NP-binding GC B cells declined from day 6 to day 14 post 
immunisation, and this change in antigen-specificity was delayed in IgMg1 mice (Fig. 
4.17C).  
 
NP-specific IgG1 switched GC B cells were stained during the time course to NP-
CGG immunisation (Fig. 4.18A). This showed that the main reason why IgMg1 GC B 
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cell numbers were increased on day 8 was the NP-specific IgG1 switched population 
(Fig. 4.18C).  This difference disappears by day 14 post immunisation. 
 
Together these results confirm the delayed specificity shift from early NP-binding to 
late non-NP-binding GCs in IgMg1 mice. This is in-line with a larger expansion of 
the IgG1+NP+ GC B cell population on day 8 after NP-CGG immunisation in IgMg1 
mice. Whether this is due to changes in Ig class switch recombination or differences 
in BCR signalling in IgG1 switched IgMg1 B cells will be investigated in the 
following experiments. 
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Figure 4.17: Delayed specificity shift of total GC B cells in IgMg1 mice. 
Mice are immunised with 20 µg alum precipitated NP-CGG on plantar surface of foot, 
heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation, popliteal 
LNs are collected sequentially from day 6 to day 14.  
A. Gate settings for total GC B cells in IgMwt and IgMg1 mice after 
immunisation. 
B. The percentages of total GC B cells within B cells from IgMwt and IgMg1 
mice. 
C. Ratio of NP-specific GC B cells to total GC B cells over time. The ratio of 
NP-specific GC B cells to total GC B cells is calculated by using the 
percentages of NP-specific GC B cells within all B cells divided by the 
percentages of total GC B cells within all B cells. 
Multiple t test. Bars indicate mean. Each symbol represents sample from one mouse. 
Data are combined from three independent experiments. 
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Figure 4.18: Accumulated NP+IgG1+ GC B cells on day 8 in IgMg1 mice. 
Mice are immunised with 20 µg alum precipitated NP-CGG on the plantar surface of 
foot, heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation, 
popliteal LNs are collected sequentially from day 6 to day 14.  
A. Gate settings to measure NP responding and class switch of total GC B cells 
from day 6 to day 14. 
      B-E. Summarizing statistic of the dynamic changes of the percentages of Q1: 
IgG1-NP+ (B), Q2: IgG1+NP+ (C), Q3: IgG1-NP- (D), Q4: IgG1+NP- (E) GC B cell 
subsets within total GC B cell populations from IgMwt and IgMg1 mice. 
Multiple t test. Bars indicate mean. Each symbol represents sample from one mouse. 
Data are combined from three independent experiments. 
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4.2.7 Surface BCR expression levels remain lower at the early stage of GC 
response in IgMg1 mice 
 
The data presented so far indicates delayed early GC B cell generation after SRBC 
immunisation (Fig. 4.8), a delay in the shift from NP-specificity during GC B cell 
response (Fig. 4.12, 4.17), and an increase of IgG1 positive cells at the time when NP-
binding cells were expanded (Fig. 4.18). Chapter 3 showed that in IgMg1 B cells IgM 
expression is reduced by a factor of 2 (Fig. 3.20-23 and 3.27-3.30). It was then 
interesting to explore whether this suppression of surface IgM expression is preserved 
after B cell activation and CSR to IgG1. In order to directly compare IgM and IgG1 
BCR expression levels in GC B cells, IgM and IgG1 were stained on days 6 and 8 
after immunisation with NP-CGG. GC B cells were identified similar to the gating 
scheme shown in Fig. 4.17.  
 
As observed before, there was an increase in the percentage of Ig class switched cells 
with fewer IgM expressing cells in IgMg1 mice on day 8 after immunisation (Fig. 
4.19, 4.20). Surface IgM expression was 30% lower on GC B cells from IgMg1 mice 
(Fig. 4.21A and B). This difference is less than that on non-activated naïve B cells 
(Fig. 3.22). The same reduction was seen on NP-specific IgMg1 GC B cells on day 6 
(Fig. 4.22A, B). After class switch to IgG1, the difference in BCR expression became 
smaller, with B cells of IgMg1 mice expressing on average 16% less IgG1 than GC B 
cells from IgMwt mice, 6 days after immunisation (Fig. 4.21C, 4.22C). Eight days 
after immunisation, however, the expression of IgG1 in IgMg1 derived total GC B 
190	
	
cells was now the same as WT counterparts (Fig. 4.21C), and higher when only NP-
specific GC B cells were gated (4.22C).  
                        
Figure 4.19: Decreased IgM+ GC B cells in IgMg1 mice after 6 days of NP-CGG 
immunisation. 
Mice are immunised with 20 µg alum precipitated NP-CGG on plantar surface of foot, 
heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation, popliteal 
LNs are collected day 6. 
A. Gate settings for IgM+ total GC B cells and NP+ GC B cells after 6 days of 
NP-CGG immunisation. 
B. Percentages of IgM+ total GC B cell subsets. 
C. Percentages of IgM+ NP-specific GC B cell subsets. 
*p < 0.05; **p < 0.01; multiple t test. Bars indicate mean. Each symbol represents 
sample from one mouse. Data are representative from two independent experiments. 
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Figure 4.20: Increased IgG1 switching in total and NP+ GC B cells in IgMg1 mice 
after 8 days of NP-CGG immunisation. 
Mice are immunised with 20 µg alum precipitated NP-CGG on plantar surface of foot, 
heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation, popliteal 
LNs are collected day 8. 
A. Gate settings for IgG1+ total GC B cells and NP+ GC B cells after 8 days of 
NP-CGG immunisation. 
B. Percentages of IgG1+ total GC B cell subsets. 
C. Percentages of IgG1+ NP-specific GC B cell subsets. 
***p < 0.001; ****p < 0.0001; multiple t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are representative from two independent 
experiments. 
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As NP-PE was used to detect antigen-specific B cells, it was also possible to measure 
the MFI of NP-PE binding in IgM or IgG1 expressing GC B cells (Fig. 4.23). The 
ratio between NP-staining intensity and MFI of BCR expression can be used as a 
measure of BCR affinity (Shimizu, Oda et al. 2003). This showed that, while the 
amount of NP-binding by GC B cells followed a similar trend to the IgM or IgG1 
BCR expression levels (Fig. 4.23B and C), there were subtle differences. On day 6 
there was an increased ratio of NP/IgM and NP/IgG1 in GC B cells from IgMg1 mice, 
indicating that IgMg1 B cells recruited into the early GC response have higher affinity 
for NP than IgMwt B cells. This changed at day 8 after immunisation, when NP was 
less efficiently bound by IgG1-expressing B cells from IgMg1 mice than by those 
from IgMwt mice. 
 
This indicates that IgMg1 B cells are less efficiently recruited in the GC response, as 
reflected in the higher BCR affinity necessary to enter a GC at the early stages of GC 
differentiation on day 6. Interestingly, this is also the time when apoptosis levels were 
increased in IgMg1 GC B cells (Fig. 4.12C). Affinity maturation is delayed, however, 
in IgMg1 B cells, shown by the lower NP/IgG1 expression ratio on day 8 (Fig. 4.23E). 
This may be the reason for the delayed expansion of NP-binding GC B cells (Fig. 
4.12B) and the delayed switch in antigen-specificity of GCs in IgMg1 mice (Fig. 4.13 
and 4.17).  
 
In order to further test this, NP-specific serum antibody affinities were measured 8 
days after immunisation. This did not show a significant change in serum IgG1 
193	
	
affinity (Fig. 4.23F). This is perhaps not surprising, as it should take several days to 
generate plasma cell output from the GC and to observe a significant change serum 
affinity. Serum antibody affinity measurements later in the response are necessary to 
address this. 
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Figure 4.21: Loss of mIgM on IgM+ total GC B cells in IgMg1 mice day 6 after 
immunisation. 
Mice are immunised with 20 µg alum precipitated NP-CGG on plantar surface of foot, 
heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation, popliteal 
LNs are collected on day 6 and day 8. Gates are the same as showed in Fig. 4.20 and 
4.21. 
A. Overlays of mIgG1 and mIgM expression levels on total GC B cells. 
B. MFI of mIgM on total GC B cells and compared between IgMwt and IgMg1 
mice. 
C. MFI of mIgG1 on total GC B cells and compared between IgMwt and IgMg1 
mice. 
****p < 0.0001; multiple t test. Bars indicate mean. Each symbol represents sample 
from one mouse. Data are combined from two independent experiments. UD: 
Undetected.  
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Figure 4.22: Loss of mIgM and increased mIgG1 on NP+ GC B cells in IgMg1 
mice after immunisation. 
Mice are immunised with 20 µg alum precipitated NP-CGG on plantar surface of foot, 
heat-inactivated Bordetella pertussis (BP) as adjuvant. After immunisation, popliteal 
LNs are collected on day 6 and day 8. Gates are the same as showed in Fig. 4.20 and 
4.21. 
A. Overlays of mIgG1 and mIgM expression levels on NP-specific GC B cells. 
B. MFI of mIgM on NP-specific GC B cells and compared between IgMwt and 
IgMg1 mice. 
C. MFI of mIgG1 on NP-specific GC B cells and compared between IgMwt and 
IgMg1 mice. 
**p < 0.01; ***p < 0.001; multiple t test. Bars indicate mean. Each symbol represents 
sample from one mouse. Data are representative from two independent experiments. 
UD: Undetected. 
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Figure 4.23: Lower affinity for NP on IgG1+ GC B cells 8 days after 
immunisation in IgMg1 mice. 
Data are from the same experiment in Fig. 4.19 – 4.22, gates are set as shown in Fig. 
4.20 and Fig. 4.21. 
A. Overlays of NP-binding on both IgM+ and IgG1+ NP-specific GC B cells after 
6 days and 8 days of immunisation. 
B. MFI of NP-binding on IgM+ NP+GC B cells and compared between IgMwt 
and IgMg1 mice. 
C. MFI of NP-binding on IgG1+ NP+GC B cells and compared between IgMwt 
and IgMg1 mice 
D. Ratio of NP-PE MFI to IgM MFI showing the relative NP-binding ability 
(affinity) of IgM. 
E. Ratio of NP-PE MFI to IgG1 MFI showing the relative NP-binding ability 
(affinity) of IgG1. 
F. Relative titers of NP specific high affinity (NP2) and low affinity (NP15) 
antibodies. Affinity of NP antibody in both IgMwt and IgMg1 mice on day 8 
after immunisation. Affinity is calculated as the ratio of relative titers of NP2 
to relative titers of NP15 in each sample. 
*p < 0.05; ****p < 0.0001; multiple t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are representative from two independent 
experiments. UD: Undetected. 
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4.2.8 Repressed BCR signalling in IgMg1 mice during T-D immune responses 
	
The last section showed that the inhibition of BCR expression is gradually lost in GC 
B cells of IgMg1 mice. In order to test whether the inhibition of BCR signalling seen 
in naïve IgMg1 B cells (Fig. 3.26) is also lost during GC differentiation, Nur77-GFP 
expression was used as a surrogate read-out for the intensity of BCR signalling 
(Zikherman, Parameswaran et al. 2012). IgMwt and IgMg1 mice were immunised 
with NP-CGG and Nur77-GFP expression measured in the popliteal lymph nodes 8 
days after immunisation. B cells were gated into B220+CD138-CD38+Fas- NP-binding 
or -nonbinding follicular B cells and NP-binding or non-binding CD138-CD38low Fas+ 
GC B cells (Fig. 4.24). As shown in chapter 3 (Fig. 3.26), non-activated splenic 
follicular B cells from IgMg1 mice show slightly lower Nur77-GFP expression than 
counterpart B cells from IgMwt mice, signalling of NP-nonspecific non-GC B cells in 
IgMg1 B cells was substantially lower than that in IgMwt B cells (Fig. 4.25A). More 
than 95% of these NP-nonspecific non-GC follicular B cells should be naive and not 
been activated by antigen. The GFP expression of these cells was higher than that of 
GC B cells, which should all have been activated by antigens (Fig. 4.25B, C). This is 
consistent with previous observations showing that BCR signalling is shortcut in GC 
B cells, as shown by PhosFlow (Khalil, Cambier et al. 2012) and in GFP-Nur77 
reporter mice (Mueller, Matloubian et al. 2015). Despite being low, Nur77-GFP 
expression was still marginally lower in GC B cells from IgMg1 than from IgMwt 
mice (Fig. 4.25B, C). While NP-binding MBCs showed higher Nur77-GFP 
expression again, IgMg1 derived MBCs continued to express lower levels of Nur77-
GFP than in IgMwt derived MBCs (Fig. 4.25D). This shows a continuous reduction 
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of BCR signalling, reflected by lower Nur77-GFP expression, in non-activated Fo B 
cells, activated GC B cells and differentiated MBCs in IgMg1 mice. 
 
The majority of GC B cells and MBCs have switched to IgG and lost the IgMg1 BCR 
on day 8 after immunisation. In order to test whether reduction in BCR signalling in 
IgMg1 B cells is lost after class switch recombination, Nur77-GFP expression was 
compared between IgM expressing and Ig class switched B cells. GC B cells were 
gated on whether they were binding the hapten NP or not, followed by gating on 
expression of IgM or IgG1 (Fig. 4.26A). This showed that IgG1 switching led to a 
general repression of Nur77-GFP expression in GC B cells, whether they were from 
IgMwt or IgMg1 mice, and regardless of their specificities (Fig. 4.26 B-D). 
Comparing side by side Nur77-GFP expression in GC B cells from IgMwt and IgMg1 
mice showed that Nur77-GFP expression was clearly suppressed in IgM expressing 
GC B cells of IgMg1 origin (Fig. 4.27A, B), whereas this difference disappeared once 
the cells had switched to IgG1 (Fig. 4.27C, D).  
 
When NP-specific B220+CD138-CD38high non-GC B cells were gated (Fig 4.28A), 
most of them being antigen-experienced memory B cells (Conter, Song et al. 2014), 
there was no reduction in Nur77 in IgG1+ memory B cells as was observed in total 
GC B-cells (Fig 4.26C). While IgM and IgG1 expressing MBCs from IgMwt showed 
the same levels of Nur77 expression, IgG1-switched memory B cells from IgMg1 
mice had significantly increased Nur77 expression (Fig. 4.28B). Remarkably, IgMg1 
derived memory B cells expressed considerably less Nur77-GFP than memory B cells 
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of IgMwt origin, even if they had switched to IgG1 (Fig. 4.28B). This indicates that 
there is a continued rewiring of BCR signalling in IgMg1 derived anergic B cells that 
continues to affect memory B cells even if they have switched to IgG. 
 
In summary, the experiment confirms that GC B cells undergo a phase of reduced 
BCR signalling (Khalil, Cambier et al. 2012, Mueller, Matloubian et al. 2015). IgG1 
switched GC B cells show a stronger suppression of Nur77 expression than non-
switched GC B cells. Once B cells differentiate into memory B cells, IgG1 provides a 
stronger signal than IgM, as expected (Waisman, Kraus et al. 2007, Weston-Bell, 
Forconi et al. 2014). Memory B cells from IgMg1 mice show a continued anergic 
footprint with repressed BCR signalling, even if the IgMg1 chimeric BCR is not 
expressed any longer. These conclusions should be confirmed by re-challenge studies 
and observation of BCR signalling after antigen-receptor stimulation in vitro.  
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Figure 4.24: Nur77-GFP expression in the T-D immune response. 
Both Nur77-GFP IgMwt and IgMg1 mice are immunised with 20 µg heat-inactivated 
Bordetella pertussis (BP) into plantar surface of foot. Popliteal LNs are collected 8 
days after immunisation. 
A. Gates for different B cell populations assessed during T-D immune response. 
B-E. Overlays of Nur77-GFP expression levels in different B cell populations from 
both IgMwt (black) and IgMg1 (red) mice.  
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Figure 4.25: Lower Nur77-GFP expressions in different B cell populations from 
IgMg1 mice during T-D immune response. 
Both Nur77-GFP and IgMg1 Nur77-GFP mice are immunised with 20 µg alum 
precipitated NP-CGG on plantar surface of foot, heat-inactivated Bordetella pertussis 
(BP) as adjuvant. After immunisation, popliteal LNs are collected on day 8. 
A-D. Statistical analysis of Nur77-GFP expression levels within different B cell 
populations during T-D immune response. 
**p < 0.01; ****p < 0.0001; multiple t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are combined from two independent 
experiments. 
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Figure 4.26: IgG1+ GC B cells transduce lower down-stream BCR signalling 
than IgM+ GC B cells. 
Both Nur77 IgMwt and IgMg1 mice are immunised with 20 µg alum precipitated NP-
CGG on plantar surface of foot, heat-inactivated Bordetella pertussis (BP) as adjuvant. 
After immunisation, popliteal LNs are collected on day 8. 
A. Gates for NP-specific and NP-non-specific total GC B cell populations, and 
IgM+, IgG1+ subsets within each population after 8 days of immunisation. 
B. Overlays of Nur77-GFP expression levels in NP-specific and NP-non-specific 
total GC B cells after 8 days of immunisation.  
C. MFI of Nur77-GFP expression levels in NP-non-specific total GC B cells and 
compared between IgM+ GC B cells and IgG1+ GC B cells. 
D. MFI of Nur77-GFP expression levels in NP-specific total GC B cells and 
compared between IgM+ GC B cells and IgG1+ GC B cells 
****p < 0.0001; multiple t test. Each symbol represents sample from one mouse. Data 
are representative from two independent experiments. 
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Figure 4.27: The suppression of BCR signalling is retained in IgM+ GC B cells 
from IgMg1 mice. 
Both Nur77-GFP IgMwt and IgMg1 mice are immunised with 20 µg alum 
precipitated NP-CGG on plantar surface of foot, heat-inactivated Bordetella pertussis 
(BP) as adjuvant. After immunisation, popliteal LNs are collected on day 8. Gates for 
NP-specific and NP-non-specific total GC B cell populations, and IgM+, IgG1+, IgM-
IgG1- subsets within each population are shown in Fig. 4.27A. 
A. MFI of Nur77-GFP expression levels in IgM+ NP-non-specific total GC B 
cells. 
B. MFI of Nur77-GFP expression levels in IgM+ NP-specific total GC B cells. 
C. MFI of Nur77-GFP expression levels in IgG1+ NP-non-specific total GC B 
cells. 
D. MFI of Nur77-GFP expression levels in IgG1+ NP-specific total GC B cells. 
*p < 0.05; **p < 0.01; multiple t test. Bars indicate mean. Each symbol represents 
sample from one mouse. Data are combined from two independent experiments  
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Figure 4.28: Continued repressed BCR signalling in IgG1-switched MBCs from 
IgMg1 mice. 
Both Nur77-GFP and IgMg1 Nur77-GFP mice are immunised with 20 µg alum 
precipitated NP-CGG on plantar surface of foot, heat-inactivated Bordetella pertussis 
(BP) as adjuvant. After immunisation, popliteal LNs are collected on day 6 and day 8. 
A. Gates for IgG1+ and IgM- NP-specific MBCs after 8 days of immunisation. 
B. MFI of Nur77-GFP expression levels in IgM+ and IgG1+ NP-specific MBCs, 
and compared between IgMwt and IgMg1 mice. 
**p < 0.01; **p < 0.001; ****p < 0.0001; unpaired t test between IgMwt and IgMg1. 
Paired T test between IgM+ and IgG1+ MBCs from the same mouse. Each symbol 
represents sample from one mouse. Data are combined from two independent 
experiments.  
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4.2.9 Increased Tfh cell differentiation in the presence of IgMg1 B cells 
 
The previous sections showed a B cell intrinsic mechanism that confers a reduction in 
BCR signalling in non-switched and switched B cells from IgMg1 mice. However, 
the general changes of population sizes in IgMwt/IgMg1 bone marrow chimeras (Fig 
4.16) indicate that there are also some general environmental changes in the presence 
of IgMg1 B cells. In order to test which non-B cell intrinsic factor might be 
responsible, Tfh cell numbers were assessed over time after immunisation with NP-
CGG.  
 
Two main functional T cell populations were tested in IgMwt and IgMg1 
homozygous mice: CD3+CD4+CD62L-CD44+ cells as activated CD4+ T cell, and 
CD3+CD4+CD62L-CD44+CXCR5+PD-1+ cell as Tfh cells (Fig. 4.29A). This showed 
that the proportions of total activated T cells in the two groups were quite similar 
during the whole time course (Fig. 4.29B). Testing the proportion of these activated T 
cells differentiating into Tfh cells showed a significantly larger fraction of activated T 
cells had differentiated into Tfh cells in IgMg1 mice compared to IgMwt mice from 
day 6 to day 14 after immunisation (Fig. 4.29C). In-line with this, there was a trend 
towards higher Tfh cell percentages within total CD4+ T cells from day 6 after 
immunisation in IgMg1 mice (Fig. 4.29D).  
 
Tfh cell differentiation was also tested in IgMwt and IgMg1 B cell bone marrow 
chimeric mice after immunisation with NP-CGG on the rear feet (Fig. 3.15). Tfh cells 
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were gated 8 days after immunisation (Fig. 4.30A). As in homozygous mice, similar 
percentages of activated T cells developed in IgMwt/IgMwt and IgMwt/IgMg1 
chimeras (Fig. 4.30B), suggesting that the presence of IgMg1 B cells did not affect 
general T cell activation. However, IgMwt/IgMg1 chimeras had significantly higher 
proportions of Tfh cells within activated T cells than IgMwt/wt chimeras (Fig. 4.30C). 
Tfh cells also accounted for higher percentages within total CD4+ T cells (Fig. 4.29D). 
Taken together these data suggest that IgMg1 B cells can promote Tfh cell 
differentiation, which may generate an environment where B cell activation is 
increased, whether B cells are IgMwt or IgMg1 derived.  
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Figure 4.29: Biased Tfh cell differentiation during T-D immune response in 
IgMg1 mice. 
WT and IgMg1 mice were immunised with 20 µg alum precipitated NP-CGG on 
plantar surface of foot, heat-inactivated Bordetella pertussis (BP) as adjuvant.  
Popliteal LNs were collected 4, 5, 6, 8 and 14 days after immunisation. 
A. Gate setting for CD3+CD4+CD62L-CD44+CXCR5+PD-1+ Tfh cells. CXCR5 
isotype control has been used for the quality control. 
B. Percentages of CD3+CD4+CD62L-CD44+ active T cells. 
C. Percentages of Tfh cells within active T cells. 
D. Percentages of Tfh cells within CD4+ T cells. 
Multiple t test. Bars and whiskers indicate mean ± SD. D4 and D5 data are from one 
experiment, with a total number of 4 mice. D6 and D8 data are from three 
independent experiments, with a total number of 12 mice. D14 data are from two 
independent experiments, with a total number of 8 mice. 
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Figure 4.30: Biased Tfh cell differentiation during T-D immune response in 
IgMg1 bone marrow chimeras. 
IgMwt/IgMwt and IgMwt/IgMg1 chimeric mice were immunised with 20 µg alum 
precipitated NP-CGG on plantar surface of foot, heat-inactivated Bordetella pertussis 
(BP) as adjuvant. Popliteal LNs were collected 8 days after immunisation. 
A. Gate setting for CD3+CD4+CD62L-CD44+CXCR5+PD-1+ Tfh cells. 
B. Percentages of CD3+CD4+CD62L-CD44+ active T cells. 
C. Percentages of Tfh cells within active T cells. 
D. Percentages of Tfh cells within CD4+ T cells. 
*p < 0.05; **p < 0.01; unpaired Student t test. Bars indicate mean. Each symbol 
represents sample from one mouse. Data are combined from two independent 
experiments.  
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4.2.10 Presence of auto-immune antibodies in aged IgMg1 mice 
 
B cell anergy is reversible (Gauld, Benschop et al. 2005, Getahun, Beavers et al. 
2016). Breakage of tolerance, development of auto-antibodies, and overt auto-
immunity has been observed in different animal models of B cell anergy during 
ageing (Hibbs, Tarlinton et al. 1995, Getahun, Beavers et al. 2016). Not only in mice, 
but also in healthy humans and non-human primates, has the production of auto-
antibodies been observed to increase with ageing (Rowley, Buchanan et al. 1968, 
Attanasio, Brasky et al. 2001). In order to test whether or not auto-antibodies develop 
during ageing in the IgMg1 mouse model, serum samples were harvested from young 
(8 weeks) or old aged mice (6-month or 1 year) and applied to rat tissue slides to 
detect crossreactive autoantibodies. Each spot on these auto-immune slides is pre-
coated with sections of rat liver, gut, stomach, and kidney. These slides allow the 
detection of anti-nuclear antibody (ANA), anti-smooth muscle antibody (ASMA), 
anti-mitochondrial antibody (AMA) and different liver and kidney-specific auto-
antibody patterns. Slides were incubated with serum overnight and screened next day 
by an experienced clinical immunologist (Dr. Abid Karim, Clinical Immunology 
Service, UoB Medical School). 
 
After incubation of slides with serum samples from young IgMwt and IgMg1 mice, 
one in four slides from both IgMwt and from IgMg1 mice showed weak non-typical 
binding of serum antibody to membranes or gastric parietal cells (Fig. 4.31A, B and 
C). The majority of aged IgMwt mice showed no specific serum antibody binding to 
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the tissue arrays, or only non-specific binding at the edge of tissue sections (Fig. 
4.32A). Two of eight aged IgMwt mice showed specific anti-smooth muscle antibody 
(ASMA) staining (Fig. 4.32C and D).  Aged IgMg1 mice, on the contrary, showed 
clear diverse auto-immune antibody binding patterns (Fig. 4.32B and D). There were 
at least four different auto-antibody patterns: anti-nuclear antibody (ANA), anti-
kidney antibody, ASMA, and anti-kidney-liver microsome (KLM) antibody (Fig. 
4.32B and D). 87.5% of IgMg1 serum samples displayed the presence of auto-
antibodies, which was more than three times higher than wildtype (Fig. 4.32C).  
 
To explore whether production of autoantibody in aged mice is due to a break of 
tolerance during ageing or due to a change of VDJ repertoire and a higher occurrence 
of B cells with auto-reactive BCRs emerging from the bone marrow in IgMg1 mice, B 
cells of young IgMg1 mice were cloned to test their autoreactive potential. Single 
follicular B cells were sorted from spleens of non-immunised young IgMwt and 
IgMg1 mice and seeded onto CD40L, BAFF, and IL-21 expressing fibroblastic feeder 
cells to generate single cell derived plasma cell colonies. Cells were cultured in 
microtitre plates for 10 days, and cell culture medium was not changed in the last 48 h 
to enrich for secreted antibodies. At the end of culture, microtitre plates were screened 
for the presence of large plasma cell colonies. Supernatants from these wells were 
harvested and tested for the presence of autoantibodies. 
  
Supernatants from all B cell colonies were applied to auto-immune slides and 
screened for the presence of tissue specific auto-antibody patterns. Among the 76 
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samples tested of each IgMwt and IgMg1 B cells, the frequency of auto-reactivity was 
quite low, with 1 in 76 from IgMwt and 2 in 76 from IgMg1 testing positive for 
autoantibody (Fig. 4.33B). While the one positive IgMwt sample showed a strong 
anti-mitochondrial antibody staining pattern (AMA), the two positive IgMg1 samples 
showed a very weak anti-kidney autoantibody pattern (Fig. 4.33A). These results 
suggest that the BCR repertoire emerging from bone marrow in young IgMg1 mice is 
not more prone to be auto-reactive than that of IgMwt mice. It does not exclude that 
the breach of tolerance observed in aged mice is due to impaired negative selection 
during B cell development, and further experiments studying the autoreactivity of the 
naïve B cell repertoire emerging from bone marrow in aged IgMwt and IgMg1 mice 
should be performed to answer this. 
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Figure 4.31: Auto-reactive B cells have not been detected to increase in serum 
samples from young IgMg1 mice. 
Serum samples have been collected from both young (8 weeks) IgMwt and IgMg1 
mice. 50 µl net sera is added to each spot on the auto-immune slide, incubated at 4 ˚C, 
overnight. Auto-antibodies are detected by FITC conjugated anti-mouse IgG1 
antibody. 
A. Representative image from negative control incubated spots. 
B. Positive images from both IgMwt and IgMg1 serum samples incubated spots. 
C. Pie charts to summarize results from auto-immune slides. Total number of 
sample, the diversity of auto-immune patterns and frequency of auto-immune 
patterns have been displayed. 
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Figure 4.32: The presence of diverse auto-antibodies in IgMg1 mice aged more 
than 6 months. 
Serum samples have been collected from both IgMwt and IgMg1 mice aged more 
than 6 months. Add 50 µl net sera to each spot on the auto-immune slides, incubated 
at 4 ˚C, overnight. Auto-antibodies are detected by FITC conjugated anti-mouse IgG1 
antibody. 
A. Representative image from PBS and IgMwt serum sample incubated spots. 
B. Representative images of IgMg1 serum samples incubated spots. 
C. Summarizing statistic of samples displaying auto-immune patterns and not 
displaying auto-immune patterns (negative). Compared between groups. 
D. Pie charts to summarize results from auto-immune slides. Total number of 
sample, the diversity of auto-immune patterns and frequency of auto-immune 
patterns have been displayed. 
*p < 0.05; Fishser’s exact test. Histogram indicates the exact sample numbers. Data 
are combined from two independent experiments. 
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Figure 4.33: Auto-reactive B cells have not been detected to increase in the 
follicular B cell pool of young IgMg1 mice. 
A. Positive images of autoimmune tissue slides incubated with supernatants from 
single cell cultures of IgMwt and IgMg1 follicular B cells. Single cell culture 
system is used to induce single sorted follicular B cells into plasma cell 
colonies. Supernatant of each plasma cell colony have been harvested, added 
to auto-immune slides and assessed for auto-immune staining.  
B. Summary of single cell culture results.  
ns, not significant; Fishser’s exact test. Histogram indicates the exact sample numbers. 
Data are combined from three independent experiments in B.  
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4.3 Discussion 
	
	
4.3.1 IgMg1 B cells are permanently programmed to be anergic 
	
After 8 days of NP-CGG immunisation, in local responding LNs, there is a 
pronounced reduction of Nur77-GFP expression in naïve follicular B cells and a 
continuous significant reduction in IgM+ non-switched GC B cells in IgMg1 mice. 
However, IgG1-switched GC B cells in IgMg1 mice seem to have similar Nur77-GFP 
expression levels as IgMwt-derived IgG1+ GC B cells. This does not necessarily 
indicate a recovery of BCR signalling after B cells switched to IgG1 in IgMg1 mice. 
Nur77-GFP expression is severely suppressed in GC B cells (Mueller, Matloubian et 
al. 2015, Gitlin, von Boehmer et al. 2016) and small differences in BCR signalling in 
IgG1+ GC B cells of IgMg1 mice may be just undetectable using this method. In 
IgG1-switched MBCs, however, signalling transduced from IgG1 increases and is 
therefore readily detectable. This shows that Nur77-GFP expression level in IgG1+ 
MBCs from IgMg1 mice is still substantially lower than their WT counterparts. Taken 
together, these findings demonstrate that IgMg1 B cells maintain a continued anergic 
footprint with repressed BCR signalling even after activation, loss of IgM expression, 
and differentiation into MBCs.  
 
Cell differentiation and the maintenance of cells in a specific state normally require 
genetic reprogramming, such as epigenetic modification. The maintenance of an 
anergic pattern in B cells is reported to depend upon continuous signalling from 
BCR/self-antigen ligation. This anergic state can be reversed after BCRs are freed 
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from contact with self-antigens (Goodnow, Brink et al. 1991, Gauld, Benschop et al. 
2005). These studies led to the assumption that B cell anergy is not a genetically 
programmed process, and the non-responsive state of these cells is just due to chronic 
BCR activation and signalling (Goodnow, Brink et al. 1991, Cambier, Gauld et al. 
2007). Nevertheless, in these studies, the ability of anergic B cells to respond is not 
completely reversed after occupied BCRs are freed from self-antigens. After culturing 
Ars-specific anergic B cells with Ars-tyrosine to free their BCRs from self-antigen 
binding, these recovered B cells can respond to BCR stimulation but still generate 
much lower down-stream signalling after activation (Gauld, Benschop et al. 2005). 
HEL-specific anergic B cells from the MD4 × ML5 mouse model need around 48 
hours to regain responsiveness when transferred to a self-antigen free environment 
and the immune response after activation remains lower afterwards (Goodnow, Brink 
et al. 1991). These studies show that following recovery from self-antigen binding, 
these B cells become less tolerized, and can partially respond to self-antigen, but are 
still in a repressed state. Thus the maintenance of an anergic state is not solely 
determined by constant BCR/self-antigen ligation, permanent genetic programming is 
likely to be involved as well.  
 
In the IgMg1 mouse model, additional signalling from the IgG1 cytoplasmic tail is 
likely to mimic the continuous BCR/self-antigen ligation signalling and induce IgMg1 
B cells into an anergic state. Consistent with findings above, the results shown here 
demonstrate that the maintenance of an anergic pattern in IgMg1 B cells is not solely 
dependent on the presence of extra signalling from the IgG1 cytoplasmic region. 
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Despite recovery of surface IgG1 expression level in IgG switched GC B cells and 
MBCs in IgMg1 mice, BCR signalling reflected by Nur77-GFP expression remains 
repressed. IgG1+ MBCs have lost the extra signalling from chimeric IgMg1, but the 
anergic pattern is maintained. This suggests that a combination of constant 
BCR/antigen ligation and genetic re-programming is involved in the maintenance of 
this anergic state in IgMg1 B cells. 
 
	
4.3.2 Continuous repression of BCR signalling in GC B cells from IgMg1 mice 
might affect GC B cell selection  
	
There was a significantly higher proliferation rate of GC B cells in IgMg1 mice on 
day 8 after immunisation with NP-CGG, and the proportion of apoptotic GC B cells 
was significantly higher on day 6 and slightly higher on days 8 and 14. Throughout 
the GC reaction, GC B cells are selected for different fate decisions, such as survival, 
differentiation, or death. The different proliferation and apoptosis rates observed in 
IgMwt and IgMg1 GC B cells reflect an altered balance of fate decisions they 
experience during GC reactions.  
 
BCR signalling has been reported to be necessary for the effective expression of c-
Myc in GC B cells (Luo, Weisel et al. 2018). As discussed above, BCR signalling in 
activated NP+ GC B cells from IgMg1 mice is continuously repressed throughout the 
T-D response. Dampened BCR signalling in GC B cells of IgMg1 mice may lead to 
lower c-Myc expression and result in enhanced apoptosis during the early GC 
response in IgMg1 mice. Despite BCR signalling remaining repressed on day 8 after 
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immunization, we observed a higher proliferation rate of GC B cells in IgMg1 mice at 
this later stage. The strength of T cell help correlates with the GC B cell proliferation 
rate (Gitlin, Mayer et al. 2015). As our results showed there were higher numbers of 
Tfh cells on day 8 after immunisation in IgMg1 mice, it is possible that by day 8 
IgMg1 GC B cells receive more help from Tfh cells to proliferate faster.  More 
experiments are probably needed to reveal the detailed mechanisms on how the 
changed BCR and co-stimulation signalling affect IgMg1 GC B cell selections during 
GC response. 
 
By studying the dynamic process of the GC response, we noticed there is a rapid shift 
in antigen specificity following immunisation with hapten-carrier protein conjugates 
(NP-CGG). Tracking of the constant decline of the fraction of NP specific GC B cells 
in IgMwt mice after immunisation showed that there are significantly higher 
percentages of NP-specific GC B cells in IgMg1 mice at day 8 after immunisation, i.e. 
there was a delayed shift in GC B cell specificity from NP to other specificities. The 
dynamic process of the GC response is regulated by GC intrinsic selection, combined 
with immigration, emigration, proliferation, and apoptosis. Firstly, the delayed shift in 
antigen-specificity could be explained by reduced immigration. There is a remarkable 
repression of BCR signalling in naïve follicular B cells of local responding LNs from 
IgMg1 mice, which can make these B cells less likely to respond to low-affinity 
epitope leading to a reduction in GC recruitment, and a longer-lasting response to NP. 
Secondly, despite the slightly higher affinity observed in non-switched IgMg1 
expressing GC B cells at earlier stages of the GC response, IgG1 switched GC B cells 
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in IgMg1 mice display lower affinity on day 8 after immunisation. This indicates a 
slower affinity maturation process in the GCs of IgMg1 mice. This reduced affinity 
maturation could affect the total GC response by limiting emigration of NP-specific 
cells from the GC, and slowing down recruitment of new Fo B cells which are 
specific for low-affinity, non-NP-specific epitopes. More experiments are needed to 
explore the link between lower BCR signalling strength of GC B cells and slower 
affinity maturation of the GC response in IgMg1 mice. 
 
4.3.3 T cells serve as a peripheral check point to regulate peripheral anergic B 
cell activation and differentiation 
	
By employing the IgMg1 mouse model, we were able to investigate polyclonal 
anergic B cells fate decisions in different immune responses. Anergic IgMg1 B cells 
respond with a significantly lower efficiency to TI-II antigen NP-Ficoll than WT B 
cells, with an impaired ability to generate NP+ B cells and NP+ plasma cells. This 
observation was compatible with reduced activated BCR signalling in anergic B cells 
(Goodnow, Crosbie et al. 1988), since NP-Ficoll activates B cells through their BCR 
only, without co-stimulation signalling from T cells (Inman 1975). The decrease of 
MZ B cells in IgMg1 mice can to some extent affect T-I immune response as well, as 
MZ B cells have been reported to be the dominant cell population that respond to T-I 
antigen stimulation (Martin, Oliver et al. 2001). However, when responding to NP-
CGG, a T-dependent antigen, B cells in IgMg1 mice were equally effective to respond 
compared to their WT counterparts. The opposite results of T-D and T-I immune 
responses imply that T cells can serve as a checkpoint to control the activation of 
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anergic B cells in the periphery. BCR signalling in anergic B cells is suppressed 
which prevents non-specific activation, and it is only with corresponding secondary T 
cell help, that these cells can be fully activated and effectively involved in the 
immune response. This observation is compatible with previous studies showing that 
the CD40-dependent activation pathway is intact in anergic B cells (Cooke, Heath et 
al. 1994, Eris, Basten et al. 1994) and that silenced auto-reactive B cells can be 
induced into a GC B cell fate after receiving cognate help from T cells (Fulcher, 
Lyons et al. 1996, Sabouri, Schofield et al. 2014, Burnett, Langley et al. 2018). 
 
Previous studies have shown that the maintenance of Tfh cells in GCs requires 
constant signalling from cognate B cells (Coffey, Alabyev et al. 2009, Kerfoot, Yaari 
et al. 2011, Baumjohann, Preite et al. 2013), indicating that the interactions between 
Tfh cells and B cells are reciprocal during GC reactions. Results from our study show 
biased Tfh cell differentiation in the presence of IgMg1 B cells, from either 
homozygous IgMg1 mice or IgMg1/IgMwt bone marrow chimeras, and that there are 
significantly more Tfh cells on day 8 after immunisation in IgMg1 mice. These results 
suggest that IgMg1 B cells can possibly provide enhanced signalling to cognate T 
cells, which may potentially affect activated T cell differentiation and promote the 
generation of Tfh cells. Despite the impairment of BCR signalling in anergic B cells, 
these cells can continuously present self-antigens to T cells (Eris, Basten et al. 1994). 
Auto-reactive B cells are also shown to trigger auto-immune disease by presenting 
self-antigen to T cells and activating them (Dai, Carayanniotis et al. 2005, Giles, 
Kashgarian et al. 2015, Giles, Neves et al. 2017). Altogether this suggests that the 
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antigen presentation capability of either anergic or auto-reactive B cells might be 
enhanced, thus they may be able to provide stronger co-stimulation signalling to 
cognate T cells. During TD immune response, there are significantly higher 
percentages of class-switched GC B cells in IgMg1 mice on day 6 after immunisation, 
which points to a potential effect of an increased Tfh population, as the CD40L co-
stimulation signal provided by Tfh cells plays a crucial role to mediate 
immunoglobulin class-switch recombination (Banchereau and Rousset 1991, Kawabe, 
Naka et al. 1994, Xu, Foy et al. 1994). Detailed mechanisms of the interactions 
between anergic IgMg1 B cells and Tfh cells during GC response should be further 
studied. 
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Chapter 5 . Conclusions 
 
Anergic B cells are defined as B cells which lose the ability or have reduced ability to 
be activated through BCR ligation. In contrast, hyper-activated B cells display 
enhanced BCR down-stream signalling, including stronger calcium influx and 
enhanced phosphorylation of JNK, which leads to higher activation and proliferation 
rates after stimulation through BCRs (O'Keefe, Williams et al. 1996, Chan, Lowell et 
al. 1998, Cornall, Cyster et al. 1998). These two contrasting response states after BCR 
ligation clearly define two different types of B cells. 
 
In this study, the cytoplasmic domain of IgM BCR was replaced with that from IgG1. 
However, instead of generating hyper-activated BCR signalling as hypothesised, the 
dominant mature B cell population, recirculating Fo B cells, display comparable tonic 
BCR signalling to IgMwt B cells. Only MZ B cells clearly display a hyper-activated 
tonic state. Despite this, after activation through BCR stimulation, both immature and 
mature B cells in IgMg1 mice transduce a reduced downstream signal (Fig.5.1), 
which resembles the defining feature of B cell anergy (Goodnow, Crosbie et al. 1988, 
Cambier, Gauld et al. 2007). During NP-Ficoll mediated TI-II immune response, 
IgMg1 mice generate very few NP+ B cells and significantly less NP-specific plasma 
cells than IgMwt mice, confirming that the chimeric IgMg1 BCR is less efficient at 
activating IgMg1 B cells by direct BCR ligation. Besides reduced BCR signalling, 
surface IgM expression was reduced by at least 50% from immature B cell stage of 
IgMg1 mice and on all subsequent B cell differentiation stages (Fig.5.1). This is 
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consistent with the observation that surface IgM down-regulated in most mouse 
models of B cell anergy (Cambier, Gauld et al. 2007, Duty, Szodoray et al. 2009). 
Together, these data suggest IgMg1 B cells are induced into an anergic state.  
 
B cell anergy is induced in negative developmental check points during B cell 
development by increased BCR signalling if BCRs ligate with self-antigen (Brink and 
Phan 2018). In the IgMg1 model, extra signalling from the IgG1 cytoplasmic tail 
possibly mimics the weak to medium BCR activation signalling from BCR ligation 
with self-antigen. Results from Nur77-GFP reporter mice confirm that chimeric 
IgMg1 BCR is intrinsically able to transduce a stronger down-stream tonic signal 
during immature and BM transitional B cell stages.  In the following transitional and 
Fo B cell populations in the spleens, however, signalling has been adjusted and 
becomes comparable to IgMwt B cells. The attenuation of Nur77-GFP is only 
observed during BM development, and immature IgMg1 B cells already display 
features of anergy, such as: down-regulation of surface IgM and low-responsiveness 
after BCR ligation. Therefore, it seems that anergy induction in IgMg1 B cells is 
induced at the transition into immature B cell stage (Fig. 5.1). The attenuation of tonic 
BCR signalling, reflected by Nur77-GFP expression, during IgMg1 B cell 
development can be achieved through two possible mechanisms. Firstly, increased 
negative selection that IgMg1 B cells experience during bone marrow development 
may have selected B cells with lower BCR signalling strength. Alternatively, 
hyperactive BCR signalling from BCR/self-ligand binding is likely to induced a state 
of anergy, during this stage. 
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This observation seems contradictory to what is found in the knock-in mouse strain 
(MG2) expressing IgM-G1 BCR-recognizing HEL (Horikawa, Martin et al. 2007). 
IgM-G1 BCR in this model is also a chimeric BCR which contains IgM extra-cellular 
domain followed with IgG1 transmembrane and cytoplasmic regions (Pogue and 
Goodnow 2000). Here IgM-G1 induces exaggerated calcium influx after activation 
and does not display any immune tolerance inductions. This discrepancy could be 
explained by the different BCR repertoires in these two mouse models. While in our 
model, the normal germline V-D-J repertoire is retained to allow random 
rearrangement and generation of B cells with a polyclonal BCR repertoire, in the 
MG2 model there is only one monoclonal BCR specific for a single foreign protein. 
HEL, the foreign antigen, is not displayed in bone marrow or the periphery and does 
not induce negative selection during bone marrow B cell development. Thus the 
chance for HEL-specific IgM-G1 B cells to experience negative selection during 
development is considerably lower than that of the polyclonal IgMg1 B cells of the 
mouse model presented here. Another significant difference between both models is 
that the HEL-specific IgM-G1 chimeric BCR contains both transmembrane and 
cytoplasmic regions from IgG1, whereas the chimeric BCR in our model used in this 
study only has the replacement of the IgM cytoplasmic region with that of IgG1. The 
difference in transmembrane regions of these two chimeric BCRs could well affect 
their BCR signalling strength as well. 
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The Germinal Centre is the antigen-induced environment where affinity maturation 
takes place. Rather than being a random process, this directed evolution of B cell 
receptor affinities is regulated by complex selection processes. Although BCR 
signalling is dampened (Khalil, Cambier et al. 2012), it is required for and involved in 
selection within GC reactions. The BCR-SYK-PI3K-AKT signalling pathway 
selectively inactivates Foxo1 in GC B cells and allows for the expression of c-Myc to 
maintain GC B cells in LZ (Luo, Weisel et al. 2018). Despite the fact that the impact 
of BCR signalling strength on GC selection remains elusive, the selections of GC B 
cells are affected by the BCR isotype they express. For example, IgE+ GC B cells are 
mainly localised in the DZ, where they are disfavoured and prone to be induced into 
apoptosis (Yang, Sullivan et al. 2012, He, Meyer-Hermann et al. 2013). As different 
BCR isotypes can lead to different down-stream signalling (Weston-Bell, Forconi et 
al. 2014), these studies suggest a potential effect of different BCR signalling strength 
on GC B cell fate. 
 
Anergic B cells display repressed BCR signalling after activation, but still are capable 
of joining the GC response (Fulcher, Lyons et al. 1996, Sabouri, Schofield et al. 2014, 
Burnett, Langley et al. 2018). Furthermore, studies from the Goodnow group 
promoted the idea of clonal redemption of anergic B cells during GC reactions, which 
involved more complicated selection within the GC, including affinity maturation 
toward foreign antigen and loss of affinity towards self-antigens (Sabouri, Schofield 
et al. 2014, Burnett, Langley et al. 2018). However, we have yet to understand if the 
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changed BCR signalling in anergic B cells would affect their selection during GC 
reactions.  
 
Results of this study show that the tolerized state of anergic B cells is not broken for 
at least 8 days after they were activated by immunisation. This anergic pattern was 
maintained even when they were activated and differentiated into GC B cells and 
MBCs, reflected by constantly repressed BCR signalling and the down-regulation of 
surface BCRs in GC B cells in IgMg1 mice during the early GC response (Fig. 5.2). 
GC B cells derived from anergic B cells still maintain the anergic feature of reduced 
BCR signalling, which makes it possible that this changed BCR signalling could 
potentially affect GC selections.  
 
Selection within the GC leads to the fate decisions of GC B cells to either live, 
proliferate, or undergo cell death (Mesin, Ersching et al. 2016). IgMg1 B cells had a 
significantly higher apoptosis rate on day 6, but an enhanced proliferation rate on day 
8 after immunisation with NP-CGG, indicating that during the early GC response 
IgMg1 GC B cells experienced different selection pressures compared to their WT 
counterparts. This could be a result of continuous anergic BCR signalling in early 
IgMg1 GC B cells. Another piece of evidence, indicating altered selection pressure, 
comes from the delayed specificity shift within the total GC response in IgMg1 B 
cells, showing that IgMg1 GC B cells had a longer-lasting response to the initially 
dominant immunogenic epitope, NP (Fig. 5.2). The proportion, proliferation and 
survival of different antigen-specific populations in the GC response are regulated by 
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positive selection inducing proliferation and/or differentiation events. It is, therefore, 
likely that changed population dynamics seen in IgMg1 GCs reflect changed selection 
efficiency during the early stages of the GC response. However, the detailed 
mechanism behind how anergic BCR signalling impacts GC B cell selection still 
waits to be answered.  
 
IgMg1 chimeric BCR not only affected B cell development and induced them into an 
anergic state, but also altered T cell differentiation during a T-D immune response. 
The presence of anergic IgMg1 B cells induces a bias towards Tfh cell differentiation 
(Fig. 5.2). In the current T cell centric model, Tfh cells are described as the providers 
of selection or regulation for GC B cells (Batista and Neuberger 2000, Allen, Okada 
et al. 2007, Schwickert, Victora et al. 2011, Gitlin, Mayer et al. 2015). However, other 
studies showed that the initiation of Tfh cell differentiation and the maintenance of 
Tfh cell phenotype in the GC require sustained signalling from cognate B cells 
(Coffey, Alabyev et al. 2009, Kerfoot, Yaari et al. 2011, Baumjohann, Preite et al. 
2013). Further, it has been shown that T cell immune responses can be regulated by B 
cells, such as regulatory B cells (Khan, Hams et al. 2015). Together, these studies 
indicate that anergic IgMg1 B cells might potentially affect the generation or 
maintenance of Tfh cells in the GC micro-environment. One possible mechanism 
could be that these anergic IgMg1 B cells can express cytokines to regulate micro-
environments around them, which could potentially affect activated T cell 
differentiation, as described previously for regulatory B cells (Tian, Zekzer et al. 2001, 
Carter, Rosser et al. 2012, Shen, Roch et al. 2014). Another possibility is that these 
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anergic IgMg1 B cells can better present pMHCII and provide stronger co-stimulation 
signalling to T cells and directly promote the differentiation of Tfh. This hypothesis is 
based on previous observations showing anergic B cells can constantly present self-
antigens to T cells (Eris, Basten et al. 1994), and auto-reactive B cells can trigger 
auto-immune diseases by presenting self-antigen to T cells and activating them (Dai, 
Carayanniotis et al. 2005, Giles, Kashgarian et al. 2015, Giles, Neves et al. 2017). The 
potential regulatory roles of anergic IgMg1 B cells on the differentiation of Tfh cells 
should be further tested. Possible mechanisms of anergic B cells regulating Tfh 
differentiation may help to gain more insights into T-B interaction and the regulation 
of the GC response. 
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 Legend:											
																										 
Figure 5.1: Graphic representation of anergy induction and anergic features in 
IgMg1 mice. 
Chimeric IgMg1 BCR is down-regulated from immature B cell stage. However, it is 
still able to transduce stronger BCR signalling in immature and transitional B cells 
during BM stage. This hyper-activate tonic signalling makes IgMg1 B cells 
experience enhanced negative selection, which results in repressed tonic BCR 
signalling and epigenetic reprogramming. During peripheral stage, all B cell 
populations in IgMg1 mice maintain this modification and display an anergic pattern, 
displaying reduced activated BCR signalling after BCR ligation and down-regulation 
of surface IgM. 
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Legend:           
 
Figure 5.2: Graphic representation of the summary of the T-D immune response 
towards NP-CGG in IgMwt and IgMg1 mice. 
During the T-D immune response, the shift in specificity in the GC B cell response 
away from the initial NP-specificity is delayed in IgMg1 mice, resulting in longer-
lasting responses to NP. In non-switched IgMg1 GC B cells, the suppression of BCR 
signalling and down-regulation of surface IgM remains. BCR signalling is repressed 
in all GC B cells, in especially in switched IgG1+ GC B cells in both IgMwt and 
IgMg1 mice. After output from GCs, MBCs (switched to IgG1) regain stronger BCR 
signalling, however, BCR signalling remains lower in IgMg1 derived MBCs than in 
those from IgMwt mice. There is a higher proportion of Tfh cells and a higher 
percentage of switched GC B cells during GC reactions in IgMg1 mice, which could 
be due to increased stimulation or antigen-presentation from IgMg1 B cells. 
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Chapter 7 . Appendices 
 
>Wildtype mouse IgM (partial) 
agggggaggtgaatgctgaggaggaaggctttgagaacctgtggaccactgcctccaccttcatcgtcctcttcctcctga
gcctcttctacagcaccaccgtcaccctgttcaaggtagtgtggttgtggggctgaggacacagggctgggacagggagt
caccagtcctcactgcctctacctctactccctacaagtggacagcaattcacactgtctctgtcacctgcaggtgaaatgact
ctcagcatggaaggacagcagagaccaagagatcctcccacagggacactacctctgggcctgggatacctgactgtat
gactagtaaacttattcttacgtctttcctgtgttgccctccagcttttatctctgagatggtcttctttctagactgaccaaagactt
tttgtcaacttgtacaatctgaagcaatgtctggcccacagacagctgagctgtaaacaaatgtcacatggaaataaatacttt
atcttgtgaactcactttattgtgaaggaatttgttttgtttttcaaacctttcctgcggtgttgacagcccaaggattatctgaata
gagcttaggaactggaaatggaacagtgcagtctgatggtacttaa 
 
>Transgenic mouse IgM (partial) 
Agggggaggtgaatgctgaggaggaaggctttgagaacctgtggaccactgcctccaccttcatcgtcctcttcctcctga
gcctcttctacagcaccaccgtcaccctgttcaaggtagtgtggttgtggggctgaggacacagggctgggacagggagt
caccagtcctcactgcctctacctctactccctacaagtggacagcaattcacactgtctctgtcacctgcaggtgaaatggat
cttctcctcggtggtggagctgaagcagacactggttcctgaatacaagaacatgattgggcaagcaccctgactctcagc
atggaaggacagcagagaccaagagatcctcccacagggacactacctctgggcctgggatacctgactgtatgactagt
aaacttattcttacgtctttcctgtgttgccctccagcttttatctctgagatggtcttctttctagactgaccaaagactttttgtcaa
cttgtacaatctgaagcaatgtctggcccacagacagctgagctgtaaacaaatgtcacatggaaataaatactttatcttgtg
aactcactttattgtgaaggaatttgttttgtttttcaaacctttcctgcggtgttgacagcccaaggattatctgaatagagctta
ggaactggaaatggaacagtgcagtctgatggtacttaa 
	
Red highlighted 75bp is the cDNA sequence encoding for C-terminal cytoplasmic 
region of IgG1 
Genotyping primer sequence: 
1. IgM/IgG1: Fwd: 5’- tgcaggtgaaatggatcttctcctc -3’ 
                   Rev: 5’ – aaccagagtgctatccattgg – 3’ 
 
Expected PCR product size from transgenic mice: 683bp. Wildtype mice will 
not give a PCR product. 
 
 
 
2. IgM/IgG1: Fwd: 5’- ttcaaggtagtgtggttgtgg -3’ 
                   Rev: 5’ – atacagtcaggtatcccagg – 3’ 
 
Expected PCR product size from transgenic mice: 289bp. Expected PCR 
product size from wildtype mice: 214bp. 
 
 
